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Abstract
In this work we investigate the design and formulation of novel non-viral 
lipopolyamine vectors capable of efficiently and safely delivering DNA to the nucleus 
in different tissue cultured cell lines. The thesis starts with a literature review about 
NVGT that provides a background about the barriers for DNA delivery and a focus on 
the NVGT vectors used in the formulation of DNA.
The first lipopolyamine in this study is A^^-dioleoyl spermine that was 
synthesized from the naturally occurring polyamine spermine. To investigate the 
ability of A^^-dioleoyl spermine on DNA condensation using ethidium bromide 
(EthBr) fluorescence-quenching and light scattering assays, model polycations were 
selected to be compared with our lipopolyamine. Transfection efficiency and 
cytotoxicity (using MTT) were studied in both cancer and primary cell lines and 
compared with Lipofectin® and Lipofectamine™. A^^-Dioleoyl spermine formula is 
efficient at condensing and transfecting DNA at a charge ratios of 2.5.
We then extended our study to the effect of varying the degree of 
unsaturation in A^^-dioctadecanoyl spermines as non-viral vectors. The saturated 
(stearoyl), mono-unsaturated (oleoyl) and the di-unsaturated (linoleoyl) were 
synthesized. The ability of these compounds to condense DNA was studied using 
EthBr and nanoparticle characterization techniques. Transfection efficiency was 
studied in a panel of primary skin cells (FEK4, FCP4, FCP5, FCP7, and FCP8) and 
in cancer cell line (HtTA), and compared with the lipospermine Transfectam®. 
A^A^-Dilinoleoyl spermine also achieves the highest transfection levels among the 
studied lipopolyamines in a series of primary skin cells and cancer cell lines at low 
charge ratios of (+/- ammonium/phosphate) 5.5.
Two refereed papers, one edited book chapter and several abstracts of this 
study presented at international meetings are included in the appendix.
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CHAPTER 1 
Introduction and Literature Review
1
Introduction
It is widely believed that gene therapy will become an efficient medicine for 
the treatment of diseases such as cancer, cystic fibrosis and for vaccination (1). For 
example in the case of cancer, the cells are characterized by their uncontrolled growth 
through their characteristic hereditary properties (2). The current strategies (surgery, 
chemotherapy and/or radiation) for cancer treatment are useful in the case of early 
stages of cancer, but in the late metastases stage although chemotherapy is the most 
successful strategy, it has several side-effects e.g. the suppression of bone marrow 
and other fast dividing tissues, potential genesis of secondary cancers, and the 
development of resistant phenotypes (3).
The essential requirements for gene therapy are the transport of DNA through 
the cell membrane and ultimately to the nucleus. Different strategies have been used 
for the delivery of genetic material into target cells which are classified as viral or 
non-viral delivery systems (4, 5). Viral delivery systems depend on the development 
of genetically-modified viruses to utilise their capability of efficiently delivering 
DNA into cells through their natural infective mechanisms without their pathogenic 
characteristics. Although high efficiency is achieved by viral vectors, there are 
concerns about their use which include a limit to the size of the DNA to be delivered 
(the “payload”), endogenous viral recombination, unexpected anti-vector immune 
response, and oncogene activation (6-8). Viral gene therapy has suffered a major 
blow by the first fatal case, the death of 18-year-old Jesse Gelsinger in a clinical trial 
after starting the treatment using adenoviral vector in 1999 (9). Also, in 2003 a child 
treated in a French viral gene therapy trial developed a leukemia-like condition that 
made the ID A  temporarily halt all gene therapy trials using retroviral vectors (9). 
These set-backs for viral vectors have served to attract several laboratories to focus 
on the development of novel non-viral formulations for efficient gene delivery.
Non-viral delivery systems include the use of DNA alone, so-called “naked 
DNA”, or complexed with synthetic cationic lipids (lipoplexes) or cationic polymers 
(polyplexes) (5). These vectors not only circumvent the drawbacks of viral vectors, 
but also have the advantages of simplicity of use and the ease of large-scale 
production (10). The major challenge for non-viral vectors is the lower transfection
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efficiency compared to viral vectors. In terms of concept, the naked DNA strategy is 
considered as the safest way (10), but due to the limitations of level of expression, 
other procedures were used to increase the transfection efficiency such as 
electroporation (11), gene gun (12), ultrasound (13) and hydrodynamic (high 
pressure) injection (14), but these techniques also suffer from the need for 
complicated medical devices for application and the limitation of only achieving drug 
(gene) delivery to the superficial tissues.
Synthetic non-viral gene carriers (lipoplexes and polyplexes) are widely 
investigated due to their advantages which include the variety of ways for 
synthesizing and assembling these transfecting agents, their formulation from well 
known components, their higher capability to deliver DNAs of larger sizes, their 
safety and ease of large scale production as reviewed by Wagner (15). Although non- 
viral carriers have poor transfection efficiency in comparison with viral vectors, they 
have received considerable attention after the formulation of Lipofectin® by Feigner 
and his research group (16) in 1987, which encouraged many other laboratories to 
develop non-viral gene delivery formulations. This research field continues to show 
promise for the improved efficiency of delivering DNA, but still there is a need for a 
better understanding of the mechanism of gene delivery to targeted cells (17) and 
detailed understanding of the barriers for non-viral gene delivery to achieve efficient 
formulation. These barriers that hinder the delivery of DNA to its physical site of 
action (the nucleus) for transcription and subsequent translation have been 
summarized (Figs. 1 and 2) as follows:
1. DNA condensation
2. Cell targeting




7. Transcription and translation
A review of the literature covers these barriers in turn, and then the excipients 
used in non-viral DNA formulation are critically surveyed.
3
condensed DNA particles
early e n d o s o m e ( t o r o i d s  or rods)
—   ©
Figure 1. Steps in the process of non-viral gene therapy by endocytosis showing the 
barriers to DNA nanoparticles. This process goes from the formation of the DNA- 
polycation complex to protein synthesis which includes complex formation between 
the DNA and cationic polymer or lipid that leads to condensation of DNA into 
nanoparticles in the form of rods or toroids. According to the results reported by 
Bottcher et al. (18) using cryo-electron microscopy, the dimensions of toroids 
produced by condensation of pEGlacZ condensed with spermine was between 15-40 
nm for the central hole, the external diameter from 50-110 nm and the thickness of 
the toroid from 11-28 nm. The calculated hollow volume was from 0.8 x 104 to 1.7 x
c o
10 nm . Cell membrane entry is thought to be mediated by cationic substances 
which interact with DNA. This interaction causes adsorptive endocytosis and 
internalization of the complex. The internalized material is fused with early 
endosome, and then leads this process to sorting to the late endosomal compartment. 
At this stage, the DNA complex should escape the endosomal vesicle before the later 





Figure 2. The steps in the process of non-viral gene therapy after endosomal escape 
that is considered to be the first barrier after cellular internalization of the 
nanoparticles. The DNA either complexed or dissociated from the condensing agent 
should finds its way (as DNA is subject to hydrolysis by DNase in the cytosol) to the 
nucleus. Also, the DNA should cross the nuclear membrane which thought to be 
occurring through the nuclear pore complex (NPC) or by direct association with the 
chromatin during mitosis. After nuclear entry, the DNA should successfully be able 
to give the desired protein through transcription and translation processes, e.g. access 
of transcription factors may be affected by the dissociation rate of the DNA complex.
Literature review
1. DNA condensation
For drug formulators, it is difficult to deliver a drug molecule of 3.3 kDa 
molecular weight carrying 10 negative charges, but in the case of the prodrug DNA, a 
5 kbp plasmid has a molecular weight of about 3.3 MegaDa and carries 10,000 
negative charges. Each base pair (bp) is defined as 660 Da (5) for an average/random 
DNA duplex sequence. So the first key step in gene delivery is DNA condensation 
into a nanoparticle form through masking the negative charges of the phosphate 
backbone. This titration with a cationic lipid or polymer causes alleviation of charge
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repulsion between remote phosphates along the DNA helix leading to collapse into a 
more compact structure. This is a phase transition from extended conformation to a 
compact structure that facilitates cell entry (19). This phase transition is favoured 
when about 90 % of the negative charges along the phosphate backbone are 
neutralized (20-22) based on the counter ion condensation theory by Manning (23- 
25).
The use of an efficient carrier for DNA is considered to be a determinant 
factor for the successful application of gene therapy. This carrier is responsible for 
the complex process of gene delivery to the nucleus (26). The ability of multivalent 
cations such as polyamines to condense DNA into rods (27) or toroids (28, 29) has 
provided DNA in a nanoparticle form suitable for gene delivery. Cationic lipids and 
polymers have the ability to condense DNA into particles that can be readily 
endocytosed by cultured cells. The formed nanoparticles and their size are essential 
for the development of gene delivery vehicles (30, 31). In addition, the cationic lipids 
and polymers increase the stability of DNA in serum (32).
DNA is condensed by naturally occurring positively charged polyamines 
spermine and spermidine (Fig. 3) working together with the basic proteins histones 
(21). Histones are relatively small, highly basic (i.e. at physiological pH 7.4 they 
carry many positive charges) proteins with molecular weights in the range of 10 to 20 
kDa (33). The five major types of histone chains are: HI, H2A, H2B, H3 and H4 
differentiated on the basis of their relative content of lysine and arginine (Fig. 3). The 
amino acid sequences of four histones (H2A, H2B, H3 and H4), from a wide variety 
of organisms, are similar among different species (33). The histones appear to be 
involved in the supercoiling of DNA in eukaryotic chromosomes through their 
recurring positive charges, due to the presence of a high ratio of positively charged 
(basic) amino acids lysine and arginine (Fig. 3) that leads to the formation of 
electrostatic associations with the negatively charged phosphate groups of DNA, 
which renders the DNA more stable and flexible (33). The double helix of DNA, 
together with the associated histones, is supercoiled and folded back and forth many 
times in the chromatin fibres. Also, polymers of histidine and the non-protein basic 
amino acid ornithine (Fig. 3) have been used for DNA condensation (34-38).
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There are few studies that utilized histones in the design of non-viral gene 
therapy. H 1 and the cationic lipid DOSPER was formulated for the investigation of 
luciferase gene (pCMV Luc) delivery in ECV 304 human endothelial cells (39). In a 
different investigation, Hoganson et al. (40) showed that ligand-mediated endocytosis 
can specifically deliver DNA to the cells that have these specific receptors in-vitro. 
They targeted FGF receptor-bearing cells by the ligand fibroblast growth factor 
(FGF2) with DNA encoding saporin. Saporin is a potent ribosomal inactivating 
protein. In addition, FGF2 was also used in their study with DNA encoding the 
conditionally catatonic herpes simplex virus thymidine kinase, a protein that can kill 
cells by activating the prodrug ganciclovir. However, when histone HI, a ligand that 
binds to cell surface heparan sulfate proteolysis (“low-affinity” FGF receptors), was 
used to deliver DNA encoding thymidine kinase, no ganciclovir sensitivity was 
observed (40).
Spermine Spermidine
Arginine (Arg, R) Lysine (Lys, K)
Ornithine (Orn, O) Histidine (His, H)
Figure 3. Spermine, spermidine and the positively charged amino acids arginine, 
lysine, ornithine and histidine.
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Chemically modified histones were also investigated in gene delivery 
formulations. Galactosylated histone, a ligand to the asialoglycoprotein receptors, 
was synthesized and constructed in an Epstein-Barr virus (EBV) based expression 
vector to improve levels of the human cytokine interleukin-2 (IL-2) cDNA gene 
expression through targeted ligand receptor mediated endocytosis into hepatoma 
(HepG2) cells via the hepatocyte cell surface receptors (41). Also, HI was 
conjugated with nuclear localization signal (NLS) for DNA binding and formulated 
with (dioleoyl phosphatidylethanolamine (DOPE) or phosphatidylserine (PS)) (42) as 
liposomal formulation.
Deas et al. (43) modified their vector (plasmid DNA with antibody) by 
introducing non-covalent binding between the antibody and DNA, allowing the 
possibility to introduce different important molecules. The non-covalent association 
was achieved with neutravidin and biotinylated components: (1) biotinylated 
antibodies; (2) a biotinylated hemagglutinin fusogenic peptide of influenza virus to 
favour endosomal escape; and (3) biotinylated histone HI to condense, protect, and 
associate DNA to the complex.
DNA interaction studies with polycations showed the condensation of DNA to 
nanoparticles with different structures and different particle sizes that affect the 
delivery of DNA to the cells. The investigation of DNA condensation into rods and 
toroids, as in most vertebrate sperm cells (44), has attracted many research 
laboratories to thoroughly study the structure of DNA toroids. Studies on DNA 
toroids have revealed different models for the organization of DNA within toroids: 
the circumferential DNA wrapping (spool) model (18, 28), the constant radius of 
curvature model (45), and the latter model assumed by Hud and Downing (46). Also, 
detection and characterization of the condensed DNA nanoparticles using polycations 
showed a great interest by several laboratories (see Table 1). In addition, 
investigations using hexamine cobalt (DI) to control the size of the condensed DNA 
particles revealed that the size of the initial nucleation loop in toroid formation has a 
major effect on the toroid size, also the ionic strength of the solution will affect the 
thickness of the formed toroids (47).
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Several experiments were applied to link a DNA complex with a targeting 
ligand in order to improve nonspecific binding of positively charged DNA 
nanoparticles to cells with a more specific interaction. This specific binding will 
lead to increase in the efficiency of transfection and reduction of the toxicity of the 
vector where DNA will be internalized by receptor-mediated endocytosis more 
efficiently to specific organs or cells that contain receptors for the target ligand. To 
utilize this improvement by targeting ligands, a number of gene delivery systems 
have been formulated to include targeting ligands. These ligands were derived from 
several classes including carbohydrates, vitamins, peptides and antibodies.
From the carbohydrate class, galactose and mannose were investigated for 
cell-specific receptor mediated endocytosis in gene delivery using mannosylated 
poly-L-lysine and galactosylated poly-L-lysine (66-68). The asialoglycoprotein 
receptor on hepatocytes and the mannose receptor on macrophages and liver 
endothelial cells are the targets for galactosylated and mannosylated gene carriers (67, 
69). Behr, Remy and coworkers designed lipopolyamine-DNA complexes with 
galactose (70) and galactosylated chitosan was formulated for hepatocyte targeting 
(71, 72). Galactosylated histone as a ligand was synthesized and constructed in a 
viral vector to improve levels of gene expression into hepatoma (HepG2) cells (41). 
Lactose was also utilized for hepatoma cell-targeting as lactose-poly(ethylene 
glycol)-grafted poly-L-lysine gene carrier, also lactose used for targeting cystic 
fibrosis (CF) airways that shows improved transfection and reduced cytotoxicity (73, 
74).
Group-B vitamins were also utilized for targeting cancer cells, the folate 
receptor is a tumor marker over-expressed in most human tumors that was studied for 
targeting using folic acid (B9) (75-77). As cancer cells have high demand for 
Vitamin B12 taken up by receptor mediated endocytosis, this opens the possibility for 
Vitamin B 12 to be used as a targeting ligand that leads to preferential uptake by 
cancer cells, invistigated by Grissom and co-workers (78, 79).
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Among the peptides class of targeting ligands, the synthetic peptide arginine- 
glycine-aspartate (RGD) that was successfully introduced in the formulation of non- 
viral vectors for integrin receptor targeting (80, 81). Transferrin, a natural iron- 
delivery protein was also investigated for targeted gene delivery. Bimstiel, Wagner 
and co-workers was a leading group to investigate transferrin as targeting ligand to 
the transferrin receptor in various cell lines using a transferrin poly(L-lysine) 
conjugate as a carrier (82-84). Transferrin was also incorporated with cyclodextrins 
polymer-based gene delivery system. The non-viral system is formed by 
condensation of a cyclodextrin polycation with nucleic acid into nanoparticles that are 
surface-modified to display poly(ethylene glycol) (PEG) for increasing stability in 
biological fluids and transferrin for targeting of cancer cells that express transferrin 
receptor (85).
The ligand fibroblast growth factor (FGF2, a 155-amino acid) targeted FGF 
receptor-bearing cells that showed efficient ligand-mediated endocytosis (40, 86). A 
cell-binding ligand, the transactivator of HIV (TAT, sequence GRKKRRQRRRGYG) 
transcription peptide stimulated cellular uptake was incorporated in liposomal 
cationic lipid formulation and compared with DOTAP/DOPE liposomes and PEI 
(87). The assembled liposomal formulation showed 80-fold enhancement of 
transfection efficiency. HIV-TAT derived peptide show efficiency in targeting DNA 
and glycosaminoglycans for directed gene and drug delivery (88). An antisense gene 
targeting formulation to brain cancer cells include epidermal growth factor chimeric 
peptides (EGFR) that reduces the growth of EGFR-dependent gliomas (89).
Antibody-based gene delivery vector was designed for tumour cell targeting to 
the G250 renal cell carcinoma-associated antigen in tumour cells (43). Antibody- 
based gene targeting was designed for ovarian carcinoma cells using pegylated 
polyethylenimine (PEG-PEI) conjugated to the antigen binding fragment (Fab’) of the 
OV-TL16 antibody directed to the OA3 surface antigen that is expressed by a 
majority of human ovarian carcinoma cell lines (90). The results revealed luciferase 
expression increased up to 80-fold compared to PEG-PEI and was even higher than 
that of PEI 25 kDa non-viral vectors. In addition, peptide nuclear localization signals 
(NLS) were successfully applied for DNA-nuclear targeting inside the cell after 
endosomal escape.
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3. Cell membrane entry
The mammalian cell membrane is a semi-permeable membrane formed from a 
phospholipid bilayer and containing various integral proteins. The cell membrane 
selectively screens the entry of foreign matter to the cell and allows the transport of 
macromolecules by endocytosis. Neutralization of the negative charges on the DNA 
by polycations will improve the delivery of DNA through the cell membrane by 
masking the negative charges on DNA because of the presence of negative charges on 
both DNA and cell membrane that hinder the delivery of DNA alone. Also, the 
positively charged lipid complex will mediate transfection by fusion with the cell 
membrane and internalization by endocytosis and/or receptor mediated endocytosis 
(91).
4. Endosomal escape
The major intracellular barriers that face the delivery of DNA into the nucleus 
are located in the cytoplasm. Although the DNA complex is efficiently internalized 
in the cell, small fraction will be transferred to the nucleus and expressed (92). As the 
DNA complex is internalized, it is retained inside the early endosomes, then sorted to 
the late endosomes that are characterized by increased acidity (low pH value). At this 
stage, the efficient escape of DNA from the endosome is an important factor for 
successful gene delivery before further trafficking of the trapped DNA to the 
lysosomal compartment where the DNA is subjected to degradation by the nucleases 
found in the lysosomes (15).
The possible mechanisms for endosomal escape are:
1. Disruption of the negatively charged endosomal membrane through mixing 
with the cationic lipid vector (93).
2. Cationic polymer interaction with the negatively charged endosomal 
membrane. (94).
3. Proton sponge hypothesis, where a cationic polymer, such as 
polyethylenimine, has the ability of endosomal pH buffering that leads to
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chloride ion influx together with water molecules that leads to membrane 
swelling and disruption. (95).
4. Membrane destabilising peptides, which includes fusogenic or lytic peptides, 
such as the basic peptide KALA (96), acidic peptide EGLA (15) or the 
uncharged peptides at neutral pH such as H5WYG (35) these peptides have 
the ability to disrupt the endosomal membrane and increase the release of 
DNA to the cytosol.
5. Compounds that act as lysosomotropic agents assist the escape of the 
endosome such as chloroquine that inhibit lysosomal processing and sucrose 
that cause endosomal compartment osmotic lysis, are used with the 
condensing agents to improve the efficiency of non-viral gene delivery 
formulations (97, 98).
5. Nuclear entry
One of the crucial steps for successful delivery of DNA into its site of action 
is crossing the nuclear membrane. The entry of macromolecules to the nucleus 
occurs through the nuclear pore complex (NPC) which allows a passive diffusion of 
molecules of up to 50 kDa molecular weight or about 10 nm in diameter, but in the 
case of larger molecules NPC is capable of actively transporting particles of about 25- 
50 MDa or 25 nm in diameter (99).
The utilization of nuclear localization signals (NLS) through their 
characteristics to target the macromolecules to the nucleus and increase the 
transfection efficiency have been applied (100). The other way for DNA entry to the 
nucleus is during mitosis where nuclear membrane is broken down so the DNA and 
macromolecules can easily gain access.
The first nuclear localization signal to be mapped in detail was characterized 
by Smith and colleagues in 1984 (101). The T-antigen nuclear localization signal is a 
seven amino acid sequence Pro-Lys-Lys-Lys-Arg-Lys-Val. Not only was this 
sequence necessary for the nuclear transport of T-antigen, but also its addition to
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other, normally cytoplasmic, proteins was also sufficient to direct their accumulation 
in the nucleus (33).
The use of nuclear localization signals in non-viral formulation has been 
investigated with encouraging results. The signal PKKKRKVEDPYC, derived from 
SV40, was used to increase PEI- and Transfectam-mediated transfection significantly 
in terms of the amount of DNA required for in-vitro transfection (100). In addition, 
the yeast transcriptional activator, GAL4, has been shown both to bind DNA and 
separately act as a nuclear localization signal (102). Nuclear localisation signals are 
used as adjuvant in the gene delivery formulation to improve transfection efficiency 
(103). Noguchi et al. (63) promoted gene transfection of the DNA-protamine- 
liposome complex with the derivative (I) more significantly into the nucleus of the 
target cells using the nuclear localization signal of protamine.
Nakanishi et al. (104) compared the ability of various synthetic NLS peptides 
to carry large molecules into nuclei. They chemically modified bovine serum 
albumin (BSA, MW 70 kDa) or IgM (MW 970 kDa, diameter 33 nm) using these 
peptides, then estimated the propensity of these molecules to translocate into nuclei 
by injecting them into cytoplasm. Although many NLS can promote the nuclear 
transfer of BSA, only 34mer peptide from SV40 T-antigen could carry IgM into the 
nucleus, as reported (105). A shorter peptide (12-mer) containing NLS of T-antigen 
could carry BSA, but not IgM into the nucleus, suggesting that the longer peptide 
contains the additional information required to transfer large molecules into nuclei 
(105). However, the understanding of this difference in transport ability on a 
molecular basis still remains unclear.
6. Decomplexation
The dissociation of DNA from the condensing agent is an important step for 
the host transcription factors to initiate the transcription reaction. The 
decomplexation process may occur after endosomal escape in the cytoplasm (93) or 
after nuclear entry as indicated by Mikos and his group (106) using confocal images 
for tracking PEI/DNA complexes. Also, the kinetics of intracellular DNA complex 
dissociation are important factor for successful non-viral gene delivery process (107).
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If the DNA dissociated from the condensing agent easily and happened in the early 
stages of cellular entry, this will lead to degradation of the delivered gene by DNase 
in the cell. On the other hand, if the dissociation rate is slow, this will hinder the 
accessibility of the host transcription factors to initiate the transcription reaction that 
leads to low or no level of protein expression.
7. Transcription and translation
Inside the nucleus, the next step for gene therapy is the transcription process 
which depends on the promoter strength and presence of enhancer in the vector which 
have an effect on the transfection efficiency (108). The successful transcription 
process leads to the translation and formation of the desired protein (the active form 
of the prodrug DNA). Kamiya et al. (107) designed a simple pharmacokinetics/ 
pharmacodynamics model for the expression of the delivered gene in the nucleus 
based on the general consideration that the total amount of mRNA depends on the 
amount of the exogenous DNA in the nucleus. They concluded from this model that 
the amount (efficiency) of DNA delivered to the nucleus is the only determinant for 
expression of the delivered gene.
Excipients used in non-viral DNA formulation
Traditionally, the process of drug design, development and preformulation 
starts with main focus on the design of the active chemical of interest (candidate 
drug) followed by the selection of the excipients. In the case of non-viral gene 
therapy, the key step is the selection of the suitable excipients (the vector) for the 
delivery of the prodrug (DNA or RNA) into its site of action. Due to the polyanionic 
nature and the size of the active ingredient, the efforts continue to design novel or 
improve existing non-viral gene delivery formulations in order to increase the 
stability of the drug (DNA), decrease the toxicity of the excipients and/or increase 
transfection efficiency. Also, as a result of the improvement in DNA delivery 
systems, the strategy of antisense oligonucleotide delivery to inhibit gene expression 
has been widely investigated (109, 110). Vectors used for non-viral gene formulation 
can be classified as cationic polymers or cationic lipids (5).
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Cationic polymers
One of the leading cationic polymers that has been used as non-viral vector 
for gene delivery is polyethylenimine (PEI) (95). PEI, either linear or branched with 
different MWs (Fig. 4), possess a buffering capability that inhibits lysosomal enzyme 
activity by lowering proton concentration (proton sponge hypothesis) and presumably 
promoting the release of DNA that leads to an improvement in the transfection 
efficiency.
Branched polyethylenimine Linear polyethylenimine
Figure 4. Branched and linear PEI.
Polyethylenimines (PEI) have shown continued investigation to improve their 
cell viability and ability as non-viral gene delivery vectors utilising their endosomal 
escape efficiency that help the complex to escape the endosome and improve the 
transfection efficiency of the delivered gene (90, 111-115). In addition, PEI was used 
in conjugation with cationic lipids to utilise the characteristics of both vectors in one 
formula (116).
On the other hand, among cationic polymers, the second class of non-viral 
vectors, are the cationic polysaccharides (amino sugars) that have received increased 
focus as promising vectors for gene delivery utilising their well known advantage of
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safety and long experience use of these compounds in pharmaceutical industry and 
drug formulations.
Chitosan (A-deacetylated chitin) is a cationic, linear biodegradable 
polysaccharide composed of p-(l,4)-linked glucosamine partly containing A-acetyl- 
glucosamine (Fig. 5). Chitosan is derived by deacetylation of naturally occurring 
chitin in crab and shrimp shells. The pKa value of the amino groups of the 
deacetylated moieties is 6.5 (117). Mumper et al. (118) were the first research group 
to use chitosan as condensing agent in non-viral gene therapy. The biocompatibility 
and safety (119, 120) of chitosan renders it potentially useful for gene delivery (121- 
123).
Chitosan was evaluated for its ability to transfect different cell lines in 
comparison with Lipofectamine'M (65, 124), Lipofectin® (72), but chitosan used in 
this paper was coupled with galactose for hepatocyte targeting (72), poly-L-lysine 
(125), PEI (126), and in-vivo administration with endosomolytic peptide GM225.1 
(127), these results showed the ability of chitosan to be used as safe DNA carrier.
OH
R = H glucosamine 
R = COCH3 A-acetyl glucosamine
Figure 5. Model structure of a typical, idealised chitosan, where n might be 200- 
3000 giving a molecular weight from 40-600 kDa.
Other laboratories tried to chemically modify chitosan in order to increase the 
transfection efficiency, enhance cell specificity and/or increase DNA complex 
stability (128-130). Chitosan was also chemically modified with hydrophobic 
cholesterol groups to prepare chitosan-based polymeric amphiphiles (131). With a 
similar strategy, Yoo et al. (132) prepared a hydrophobically modified glycol chitosan 
with 5p-cholanic acid (Fig. 6) based upon their earlier studies (133, 134). The in-
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vivo results revealed higher transfection efficiency over naked DNA. Chitosan 
microspheres were used to encapsulate two plasmids without affecting their structural 
and functional integrity that leads to sustained and high protein production (135). 
Chitosan was also combined with adenoviral vectors to increase the adenoviral 




Figure 6. 5p-Cholanic acid hydrophobically modified glycol chitosan.
To show the mechanism of gene delivery by chitosan, Ishii et al. (138) 
analysed the transfection mechanism of plasmid/chitosan complexes as well as the 
relationship between transfection activity and cell uptake by using fluorescein 
isothiocyanate-labelled plasmid and Texas Red-labelled chitosan. They found that 
plasmid/chitosan complexes most likely condense to form large aggregates (5-8 pm), 
which absorb to the cell surface. After this, plasmid/chitosan complexes are 
endocytosed, and possibly released from endosomes due to swelling of lysosomal 
compartment in addition to swelling of plasmid/chitosan complex, causing the 
endosome to rupture. Ultimately, complexes were also observed to accumulate in the 
nucleus using a confocal laser scanning microscope.
Chitosan was also investigated for its interaction with a lipid bilayer 
(didodecyl dimethylammonium bromide, DDAB) (139). The results showed that the 
low MW chitosan could disrupt the lipid bilayer, and the effect seemed to be in a 
concentration-dependent manner. Also, the modification of chitosan using alkyl 
bromide leads to the formation of DNA complexes at lower charge ratios than the 
unmodified chitosan (140).
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The long-term stability of chitosan-based polyplex solutions (25mM sodium 
acetate buffer, pH 5.5) was investigated at different temperatures (4°C, 25°C, 45°C) 
over a period of up to 1 year (141). The results show that, one year of storage at 4°C 
did not result in any major changes in the properties of the polyplexes. At 25°C there 
were minor changes in the physicochemical characteristics of the polyplexes (particle 
size and zeta potential), and the in-vitro transfection efficiency was reduced at 1 year 
of storage. Storage at 45°C altered both the in-vitro transfection efficiency and the 
physicochemical properties of the polyplexes after a short time.
Novel non-viral vectors were also synthesized from a carbohydrate co­
monomer (esterified D-glucaric acid) within a PEI-like backbone and also, a polymer 
of esterified D-glucaric acid with diethylenetriamine, triethylenetetraamine, 
tetraethylenepentamine, and pentaethylenehexamine (Fig. 7) by Reineke and 
colleagues (142, 143), these 2.2.2-mers have previously been purified and conjugated 
(144, 145). With the same concept, the carbohydrates D-trehalose and (3- 
cyclodextrin (CD) were used within the polycation backbone to condense DNA into 
particles that can be readily endocytosed by cultured cells (146). Cyclodextrins 
continue to be promising non-toxic non-viral vectors. Their structural effects were 
investigated on both gene delivery and conjugation with polyamidoamine dendrimers 
(146-149). p-Cyclodextrins were modified to form cationic amphiphiles and 
Polycationic (polyamino) P-cyclodextrins with different cationic groups (amino, 
pyridylamino or butylimidazole) that were used for efficient DNA condensation and 
transfection (150, 151). Cyclodextrins were also conjugated with the targeting ligand 
transferrin for tumour cells and polyethylene-glycol (PEG) to improve stability in 
biological fluids (85). Azzam et al. (152) have synthesized spermine conjugated 
with different molecular weight dextrans as gene delivery vectors.
Also, Zhang et al. (153) used the sugar-based non-ionic surfactant, 
octylpolyglucosides (C(8)APG), which caused DNA conformational collapse in 
aqueous solution as the concentration increased. They have used UV and CD to 
determine the change of DNA second-order structure to confirm the above results.
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Figure 7. Synthesis of poly(glycoamidoamine)s (143).
Cationic peptides
Cationic peptides that include the positively charged amino acids lysine, 
ornithine and arginine are utilized in the design of non-viral delivery vectors.
Arginine has a pKa value of 12.5 and both lysine and ornithine have similar pJfa 
values of 10.8. Arginine and lysine are the major constituents of histones 
(responsible for DNA condensation in the nucleus) and nuclear localisation signals of 
the delivered proteins from the cytoplasm to the nucleus where they have been used 
as vectors for DNA delivery (154, 155).
Some research groups are interested in the use of the basic amino acid 
polymers such as poly-L-omithine, poly-L-lysine and poly-L-arginine (Fig. 8) that 
carry multiple positive charges at physiological pH in DNA condensation and gene 
delivery (37, 38). Also, Wender, Rothbard and their co-workers investigated the role 
of arginine oligomers as drug transporters for their ability to cross the biological 
barriers (156, 157). Wender, Siprashvili and others also reported (158) that flanking a 
core of consecutive arginines with cysteines improve the efficiency of the delivered 
gene not only in-vitro, but these new peptides also increased gene expression in both 
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Figure 8 . Poly-L-lysine, poly-L-arginine, poly-L-omithine and poly-L-histidine.
Chamarthy et al. (36) examined the binding, toxicity and gene delivery 
efficiency of three low molecular weight peptides, K-16, K10H6, and O10H6, 
derived from the peptides poly-L-omithine, poly-L-lysine and poly-L-histidine (Fig. 
8). They concluded that the in-vitro transfection with DNA complexed with cationic 
peptide O10H6 resulted in the highest level of gene expression and lower toxicity in 
comparison with K-16 and K10H6 cationic peptides.
Poly-L-lysine and poly-L-omithine (Fig. 8) were converted into amphiphilic 
colloid by incorporation of a distearoylphosphatidylethanolamine poly(ethylene 
glycol)-galactosamine conjugate (with the galactosamine unit at the distal end of the 
poly(ethylene glycol) moiety) into the polyamino acid formulations forming 
molecules that reduced their toxicity (159).
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On the other hand, the efficient entry of viruses and toxins into cells and the 
action of antibacterial peptides have directed some laboratories to test membrane- 
active agents as components to enhance transgenic expression in non-viral gene 
delivery. Wagner (15, 160) and Szoka (161) and their respective research groups 
have used synthetic peptides derived from the N-terminus of influenza virus 
haemagglutinin, for example INF6 , INF7, ENFA, INF 10, E5CA and the artificial 
amphipathic peptides such as EGLA-I (sequence listed in Table 2) and the rhino virus 
HRV2 VP-1 protein. These peptides may have specificity for endosomal pH due to 
acidic residues (glutamic and aspartic acids) aligning on one side of an amphipathic 
helix. At neutral pH, the negatively charged carboxylic groups destabilize the alpha- 
helical structure; acidification of the carboxylic groups shifts the equilibrium towards 
amphipathic helical structure, which promotes multimerization of peptides and/or 
membrane interaction.
The pH specificity can be enhanced by the introduction of additional glutamic 
acids into the peptide sequence (15). Additionally, the incorporation of a fusogenic 
peptide JTS-1 (Table 2), into either a DNA-liposome or a DNA liposome-polylysine- 
complex gave a 6-14-fold improvement in the expression level of luciferase (162). 
Also, amphiphilic basic peptides such as melittin (peptide from bee venom) (163), K5 
the cationic counterpart of E5 (164) and KALA the lysyl counterpart of GALA (96) 
(Table 2 ) exhibit efficient membrane fusion and permeabilization activities at both 
neutral and acidic pH. KALA, by its cationic nature, can form a complex with DNA, 
gave a 100-fold higher luciferase expression level than the polylysine-DNA complex 
in CV-1 cells. KALA itself was used for both DNA condensation and membrane 
destabilization, and thus induced increase in transfection efficiency (165). However, 
the KALA peptide cannot transfect primary airway epithelial cells (108).
Pichon et al. (35) designed uncharged peptides at neutral pH that neither 
interact with the plasma membrane nor with serum proteins, but become fusogenic in 
endosomes and this is achieved by making use of histidine. The imidazole group in 
histidine (Fig. 8 ) has a pKa value of 6.0 and in the acidic environment of the 
endosomal compartment (pH 5.5) induces a buffering effect due to imidazole 
protonation leads to destabilization of the endosome that leads to the escape of the
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delivered gene from the endosomal compartment before the lysosomal stage that will 
degrade DNA.
H5WYG peptide (GLFHAIAHFfflGGWHGLfflGWYG) was designed as 
analogous to the N-terminal segment of the HA-2 subunit of the influenza virus 
hemagglutinin (GLFGAIAGFffiGGWTGMIDGWYG) in which G-4, G-8 , E -l 1, T- 
15 and D-19 were replaced by histidyl residues and M -17 by a leucyl residue (166). 
Other peptides containing histidines together with other peptides that have application 
in non-viral gene therapy are presented in Table 2. Other lysosomal enzyme 
inhibitors that assist the escape of the endosome, such as catapsin D and chloroquine, 
are used to improve the efficiency of non-viral gene delivery formulations (108).



















Cationic lipids are the most studied among the non-viral vectors as indicated 
by their encouraging transfection results over cationic polymer and naked DNA 
strategies. Since the design and formulation of Lipofectin by Feigner and co-workers 
in 1987, the focus on non-viral vectors in general, particularly on cationic lipids for 
DNA delivery, has shown a remarkable increase worldwide in comparison with the 
attention to viral vectors. The focus on cationic lipids as non-viral vectors was also 
clear from the 10 reviews in one issue of the journal Current Medicinal Chemistry 
(Volume 10, Number 14, July 2003) as well as other reviews (171, 172) dealing with 
cationic lipids and their roles in gene delivery. In non-viral gene therapy, cationic 
lipids are either in the form of liposomal or non-liposomal formulations. Liposomal 
formulations are composed of two types of lipid, a cationic lipid for DNA 
condensation and a helper lipid to improve both the stability and the transfection 
efficiency of the formed liposomes. Most commonly used helper lipids are dioleoyl 
phosphatidylethanolamine (DOPE), dioleoyl phosphatidylcholine (DOPC) or 
cholesterol (Fig. 9). A liposomal formulation of the cationic lipid DDAB and DOPE 
interacted faster with model cell membrane than the same liposomal formulation 
containing cholesterol as the helper lipid (173).
Lipofectin was formulated as a liposomal formulation, a well studied drug 
delivery system, that contains 1/1 w/w cationic lipid, V-[l-(2,3-dioleyloxy) propyl]- 
N,N, V-trimethylammonium chloride (DOTMA), and the helper lipid DOPE, 
respectively (16). Neutral phospholipid DOPE is used in liposomal formulation to 
increase transfection efficiency as it has a membrane destruction promoting ability in 
acidic conditions (108). Following the formulation of DOTMA, efforts continue to 
improve the transfection efficiency of cationic lipid formulations by modifying the 
structure of the cationic lipid. These efforts led to the synthesis of the monovalent 
cationic lipids, DOTAP (A/-[l-(2,3-dioleoyloxy) propyl]-A, V, V-trimethyl ammonium 
(174) and GAP-DLRIE [V-(3-aminopropyl)-A/,V-dimethyl-2,3-bis(dodecyloxy)-l- 
propanaminium bromide] (175) (Fig. 10). Heyes et al. (176) investigated the change 
in degree of unsaturation of the monovalent cationic lipid (l,2-distearyloxy-/V^V- 
dimethyl-3-aminopropane (DSDMA). They concluded that increase in the degree of 
unsaturation improves gene silencing (siRNA delivery) efficiency.
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A different strategy is to increase the number of the positive charges of the 
cationic lipid in the liposomes. These efforts presented spermine lipid conjugates, 
2,3-dioleyloxy-A/-[2 (sperminecarboxamido) ethyl]-A,A-dimethyl-1 -propanaminium 
(DOSPA) that carry 4 positive charges at pH 7.2, and l,3-di-oleoyloxy-2-(6-carboxy- 
spermyl)-propylamid (DOSPER) (177) with 3 positive charges at pH 7.2 were 
synthesized (Fig. 10). Lipofectamine (Invitrogen) is a commercially available 






Figure 9. Neutral helper lipids DOPE, DOPC and cholesterol used in liposomal non- 
viral gene formulations.
Safinya, Ewert and co-workers synthesized and characterized MVL5 a 
multi valent cationic lipid with a double-branched head-group structure (Fig. 10) 
(178). They formulated the cationic lipid with DOPC. The lipid head-group is 
attached to an unsaturated c/s-C18 double chain hydrophobic moiety based on 3,4- 
dihydroxybenzoic acid. In their study, MVL5/DOPC liposomal formulation achieved
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Figure 10. Monovalent and multivalent cationic lipids used as non-viral gene 
delivery vectors in the form of liposomal formulations with the neutral helper lipids 
DOPE, DOPC and cholesterol.
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On the other hand, some research groups including us are focusing on the 
design, synthesis and formulation of novel simple non-liposomal cationic lipids. The 
lipopolyamine dioctadecylamidoglycylspermine DOGS (Fig. 11), commercialized as 
Transfectam (Promega), was the first non-liposomal formulation to be synthesized by 
Behr and co-workers (179). In the same work, they synthesized the lipospermine 
dipalmitoyl phosphatidylethanolamidospermine (DPPES) (Fig. 11) (179). Also, 
Dauty and Behr (180) investigated the control of the size of condensed DNA particles 
through monodisperse lipoplex population of 35-nm particles. They achieved this 
size through condensation of DNA molecules by cationic thiol-detergent, tetradecane- 
cysteine-omithine (C14-COm) detergent. The stability of DNA complexes with two 
cysteine surfactants (guanidinocysteine AT-decylamide, C10-CG, and omithinyl- 
cysteinyl-tetradecylamide, C14-CO) was investigated. These complexes were able to 
convert themselves, via oxidative dimerization, into cationic cystine lipids (181).
Scherman, Byk and co-workers synthesized the lipopolyamine RPR-120535 
(182), they also introduced a reduction sensitive disulfide bridge between the 
lipopolyamine and side chain entity by adding a third hydrophobic chain, RPR132688 
(Fig. 11), that improves the transfection efficiency over the non reducible RPR- 
120535 (183). Vierling and co-workers have synthesized fluorinated lipospermines 
that have hydrophobic and lipophobic chains (184, 185). They synthesized close 
analogues to DOGS, for example [F4C11][C14]-GS and [F4C11][F8C2]-GS (Fig.
11), to improve the transfection efficiency of non-viral vectors. Camilleri, Kirby and 
co-workers, have designed a series of cationic Gemini surfactants, for example 
GSC103 (Fig. 11) and GS11, that shows an increase in the level of gene expression 
compared to commercially available non-viral formulations (186, 187).
Gao and Huang, synthesized the first cholesterol based cationic lipid, (3 P [A^ - 
(A^Af'-dimethylaminoethane) carbamoyl] cholesterol) DC-Chol (188) (Fig. 12). 
Cholesterol derivatives can be used as liposomal formulation with DOPE or as non- 
liposomal formulation without the use of DOPE. In an effort to modify the structure 
of cationic cholesterol lipids to improve the transfection efficiency, Lehn and co­
workers have synthesized guanidinium cholesterol cationic lipids, bis-guanidinium 
spermidine cholesterol (BSGC) and bis-guanidinium tren cholesterol (BGTC) (Fig.























Figure 11. Spermine based lipopolyamines that can be used as non-liposomal 





Figure 12. DC-Chol and bis-guanidinium-spermidine-cholesterol (BGSC) and bis- 
guanidinium tren-cholesterol BGTC. TREN, tris (2-aminoethyl) amine.
BGTC shows a high efficiency when used as a non-liposomal cationic lipid. 
In addition, both BGTC and BGSC are efficient when used as liposomal formulation 
in combination with DOPE in a variety of cell lines (189). Thiocholesterol-based 
liposomal cationic lipid nano-lipoparticles (NLP) were synthesized in which a cell- 
binding ligand (TAT peptide) was incorporated with a negatively charged 
(glutathione) or zwitterionic (cysteine) reducing agent to the particle surface and 
compared with DOTAP/DOPE liposomes and PEI (87). This assembled NLP, with a 
zwitterionic surface, gave a larger transfection yield than the cationic thiocholesterol- 
based cationic liposomes at all concentrations tested, but still these are liposome 
formulations of some complexity. A simpler medicine would be a non-viral non- 
liposomal DNA formulation.
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The aims of this thesis are to design, synthese and formulate an efficient and 
non-toxic non-viral lipopolyamine vector for possible future in-vivo application. This 
could be achieved by the ability of our novel polyamine (spermine) conjugates to 
condense DNA, leading to the formation of nanoparticles that are suitable for gene 
delivery.
The study will focus on the lipopolyamines synthesized from the naturally 
occurring tetra-amine spermine by conjugation with C18 fatty acids that vary in their 
degree of unsaturation to investigate and understand the effect of degree of 
unsaturation on the gene delivering ability of the synthesized lipopolyamine. As the 
first step in gene delivery is the condensation of DNA and formation of nanoparticles, 
this step is monitored using ethidium bromide (EthBr) fluorescence quenching assay, 
light scattering assay and gel electrophoresis. Also, the ability of the synthesized 
lipopolyamines to condense DNA will be compared with well known, in the 
literature, efficient DNA condensing agents and with commercially available 
transfection agents.
The transfection efficiency of these novel lipopolyamines will be investigated 
in immortalized cancer cell line (HtTA) and in a panel of primary skin cell lines 
(FEK4, FCP4, FCP5, FCP7 and FCP8 ) that are known for their resistance to accept 
foreign genes. Also, the cytotoxicity of these compounds will be investigated in the 
same cell lines used in the transfection experiments.
Finally, characterization of the lipoplex nanoparticles will be investigated by 
measuring the particle size of the lipoplexes to understand the role of the lipoplex 
nanoparticle in improving the transfection efficiency. Also, zeta potential of the 






Polyamines (spermine, PEI and PLL), ethyl trifluoroacetate, 1,3- 
dicyclohexylcarbodiimide (DCC), W-hydroxy-benzotriazole (HOBt), oleic acid, 
oleoyl chloride, stearoyl chloride, linoleoyl chloride, triethylamine, ethidium bromide 
(EthBr), NaCl, (4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid) (HEPES), 
ethylenediaminetetraacetic (EDTA) sodium salt, tris-acetate-EDTA (TAE lx), 3-(4,5- 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), dimethyl sulfoxide 
(DMSO), ninhydrine, were routinely purchased from Sigma-Aldrich unless otherwise 
stated and used without purification.
Analytical thin layer chromatography (TLC) was conducted on pre-coated 
silica gel plates (Merck TLC aluminium sheets silica 60 F 2 5 4 )  from Merck (VWR 
International Ltd). Chromatograms were visualised with UV light (254 or 366 nm) or 
stained with ninhydrin (ninhydrin solution (0.5 % w/v in 97 % n-butanol and 3 % 
acetic acid) was used for spot detection. Flash column silica gel was obtained from 
BDH or Merck (VWR International Ltd). Preparative flash column chromatography 
was performed on columns packed with slurry of silica gel 60 (30-75 pm) suspended 
in the solvent system used in the separation process, either under gravity or under 
pressure with an aquarium-type pump. Sand (acid washed) used in the preparation of 
silica gel column was from Sigma-Aldrich. Sand was pre-washed with the solvent 
used in each separation system.
All organic solvents either GPR or HPLC grade were purchased from Fisher. 
Solvents were evaporated using a rotary evaporator (Buchi R411) in a temperature 
controlled water bath (Buchi B480) under a vacuum system PC2001 Vario™ 
(BrandTech Scientific). Luria Bertani (LB) broth, LB agar and ampicillin were 
purchased from Sigma-Aldrich. Escherichia coli competent cells JM109, high 
efficiency (>108 cfu/pg) were purchased from Promega.
LB broth and LB agar were prepared by dissolving the specified amount of 
powder in 1 L milliQ water according to the formula shown below. Both LB agar
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and LB broth were autoclaved (121 °C, 15 lb/inch2) for 30 mins, then both media 
were allowed to cool to 40 °C.
LB broth is composed of:
Tryptone (pancreatic digest of casein)
Yeast extract
NaCl
2 parts (10 g/L)* 
1 part (5 g/L)
1 part (5 g/L)
*(g/L) is the concentration of each ingredient after preparation of 20 g/L milliQ water 
as recommended by the manufacturer.
LB agar is composed of:
*(g/L) is the concentration of each ingredient after preparation of 35 g/L milliQ water 
as recommended by the manufacturer.
Cell culture chemicals used for media preparation were purchased from Gibco 
used without further purification. Lipofectin and Lipofectamine were purchased from 
Invitrogen, Transfectam® was from Promega and Foetal calf serum FCS was from 
PAA laboratories. Autoclaved (sterile) Phosphate Buffered Saline (PBS) pH 7.3 
contains, 0.01 M phosphate buffer, 0.0027 M KC1 and 0.137 M NaCl in MilliQ water. 
Trypsin was diluted to a working concentration at 0.25 % w/v with PBS.
pEGFP vector (4.7 kbp) was purchased from Clontech, pSV-p-galactosidase 
(pp-gal) vector (6 .8  kbp) obtained from Promega, and deoxyribonucleic acid from 
calf thymus, Activated and lyophilized powder purchased from Sigma-Aldrich. 
Deoxyribonucleic acid, from herring sperm purchased from Sigma-Aldrich. Plasmids 
were isolated and purified using HiSpeed™ plasmid Maxi kit, obtained from Qiagen. 
MilliQ water was obtained from a MilliQ PF plus system with ultra-filtration 
cartridge, Millipore Ltd., free of DNase and RNase.
Agar
Tryptone (pancreatic digest of casein)
Yeast extract
NaCl
3 parts (15 g/L)*
2 parts (10 g/L) 
1 part (5 g/L)
1 part (5 g/L)
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Suppliers
Chemicals, reagents, kits, solvents, plasmids, disposables, instruments were 
obtained from UK suppliers (unless otherwise stated):
1. BDH, VWR International Ltd, Merck House, Poole, Dorset.
2. Beckman Coulter, Oakley Court, Kingsmead Business Park, London Road, 
High Wycombe, Buckinghamshire.
3. Becton Dickinson Biosciences, 21 Between Towns Road, Cowley, Oxford.
4. Biochrom Ltd, Cambridge Science Park, Milton Road, Cambridge.
5. Bio-Rad Laboratories Ltd., Bio-Rad House, Maxted Road, Hemel 
Hempstead, Hertfordshire.
6 . BrandTech Scientific, 11 Bokum Rd, Essex.
7. Buchi, Buchi UK Ltd, 5 Whitegate Business Centre, Jardine Way, (off) 
Broadway, Chadderton, Oldham.
8 . Clontech, Clontech BD Biosciences, Between Towns Road, Cowley Oxford.
9. Corning Ltd., Fisher Scientific UK Ltd., Bishop Meadow Road, 
Loughborough, Leicestershire.
10. Eppendorf, Fisher Scientific UK Ltd., Bishop Meadow Road, Loughborough, 
Leicestershire.
11. Falcon, Fisher Scientific UK Ltd., Bishop Meadow Road, Loughborough, 
Leicestershire.
12. Fisher, Fisher Scientific UK Ltd., Bishop Meadow Road, Loughborough, 
Leicestershire.
13. Gibco, Gibco-Invitrogen Ltd, 3 Fountain Drive, Inchinnan Business Park, 
Paisley.
14. Grant, Keison Products, Chelmsford, Essex.
15. Heraeus, Kendro Laboratory Products Pic, Stortford Hall Park, Bishop's 
Stortford, Hertfordshire.
16. Intermed MDH Ltd., Kenn Road, Clevedon, Somerset.
17. Invitrogen Ltd, 3 Fountain Drive, Inchinnan Business Park, Paisley.
18. Kodak, Hemel Hempstead, Hertfordshire.
19. Malvern Instruments Ltd, Enigma Business Park, Grovewood Road, 
Malvern, Worcestershire.
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20. Merck, VWR International Ltd., Merck House, Poole, Dorset.
21. Millipore UK Ltd., Units 3&5 the Courtyards, Hatters Lane, Watford.
22. New Brunswick Scientific, 17 Alban Park, Hatfield Road, St. Albans, 
Hertfordshire.
23. NUNC, Fisher Scientific UK Ltd Bishop Meadow Road, Loughborough, 
Leicestershire.
24. PA A laboratories Ltd, 1 Technine, Guard Avenue, Houndstone Business 
Park, Yeovil, Somerset.
25. Promega, Delta House, Southampton Science Park, Southampton.
26. Qiagen Ltd., Qiagen House, Fleming Way, Crawley, West Sussex.
27. Rank Brothers Ltd., 56 High Street, Bottisham, Cambridge
28. Sanyo, Integrated Services TCP Inc., Palisades Park, New Jersey, USA.
29. Sigma-Aldrich Company Ltd. The Old Brickyard, New Road, Gillingham, 
Dorset.
30. Syngene, Beacon House, Nuffield Rd., Cambridge.
31. Wilovert Hund, the Helmut Hund Ltd. Company, Helmut Hund GmbH, 
Wilhelm-Will-Str. 7, Wetzlar, Germany.
Methods
Amplification and purification of plasmid DNA
pEGFP and pp-gal plasmids
DNA plasmid encoding enhanced green fluorescent protein (EGFP) under 
CMV promoter, obtained from Clontech, was used as reporter gene in this study. The 
pSV-(3-galactosidase control vector (pp-gal) with SV40 early promoter and enhancer 
drive transcription of the lacL gene, which encodes the P-galactosidase enzyme, from 
Promega, was used in DNA condensation studies. DNA can amplifie on a small scale 
(less than 20 jig yield) using Minipreps Kit from Promega or in a large scale (up to 
750 |ig) using Qiagen HiSpeed™ plasmid Maxi kit (Qiagen Ltd.). Large-scale 
preparation of plasmids DNA protocol, described below, is based on a modified 
method described by Sambrook et al. (190) and using Qiagen anion-exchange resin.
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A positively charged diethylaminoethanol (DEAE) resin was used to separate 
negatively charged phosphate groups of DNA, by properly adjusting the NaCl 
concentration of the elution solution. 1.2-1.6 M Aqueous NaCl solution was used to 
elute DNA and separate the plasmid.
Plasmids amplification
Both plasmids, pEGFP and pp-gal, were transformed into E. coli JM 109 
bacterial host strain. The transformed cells were grown in larger quantities (0.2-0.3 
L) of LB broth supplemented with 100 mg/L ampicillin as follows:
LB broth was prepared by dissolving LB broth base powder (10 g) in 500 ml 
milliQ water. LB agar, for the preparation of agar plates, was prepared by dissolving 
LB agar powder (17.5 g) in 500 ml milliQ water. Both LB agar and LB broth were 
autoclaved (121 °C, 15 lb/inch2) for 30 mins. Then, both media were left to cool 
down to 40 °C. Ampicillin solution (0.1 g/ml in milliQ water, 500 pi) was added to 
both (500 ml) media and mixed well.
Sterile LB broth can be kept at 20 °C in a tightly closed bottle for one month. 
To prepare LB agar plates, about 10 ml of warm LB agar was poured in a 9 cm plate, 
obtained from Fisher, using aseptic techniques. LB agar was then left for 30 mins to 
cool. LB agar plates were then incubated for 20 mins in a hot room (37 °C) upside 
down until dry. The solidified agar plates were kept in a cold room (4 °C) for use 
within 3 months.
Transformation of competent cells and plasmid propagation
Heat shock technique was used for E. coli JM 109 transformation. Sterile 
Falcon polypropylene tubes (50 ml) obtained from Falcon were chilled on ice one per 
transformation. Competent cells (E. coli JM 109) were thawed from -80 °C on ice. 
The thawed competent cells were gently mixed by flicking, and then 100 pi were 
transferred to each chilled tube. For each 100 pi competent cells, 50-100 ng of DNA 
was added and mixed by flicking. Tubes were placed on ice for 10 mins. Cells were
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heat-shocked for 45-50 seconds in a temperature controlled water bath (Grant) at 42 
°C without shaking. Tubes then immediately put on ice for 2 mins. 900 pi of cold (4 
°C) LB broth was added and the tubes were incubated for 60 mins at 37 °C with 
shaking (200 rpm) using a temperature-controlled flask shaker (New Brunswick 
Scientific).
For each transformation, 100 pi transformed cells were plated on LB agar 
medium containing 100 pg/ml ampicillin. Plates were then incubated upside down 
for 18 h in an incubator (Heraeus Instruments) at 37 °C. A single colony was isolated 
from LB plate and incubated in 2 ml of LB broth containing ampicillin (100 pg/ml) in 
a 50 ml Falcon tube. The culture was grown for 8  h at 37 °C with shaking (200 rpm). 
The culture was then scaled up by adding the starter culture (2 ml) into a flask (at 
least one litre size flask) containing LB broth (250 ml) with ampicillin (100 pg/ml). 
The flask was then incubated for 18 h at 37 °C with shaking (200 rpm) using a 
temperature-controlled flask shaker.
Long term storage of transformed cells
A single colony was isolated from LB plate and incubated in 1-2 ml of LB 
broth containing ampicillin. The culture was grown for 8  hrs. Glycerol solution (30 
% v/v) was prepared and sterile filtered. The culture (0.5 ml) was mixed with 0.5 ml 
of sterile glycerol solution and transferred to a cryo-preservation vial, obtained from 
Coming Ltd., then stored at -80 °C.
Plasmids isolation and purification
After incubating the 250 ml bacterial culture flask for 18 h at 37 °C with 
shaking ( 2 0 0  rpm) using a temperature-controlled flask shaker, cells were harvested 
by centrifugation, using Beckman floor centrifuge model J2-MC (Beckman Coulter) 
at 6000 rpm using Beckman JA-10 rotor for 15 mins at 4 °C. Cell pellets, obtained 
after completely removing the supernatant liquid, were resuspended in 1 0  ml ice- 
cooled PI buffer (50 mM Tris-Cl, 10 mM EDTA and 100 pg/ml RNase A, pH 8.0), 
complete mixing was allowed by vortexing until no cell clumps remain. Then, 10 ml
38
of P2 lysis buffer (200 mM NaOH, 1 % w/v sodium dodecyl sulfate) was added to the 
cell suspension. The tube was then inverted gently 4 times and incubated at 20 °C for 
5 mins. Ice-cooled P3 neutralisation buffer (10 ml, 3.0 M potassium acetate, pH 5.5) 
was added into the cell lysates and the mixture was inverted gently 4 times. The 
lysate was poured into the barrel of the Qiafilter cartridge and incubated for 10 mins, 
with the outlet nozzle closed.
The HiSpeed Maxi Tip (a syringe column with a filtration unit) was 
equilibrated with 10 ml buffer QBT (750 mM NaCl, 50 mM 3-|7V-morpholino] 
propanesulfonic acid (MOPS), 15 % v/v isopropanol, 0.15 % v/v Triton X-100) and 
the column was allowed to empty by gravity flow. The outlet nozzle cap of the 
Qiafilter cartridge was removed and the plunger was gently inserted into the 
cartridge. The filtrate was collected into the equilibrated Maxi Tip and allowed to be 
filtered through the resin. After that, 60 ml of buffer QC (1.0 M NaCl, 50 mM 
MOPS, 15 % v/v isopropanol, pH 7.0) was added to wash the HiSpeed Maxi Tip. 
Entrapped DNA in the resin was eluted by adding 15 ml of buffer QF (1.25 M NaCl, 
50 mM Tris-Cl, 15 % v/v isopropanol, pH 8.5) into the tip. The eluted solution was 
kept in a 50 ml Falcon tube. Isopropanol (10.5 ml) was then added and mixed well to 
precipitate the DNA, then the mixture was incubated for 5 mins at 20 °C.
A DNA collection unit (QIA precipitator tip) was attached to the nozzle of a 
30 ml syringe from which a plunger was removed. Then, the eluate/isopropanol 
mixture that has the precipitated DNA was added to the precipitator unit, and the 
plunger was inserted into the syringe using constant pressure. DNA was entrapped in 
the precipitator unit. Then, the tip and the plunger were removed from the syringe. 
After that, the tip was reconnected again to the syringe nozzle and 2 ml of 70 % v/v 
EtOH was added into the syringe. DNA was washed by pressing EtOH through the 
QIA precipitator using inserted plunger at a constant pressure. The tip and the 
plunger were removed from the syringe and DNA was dried by pushing air through 
the precipitator 2-3 times and the outlet nozzle of the precipitator was dried with 
absorbent paper.
To elute the DNA in the tip, 1 ml of buffer TE (lOmM Tris-HCl, ImM EDTA, 
pH 8 ) was added into a new 5 ml syringe to which the precipitator tip was connected.
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The plunger was attached and pushed gently. The eluted solution was collected in an 
ultracentrifuge tube (1.5 ml), obtained from Eppendorf Ltd. The previous step was 
repeated by the transfer of the eluate in the 1.5 ml ultracentrifuge tube to the 5 ml 
syringe to which the precipitator tip was connected and eluted again in the same 1.5 
ml tube. DNA solution was stored at -20 °C.
Analysis of the purification procedure
The DNA obtained can be quantified by the maximum UV absorption at 260 
nm. This wavelength is an average of the absorption of the individual nucleotides 
which vary between 256 -  281 nm. DNA was determined by measuring the 
maximum absorption at 260 nm for nucleic acids and 280 nm for proteins. Ratios of 
A260/A280 between 1.75-1.90 are considered acceptable for DNA purity (191, 192).
Plasmid DNA yields and quality were analyzed spectrophotometrically using 
Gene Quant IIRNA/DNA calculator (Biochrom Ltd). Plasmid DNA sample 5 pi was 
diluted to 100 pi with TE buffer, in a microcuvette. The absorbance was measured at 
260 nm (A260) and 280 nm (A28o)- TE buffer 100 pi was used as a standard reference. 
The calculation for DNA concentration by dilution factor 20, and a conversion factor 
for double stranded dsDNA, 50 pg/ml/A26o.
Lipopolyamines synthesis
Spermine was used as the starting material for the synthetic process that was 
protected on both the primary amino functional groups. Then acylation of the 
protected spermine was carried out, to covalently bound two fatty acyl chains on the 
free secondary amines of the protected spermine, either by the fatty acid or fatty acyl 






Figure 1. Our novel lipospermines, A^^-distearoyl spermine, A^^-dioleoyl 
spermine and A^^-dilinoleoyl spermine investigated in this study.
Synthesis of A^,A9-dioIeoyI spermine
Synthesis of A^jA^-ditrifluoroacetyl spermine
Spermine lg (4.94 mmole) was dissolved in methanol (MeOH, 20 ml). A 
primary amino protecting group, ethyl trifluoroacetate (2.2 eq) was added drop wise. 
The reaction mixture was then stirred using a magnetic stirrer (Buchi, Buchi 
Labortechnik) for 18 h at 25 °C. The solvent was evaporated to dryness in vacuo to
i |  ^
form N ,N -ditrifluoroacetyl-1,12-diamino-4,9-diazadodecane which was 
homogenous on silica gel thin-layer chromatography (MeOH-conc. aq. NH3 4:1 v/v) 
with Rf = 0.8 compared to the starting substance spermine Rf = 0.1 using the same 
solvent system. Ninhydrin solution (0.5 % w/v in 97 % n-butanol and 3 % acetic 
acid) was used for spot detection.
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Synthesis of A^ 1^ V12-ditrifluoroacetyl-iV4^ V9-dioleoyl spermine
DCC 2.5 eq, HOBt 0.2 eq and oleic acid (2.2 eq) were added to the 
diprotected spermine solution in dichloromethane CH2CI2 and MeOH (1:1 v/v, 15 
ml). The reaction solution was stirred for 18 h at 25 °C. The solvent was evaporated 
to dryness in vacuo. The tetra-amide residue was re-dissolved in CH2CI2 for DCU to 
precipitate. The solution was then filtered to give pale yellow filtrate that was 
evaporated to dryness in vacuo to form A^^-dioleoyl-A 1 ,/V12-ditrifluoroacetyl-1,12- 
diamino-4,9-diazadodecane. The tetra-amide was detected on silica gel thin-layer 
chromatography by the disappearance of the diprotected spermine 
ditrifluoroacetyl-l,12-diamino-4,9-diazadodecane) spot and compared to the starting 
substance spermine R f  = 0.1 and oleic acid R f  = 0.2. The TLC plate was observed 
under UV for C=C double bond of oleic acid, and then derivatised with ninhydrin 
solution (0.5 % w/v in 97 % n-butanol and 3 % acetic acid) was used for spot 
detection.
Deprotection of iV^^-ditrifluoroacetyl-A^^-dioleoyl spermine
For the removal of the di-trifluoroacetyl groups, the tetra-amide was dissolved 
in methanol and the pH of the solution was increased by saturating with ammonia 
gas, then it was left for 18 h at 25 °C with stirring. The solution was then evaporated 
to dryness in vacuo, to remove ammonia and all solvents, to give a residue which was 
purified by column chromatographic elution over flash silica gel using two mobile 
phase systems. First system, CH2Cl2-MeOH 5:3 v/v, to remove unprotonated 
compounds in the reaction mixture (e.g. oleic acid and remaining DCU). This 
followed by elution with CH2Cl2-MeOH-conc. aq. NH3 25:10:1 v/v/v to afford A^^V9- 
dioleoyl spermine that was homogenous on silica gel thin-layer chromatography 
CH2Cl2-MeOH-conc. aq. NH3 25:10:1 v/v/v R f  = 0.44. The lipopolyamine was 
characterized by low and high-resolution mass spectroscopy (HRMS) measured on a 
VG Autospec Q spectrometer.
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Synthesis of iV^A^-distearoyl spermine
Synthesis of TV^^-ditrifluoroacetyl-T^jTV^distearoyl spermine
Triethylamine 2.5 eq, stearoyl chloride 2.2 eq were added to the diprotected 
spermine solution in CH2CI2 and MeOH (1:1 v/v, 15 ml). The reaction solution was 
stirred for 72 h at 20 °C. The solvent was evaporated to dryness in vacuo to form 
TN^^-distearoyl-TV1,7V12-ditrifluoroacetyl-1,12-diamino-4,9-diazadodecane. The tetra- 
amide spermine was detected on silica gel thin-layer chromatography by the 
disappearance of the diprotected spermine (TV1 ,7V12-ditrifluoroacetyl-1,12-diamino-4,9- 
diazadodecane) spot and compared to the starting material spermine R f  = 0.1 and 
oleic acid R f  = 0.2.
Deprotection of TV1^ V12-ditrifluoroacetyl-TV4^ V9- distearoyl spermine
For the removal of the di-trifluoroacetyl groups, the tetra-amide was dissolved 
in methanol and the pH of the solution was increased by saturating with ammonia 
gas, then it was left for 18 h at 25 °C with stirring. The solution was then evaporated 
to dryness in vacuo, to give a residue which was purified by column chromatographic 
elution over flash silica gel using two mobile phase systems. CH2Cl2-MeOH 5:3 v/v, 
followed by elution with CH2Cl2-MeOH-conc. aq. N H 3  25:10:1 v/v/v to afford TV4,7V9- 
distearoyl spermine that was homogenous on silica gel thin-layer chromatography 
CH2Cl2-MeOH-conc. aq. N H 3  25:10:1 v/v/v R f  = 0.41 and was characterized by 
HRMS.
Synthesis of TV^TV -^dilinoleoyl spermine
Synthesis of A^ 1^ V12-ditrifluoroacetyl-A^^V9-dilinoleoyI spermine
Triethylamine 2.5 eq, linoleoyl chloride 2.2 eq were added to the diprotected 
spermine solution in pyridine. The reaction solution was stirred for 72 h at 20 °C.
The solvent was evaporated to dryness in vacuo to form A^^-dilinoleoyl-TV1,7V12- 
ditrifluoroacetyl-1,12-diamino-4,9-diazadodecane. The tetra-amide spermine was 
detected on silica gel thin-layer chromatography by the disappearance of the
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diprotected spermine (/V1 ,/V12-ditrifluoroacetyl-1,12-diamino-4,9-diazadodecane) spot 
and compared to the (original) starting materials spermine R f  = 0.1 and oleic acid R f  =
0.2. The TLC plate was observed under UV for C=C double bond of linoleic acid, 
and then derivatised with ninhydrin solution.
Deprotection of iV1^ V12-ditrifluoroacetyl-A^4^ V9-dilinoleoyl spermine
For the removal of the di-trifluoroacetyl groups, the tetra-amide was dissolved 
in methanol and the pH of the solution was increased by saturating with ammonia 
gas, then it was left for 18 h at 25 °C with stirring. The solution was then evaporated 
to dryness in vacuo, to give a residue which was purified over silica gel CH2CI2- 
MeOH 5:3 v/v, followed by CH2Cl2-MeOH-conc. aq. NH3 25:10:1 v/v/v to afford 
A^^-dilinoleoyl spermine that was homogenous on silica gel thin-layer 
chromatography CH2Cl2-MeOH-conc. aq. NH3 25:10:1 v/v/v R f  = 0.49 and was 
characterized by HRMS.
DNA condensation studies
DNA condensation was carried out to investigate the neutralization of the 
negative charges of the phosphate groups on the DNA back bone. Neutralization of 
the negative charges leads to collapse of DNA into a more compact structure 
(nanoparticles). Nanoparticles formation improves the delivery across cellular 
barriers (as described before) and hence increases the transfection efficiency of the 
delivered DNA. These studies include:
1. Ethidium bromide fluorescence quenching assay
2. Light scattering assay
3. Gel electrophoresis study
Ethidium bromide fluorescence quenching assay
Each concentration of the DNA (calf thymus DNA, herring testes, pEGFP and
p(3-gal) stock solutions (approximately 1 |ig/pl) was determined spectroscopically and
6  jig (approximately 6  pi) of DNA was diluted to 3 ml with HEPES buffer (20 mM
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NaCl, 2 mM HEPES,10 pM EDTA, pH 7.4) in a glass cuvette stirred with a micro- 
flea. Immediately prior to analysis, EthBr solution (3 pi, 0.5 mg/ml) was added to the 
stirring solution and allowed to equilibrate for 1 0  mins.
Aliquots (5 pi) of spermine (10 x 0.04 mg/ml, and then 5 x 0.2 mg/ml) were 
then added to the stirring solution and the fluorescence measured after 1 min 
equilibration using Perkin-Elmer LS 50B luminescent spectrometer (X«xcit = 260 nm 
and Acmiss = 600 nm with slit width 5 nm) while stirring using an electronic stirrer 
(Rank Brothers Ltd.). The total polyamine solution added to the DNA solution did 
not exceed 5 % of the total volume of the solution, so no correction was made for 
sample dilution. The fluorescence was expressed as the percentage of the maximum 
fluorescence when EthBr was bound to the DNA in the absence of competition for 
binding and was corrected for background fluorescence of free EthBr in solution 
(193). This correction and the subsequent normalization were performed using an 
Excel spreadsheet.
In the case of poly-L-lysine (PLL, average molecular weight. 9,600 Da (PLL 
9.6k) and 27000 Da (PLL 27k) the same amounts of DNA were used and aliquots of 
PLL 9.6k were (5 pi) of (10 x 0.08 mg/ml, and then 6  x 0.2 mg/ml) were used. For 
PLL 27k, aliquots of (5 pi) of (8  x 0.16 mg/ml) were used. Aliquots were then added 
to the stirring solution of 3 ml HEPES buffer in a glass cuvette that have 6  pg DNA 
and 1.5 pg EthBr. The fluorescence was measured after 1 min equilibration using 
Perkin-Elmer LS 50B luminescent spectrometer (AexCit = 260 nm and Aemiss = 600 nm 
with slit width 5 nm) while stirring using an electronic stirrer (Rank Brothers Ltd.). 
The total polyamine solution added to the DNA solution did not exceed 5 % of the 
total volume of the solution, so no correction was made for sample dilution. The 
fluorescence was expressed as the percentage of the maximum fluorescence when 
EthBr was bound to the DNA in the absence of competition for binding and was 
corrected for background fluorescence of free EthBr in solution. This correction and 
the subsequent normalization were performed using an Excel spreadsheet.
In the case of polyethylenimine (PEI average molecular weight 2000 Da (PEI 
2k) and 60000 Da (PEI 60k)) the same amounts of DNA were used and aliquots of
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PEI 2k were (5 jil) of (10 x 0.3 mg/ml) were used. For PEI 60k, aliquots of (5 jllI) of 
(10 x 0.3 mg/ml) were used. Aliquots were then added to the stirring solution of 3 ml 
HEPES buffer in a glass cuvette that have 6  |ig DNA and 1.5 jig EthBr. The 
fluorescence was measured after 1 min equilibration using Perkin-Elmer LS 50B 
luminescent spectrometer (A^ Xcit = 260 nm and Remiss = 600 nm with slit width 5 nm) 
while stirring using an electronic stirrer (Rank Brothers Ltd.). The total polyamine 
solution added to the DNA solution did not exceed 5 % of the total volume of the 
solution, so no correction was made for sample dilution. The fluorescence was 
expressed as the percentage of the maximum fluorescence when EthBr was bound to 
the DNA in the absence of competition for binding and was corrected for background 
fluorescence of free EthBr in solution. This correction and the subsequent 
normalization were performed using an Excel spreadsheet.
In the case of the synthesized lipopolyamines, A^^-distearoyl spermine, 
A^^-dioleoyl spermine and A^^-dilinoleoyl spermine, the lipopolyamines were 
prepared as stock solutions using absolute EtOH as solvent and diluted with HEPES 
buffer to the specified concentrations directly before use. Aliquots were added to the 
stirring solution of 3 ml HEPES buffer in a glass cuvette that have 6  jig DNA and 1.5 
jig EthBr. The fluorescence was measured after 1 min equilibration using Perkin- 
Elmer LS 50B luminescent spectrometer (XeXCit = 260 nm and Xemiss = 600 nm with slit 
width 5 nm) while stirring using an electronic stirrer (Rank Brothers Ltd.). The total 
lipopolyamine solution added to the DNA solution did not exceed 5 % of the total 
volume of the solution, so no correction was made for sample dilution. The 
fluorescence was expressed as the percentage of the maximum fluorescence when 
EthBr was bound to the DNA in the absence of competition for binding and was 
corrected for background fluorescence of free EthBr in solution. This correction and 
the subsequent normalization were performed using an Excel spreadsheet.
In the case of the commercially available transfecting agents, Lipofectin, 
Lipofectamine (available as liposomal formulations) and the non-liposomal 
formulation Transfectam®, aliquots were added to the stirring solution of 3 ml 
HEPES buffer in a glass cuvette that have 6  |ng DNA and 1.5 pg EthBr. The 
fluorescence was measured after 1 min equilibration using Perkin-Elmer LS 50B
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luminescent spectrometer (AeXCit = 260 nm and A^miss = 600 nm with slit width 5 nm) 
while stirring using an electronic stirrer (Rank Brothers Ltd.). The total 
lipopolyamine solution added to the DNA solution did not exceed 5 % of the total 
volume of the solution, so no correction was made for sample dilution. The 
fluorescence was expressed as the percentage of the maximum fluorescence when 
EthBr was bound to the DNA in the absence of competition for binding and was 
corrected for background fluorescence of free EthBr in solution. This correction and 
the subsequent normalization were performed using an Excel spreadsheet.
The DNA polyamine complex composition is expressed as N/P 
(ammonium/phosphate) as follows:
^ p _  Ammonium equivalents o f the cationic compound 
Phosphate equivalents o f the DNA used
Ammonium equivalents of the polyamine were determined from pK& value of 
each amino group at pH 7.4 (HEPES buffer) according to Henderson-Hasselbach 
equation:
pH = pga + log10 l ^ a t e b a s e ]  [2]
[conjugate acid\
The charge ratio was calculated according to the ammonium/phosphate (+/-) 
charge ratio of the investigated lipopolyamines to DNA. For DNA it was calculated 
as 330 g/mole is DNA that contains one negative charge (5). In the case 
distearoyl spermine it was calculated as 735.7g/mole that contains two primary amino 
groups that are protonated (positively charged) at pH 7.4. In the case of P tjs t-  
dioleoyl spermine it was calculated as 731.26 g/mole that contains two primary amino 
groups that are protonated (positively charged) at pH 7.4. In the case of N^N9- 
dilinoleoyl spermine it was calculated as 727.7g/mole that contains two primary 
amino groups that are protonated (positively charged) at pH 7.4.
In the case of the commercially available lipopolyamine (DOGS, 
Transfectam®) it was calculated as 1263 g/mole that contains three nitrogens (more
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accurately 2.92) that are protonated at pH 7.4, although Transfectam® has four 
nitrogens (two secondary amines and two primary amines) that can be protonated in 
strong acid.
Charge ratios of PEI 2k and PEI 60k were calculated by multiplying the 
weight ratio of PEI to DNA by 1.9 (75). In the liposomal formulation Lipofectin, the 
cationic lipid DOTMA carries 1 positive charge (ammonium eq/mole) (16) while the 
cationic lipid DOSPA in the Lipofectamine formulation carries 4 positive charges 
(ammonium eq/mole) (185). In the non-liposomal formulations, Transfectam® carries 
3 positive charges (185), while A^^-distearoyl spermine, A^JS^-dioleoyl spermine 
and A^JN^-dilinoleoyl spermine each lipopolyamine carries 2 positive charges.
Binding constant calculation
From EthBr fluorescence quenching results for DNA interaction with the 
condensing agent, the binding constant of the DNA condensing agent (vector) to 
DNA can be calculated and compared by the loss of EthBr fluorescence as a function 
of DNA condensing agent concentration. The drug concentration producing 50 % 
inhibition of fluorescence is approximately inversely proportional to the binding 
constant (194). Denny and co-workers (195) established the binding equations of 
DNA to both EthBr and vectors as follows:
[DNA] + [vector] [DNA—vector] [3]
[DNA]+[EthBr\ [DNA-EthBr] [4]








[vector] x [DNA -  EthBr]
[7]
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At 50 % residual fluorescence, the ratio of [DNA-vector] over [DNA-EthBr] 
equal to 1. So, the “apparent” equilibrium constant (K^) of polyamine binding was 
calculated, taking into account that Morgan et al. (194) reported that the binding
7 1constant of ethidium bromide was 10 M' , as follows:
, [Ef/iBrlxlO7Kb (vector) = — r— —  [8 ]
\yector\
The concentration of the condensing agent producing 50 % intercalated EthBr 
fluorescence inhibition was calculated experimentally.
Light scattering assay
A light scattering experiment was designed to investigate particle formation as 
a result of DNA condensation by polyamines and lipopolyamines. The apparent UV 
absorbance at 320 nm, where there is no DNA absorbance interference above 300 nm 
was measured showing light scattering (i.e. decreased light transmission) (145).
DNA (linear calf thymus or herring testes) was purchased from Sigma- 
Aldrich. Plasmids DNAs pEGFP and p(3-gal were prepared by MaxiPrep as 
mentioned before. All DNA solutions were diluted using TE buffer and their 
concentrations were measured by GeneQuant II spectrophotometer. HEPES buffer 
was made of 2 mM HEPES, 20 mM NaCl, 10 pM EDTA, and MilliQ water, the pH 
was adjusted to 7.4 with aqueous NaOH solution. HEPES buffer was filtered through 
a 0 . 2 2  pm membrane prior to use.
Spermine (17 mg) was dissolved in MilliQ water (1 ml as a stock solution). 
DNA 60 pg, of 1 mg/ml solution) diluted to 3 ml with HEPES buffer in a cuvette 
with a micro-flea, and the concentration determined spectroscopically (Milton Roy 
Spectronic 601 spectrometer, 1 cm path length, 3 ml cuvette). UV measurement of 
DNA in buffer was performed and adjusted to zero. Then, aliquots (5 pi) of 
spermine (10 x 0.4 mg/ml, and then 5 x 2.0 mg/ml) were then added to the stirring
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solution and the absorbance (light scattering) at 320 nm measured after 1 min stirring 
to allow the mixture to reach equilibrium. The Apparent UV absorbance values were 
then plotted against N/P ratios.
In the case of poly-L-lysine (PLL 9.6k and PLL 27k) the same amounts of 
DNA were used and aliquots of PLL 9.6k were (5 pi) of (10 x 0.8 mg/ml, and then 6  
x 2.0 mg/ml) were used. For PLL 27k, aliquots of (5 jul) of ( 8  x 1.6 mg/ml) were 
used. In the case of polyethylenimine (PEI 2k and PEI 60k) the same amounts of 
DNA were used and aliquots of PEI2k were (5 pi) of (10 x 3.0 mg/ml) were used.
For PEI 60k, aliquots of (5 pi) of (10 x 3.0 mg/ml) were used. In the case of the 
synthesized lipopolyamines, A^^-distearoyl spermine, A^^-dioleoyl spermine and 
A^^-dilinoleoyl spermine, the lipopolyamines were prepared as stock solutions 
using absolute EtOH as solvent and diluted with HEPES buffer to the specified 
concentrations directly before use.
del electrophoresis study
1 gm of agarose (electrophoresis grade, Gibco) was added to 100 ml of lx 
TAE (Tris-Acetate-EDTA, 40 mM Tris-Acetate and 1 mM EDTA) buffer. The 
mixture was then heated in a microwave oven to boiling for 2  mins with swirling the 
flask 3-4 times while boiling to dissolve the agarose. When the agarose is completely 
dissolved, the solution was then allowed to cool to a consistency that can be poured. 
Then EthBr was added to a concentration of 1.0 pg/ml. When the gel is cooling 
down, the gel tray was securely sealed at the ends with tape strips to form a fluid-tight 
seal. The comb was placed over the gel tray. After that, when agarose has cooled to 
about 60°C, the agarose was poured into the gel tray to a depth of 4-8 mm. Then the 
gel was allowed to set at room temperature for 30 mins followed by refrigeration for 
further 15 mins for complete solidification of the gel. The comb was removed from 
the solidified gel as well as the tape from the edges of the gel tray. The gel was then 
transferred to the electrophoresis chamber, Kodak Biomax QS 710 (Kodak), and 
submerged into the electrophoresis buffer (TAE buffer).
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For pEGFP lipoplex formation, two solutions were prepared for each well, 
solution A (DNA) and solution B (lipopolyamine). Solution A was prepared by 
diluting DNA solution (0.5-1 jug/well) to 5 pi using lx  TAE buffer, in a sterile 1.5 ml 
micro-centrifuge tube obtained from Eppendorf Ltd., gently mixed using a vortex, for 
2 secs and incubated for 30 mins at room temperature. Solution B was prepared by 
diluting the lipopolyamine solution to 10 pi using lx  TAE buffer, in a sterile 1.5 ml 
micro-centrifuge tube, gently mixed using a vortex, for 2 secs and incubated for 30 
mins at room temperature. The complex was then prepared by mixing solution A and 
B (vortex) for 1 sec then incubated for 20 mins at room temperature.
Each lipopolyamine used in solution B was at a different volume according to 
the required N/P ratio for 0.5-1 pg DNA/well, as described before in the N/P 
determination section for EthBr assay. In the non-liposomal formulations, 
Transfectam®, DOGS carries 3 positive charges (185), while A^^-distearoyl 
spermine, A^^-dioleoyl spermine and A^^-dilinoleoyl spermine each of these 
lipopolyamines carries 2  positive charges (on their two primary amines).
Samples (15 pi) of plasmid DNA (0.5 pg), either free or complexed with the 
lipopolyamine (according to the charge ratio) were mixed with the loading dye 
(blue/orange loading dye 6 X, Promega) and loaded into the wells. The loading dye is 
used at a IX final concentration and contains 0.03 % xylene cyanol FF (4 kbp 
migration), 0.03 % bromophenol blue (300 bp migration), 0.4 % orange G (50 bp 
migration), lOmM Tris-HCl (pH 7.5) and 50mM EDTA (pH 8 ). Electrophoresis at 75 
V/cm (Bio-Rad Power Pack 300, Bio-Rad Laboratories Ltd) was carried out for 1 
hour. The gel was removed and the (unbound) free DNA in the agarose gel was 
visualized under UV using GeneGenius (Syngene).
Tissue culture and transfection experiments 
Primary skin cell lines
Six primary cell lines were used in the transfection experiments, FEK4 (196, 
197), FCP4, FCP5, FCP7 and FCP8  cells are human primary fibroblasts derived from
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newborn foreskin explants (198), which were used as a model for human primary 
cells (passage dependent cell line). FEK4 cells were kindly provided by Prof. R. M. 
Tyrrell, Department of Pharmacy and Pharmacology, University of Bath, UK. Cells 
were cultured in Earle’s Minimal Essential Medium (EMEM) with a final Foetal calf 
serum (FCS) concentration of 15 % v/v according to the following formula (for 500 
ml):
10X EMEM 50 ml
7.5 % NaHC03 13.5 ml
200 mM L-glutamine 5 ml
Penicillin (10,000 IU/ml)/Streptomycin (10,000 IU/ml) 2.5 ml
Foetal calf serum (FCS) 75 ml
Autoclaved MilliQ Water 354 ml
FCS was heat inactivated before use by defrosting at 37 °C and heating at 56 
°C for 45 mins in a temperature-controlled water bath (Grant). Sterile Phosphate 
Buffered Saline (PBS) solution was used in all transfection experiments to wash cells 
and contains 0.01 M phosphate buffer, 0.0027 M KC1 and 0.137 M NaCl in MilliQ 
water, pH 7.4. Trypsin was diluted to a working concentration at 0.25 % w/v with 
PBS.
Cells were visually assessed daily for evidence of microbial contamination 
under an inverted light microscope (Wilovert Hund). All aseptic techniques for cell 
culture were carried out in a laminar flow cabinet (Intermed MDH Ltd.) designed for 
vertical re-circulation of air. A temperature-controlled water bath (Grant) was used to 
warm the media for cell culture experiments. A monolayer of primary skin cell lines 
was grown in 25 ml EMEM supplemented with 15 % v/v FCS in 150 cm2 (T150) 
flasks from NUNC. Cell lines were incubated at 37 °C, 5 % CO2, 95 % air and 
humidified atmosphere by using LEEC PF2 incubator (Sanyo). Primary skin cells 
were passaged twice, maximum once, a week and used between passages 7-15.
Primary cells were passaged (subcultured) by trypsinisation technique. The 
growth medium was aspirated from the flasks. Then, cells were washed twice with 
PBS solution (10 ml/Tiso flask). PBS solution was then removed by aspiration. Cells
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were treated with trypsin 0.25 % w/v (3 ml/Tiso flask) and incubated for 5-10 mins at 
37 °C and 5 % v/v CO2 for trypsinisation reaction. After that, the flasks were gently 
tapped to assess the detachment of the cells, which were checked under microscope to 
ensure at least 85 % cell detachment. To stop trypsinisation, 10 ml of 15 % v/v FCS 
EMEM was added to the flask. The cell suspension was then transferred to a 50 ml 
Falcon tube, obtained from Falcon, for separation of cells by centrifugation at 1000 
rpm for 5 mins using a cells centrifuge, Falcon 6/300 MSE (Sanyo). Cells were re­
suspended in 6  ml of 15 % v/v FCS EMEM and was seeded at a concentration of 1 x 
106 cells/flask (T150) that have 25 ml 15 % v/v FCS EMEM for next passage.
To determine the concentration of cells in a sample, a viable count was carried 
out using a haematocytometer slide. Stained cell suspension was prepared by mixing 
trypsinized cells (50 pi) with same volume of nigrosin or trypan blue (50 pi) 0.4 % 
(w/v) solution in PBS. The cell sample was loaded into the raised sides of the glass 
chambers (top and bottom) covered with a coverslip 0 .1  mm above the chamber floor 
until the whole chamber was fully loaded. The slide was then placed under an 
inverted light microscope. Viable cells were detected using a bright halo light around 
their cell membrane. On the other hand, dead cells were permeabilized by the dye 
and appear as black spheres under the microscope. The viable cell number in the four 
squares surrounding the central square and this was repeated for the other side of the 
haemocytometer chamber. The viable cell concentration in the original cell 
suspension was calculated using the following equation:
_ „ . , » » / » *  total cell count in A squares ... . . ___Cell concentration (cells/ml) = ------------------------------------ x dilution factor x 10 [9]
4
For cell storage, cells were detached from a confluent monolayer by 
trypsinisation as described before followed by centrifugation at 1000 rpm form 5 
mins. The supernatant was then discarded and the cell pellets were re-suspended in 
the growth media at a concentration of 2 x 105 cells/ml. A cell freezing solution (10 
% v/v) of growth media with a filter-sterilized solution of dimethylsulfoxide (DMSO) 
as a cryopreservative was prepared. Cell suspension (0.4 ml) was dispensed with 0.6 
ml of cell freezing solution into cryotubes and stored at -70 °C overnight. After that,
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tubes were fitted into a Union Carbide LR-40 liquid nitrogen freezer where they were 
stored at approximately -150 °C (long-term, years).
For cell recovery, the contents of the cryotube were thawed rapidly by brief 
incubation at 37 °C water bath followed by dilution with 10 ml of fresh growth 
medium. Cells were centrifuged for 5 mins at 1000 rpm and the supernatant was 
discarded. Cell pellets were then re-suspended in 10 ml of fresh medium, and then 1 
x 106 cells were transferred to flask (T150) containing 25 ml of growth medium and 
incubated under standard culture conditions. Cells were cultured for at least two 
passages in order to establish them before any experiments were carried out.
Transfection experiments were carried out using pEGFP, encoding for green 
fluorescent protein as a reporter gene, either complexed with DNA condensing 
agents, or free (naked DNA) as a negative control. Cells were seeded in 6 -well 
plates, obtained from NUNC. DNA was used at a concentration of 2 jig/well. DNA 
condensing agents used for FEK4 primary cells transfection were the liposomal 
formulations Lipofectin (DOTMA/DOPE 1:1 w/w), Lipofectamine (DOSPA/DOPE 
3:1 w/w) and the non-liposomal formulations Transfectam® (DOGS), 
distearoyl spermine, A^^-dioleoyl spermine, A^^-dilinoleoyl spermine. For FCP4, 
FCP5, FCP7 and FCP8  primary cells, transfection experiments were carried out using 
Transfectam® (DOGS), A^^-distearoyl spermine, A^^-dioleoyl spermine and 
A^^-dilinoleoyl spermine.
For the DNA-vector complex formation experiment, two solutions were 
prepared for each well (6 -well plate), solution A (DNA) and solution B (condensing 
agent). Solution A was prepared by diluting DNA solution ( 2  jug/well) to 100 j l l I  
using Opti-MEM, a serum free media (Gibco), in a sterile 1.5 ml micro-centrifuge 
tube obtained from Eppendorf Ltd., gently mixed using a vortex, for 2 secs and 
incubated for 30 mins at room temperature. Solution B was prepared by diluting 
transfection agents solution to 100 pi using Opti-MEM, serum free media, in a sterile
1.5 ml micro-centrifuge tube, gently mixed using a vortex, for 2 secs and incubated 
for 30 mins at room temperature. The complex was then prepared by mixing solution 
A and B with vortex for 1 sec then incubated for 20 mins at room temperature.
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Each transfection agent used in solution B was at a different volume according 
to the required N/P ratio for 2 jug DNA/well, as described before in the N/P
determination section for EthBr assay. In the liposomal formulation Lipofectin, the
*
cationic lipid DOTMA carries 1 positive charge (ammonium eq/mole) (16) while the 
cationic lipid DOSPA in the Lipofectamine formulation carries 4 positive charges 
(ammonium eq/mole) (185). In the non-liposomal formulations, Transfectam®,
DOGS carries 3 positive charges (185), while A^^-distearoyl spermine, N4^ -  
dioleoyl spermine, A^^-dilinoleoyl spermine each of these lipopolyamines carries 2 
positive charges (on their two primary amines).
For FEK4 transfection, lx  105 cells/well were seeded in 6 -well plates in 4 ml 
of 15 % v/v FCS EMEM. Cells were incubated at 37 °C and 5 % v/v CO2 in a CO2 
incubator for 24 h to reach 50-60 % confluency. Prior to transfection, the adherent 
cells were washed twice with PBS solution, and then washed once with Opti-MEM. 
Washed medium was removed and replaced with 800 pi of Opti-MEM to which 200 
jllI of the transfection complex, as a result of mixing solution A and B, was added to 
the plates except for control cells where 1000 pi of Opti-MEM was added (no DNA 
complex solution). The transfected plates were incubated for 4 h at 37 °C in an 
atmosphere of 5 % v/v CO2. After that, the Opti-MEM in the incubated plates was 
aspirated and replaced with 2 ml of 15 % v/v FCS EMEM media and incubated for a 
further 44 h at 37 °C in an atmosphere of 5 % v/v CO2.
The study using naked DNA was performed to asses if there was any 
transfection efficiency from naked DNA compared to the lipoplexes. The same 
transfection protocol used before was applied, except for solution B that contains only 
serum free media without any DNA condensing agent to be added. For all 
transfection studies, each data point represents the mean ± standard deviation (± SD) 
of triplicate samples and each experiment was repeated three times.
HtTA cell transfection
Human cervix carcinoma, HeLa derivative and transformed cell line (HtTA) 
was used as a model for carcinoma cells (an immortal cell line). The HtTA cells
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being stably transfected with a tetracycline-controlled transactivator (tTA) consisting 
of the tet repressor fused with the activating domain of virion protein 16 of the herpes 
simplex virus (HSV). HtTA cells were kindly provided by Prof. R. M. Tyrrell, 
Department of Pharmacy and Pharmacology, University of Bath, UK. Cells were 
cultured in Earle’s Minimal Essential Medium (EMEM) with a final FCS 
concentration of 10 % v/v according to the following formula (for 500 ml):
10X EMEM 50 ml
7.5 % NaHCOs 13.5 ml
200 mM L-glutamine 5 ml
Penicillin (10,000 IU/ml)/Streptomycin (10,000 IU/ml) 2.5 ml
Foetal calf serum (FCS) 50 ml
Autoclaved MilliQ Water 379 ml
FCS was heat inactivated before use by defrosting at 37 °C and heating at 56 
°C for 45 mins in a temperature-controlled water bath (Grant). Trypsinisation 
procedures were carried out using the same protocol for FEK4 sub-culturing. The 
culture was incubated at 37 °C in an atmosphere of 5 % v/v CO2. HtTA cells were 
passaged every 3 days.
For the transfection (gene delivery) and the resultant gene activity 
(transfection efficiency) the same protocol for FEK4 transfection was used as 
described before. Briefly, HtTA cells were seeded at 1 x 105 cell/well in 6  well plates 
in 4 ml EMEM media with 10 % v/v FCS for 24 h to reach a plate confluency of 50- 
60 % on the day of transfection. The complex was prepared by mixing pEGFP (2 jig) 
with the cationic liposomes or lipopolyamine in serum free media Opti-MEM 
according to the charge ratio at room temperature for 30 mins, and then incubated 
with the cells for 4 h at 37 °C in 5 % v/v CO2, then the cells were washed and cultured 
for further 44 h in growth medium at 37 °C in 5 % v/v CO2 before the assay.
Fluorescence-activated cell sorting experiment
To analyse the transfection efficiency of the delivered pEGFP, levels of green 
fluorescent protein (GFP positive cells) in the transfected cells were detected using a
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fluorescence activated cell sorting (FACS) machine (199) Becton Dickinson FACS 
Vantage dual Laser Instrument, (argon ion laser 488 nm) (Becton Dickinson 
Biosciences). FACS is used for to determine the fluorescent molecules (or 
biomolecules) inside studied cells. Individual cells pass through a laser beam 
allowing the light scatter and fluorescence characteristics of each cell to be measured. 
Filter lens (F) for emission detection was chosen based on the fluorophore used. In 
our experiment, EGFP is detected by FI (A«m = 530 ±15  nm).
Preparation of cell sample for FACS analysis
The cells were detached through aspiration of the media from 6 -well plates. 
Then, cells were washed twice with PBS solution (2 ml/well). PBS buffer was 
removed by aspiration. Cells were treated with trypsin 0.25 % w/v (0.5 ml/well) and 
incubated for 5 mins at 37 °C and 5 % v/v CO2 for trypsinisation reaction. After that, 
the plates were gently tapped to assess the detachment of the cells, which were 
checked under microscope to ensure at least 85 % of cell detached. To stop 
trypsinisation, 1 ml of 15 % v/v FCS EMEM was added for each well. The cell 
suspension was then transferred to FACS polystyrene test tubes (12 x 75 mm), 
obtained from Falcon, filled with 1 ml of 15 % FCS EMEM for separation of cells by 
centrifugation at1000 rpm for 5 mins at room temperature using a cells centrifuge, 
Falcon 6/300 MSE (Sanyo). Cells were re-suspended in PBS (1 ml/tube) for further 
centrifugation at1000 rpm for 5 mins at room temperature. Cell suspension for FACS 
analysis was obtained by dissolving the pellet in 500 pi PBS/tube. Untreated 
(untransfected) cell sample was used as a control in the measurement.
CELLQuest v.1.0 software (Becton Dickinson Biosciences) was used to 
analyse FACS data. Typically, 10,000 events were collected. Recordings were made 
at green fluorescence (FL1) and data were expressed as histograms. Only a subset of 
the data obtained from healthy cells data (major population) was analysed through a 
gate setting. This gating was determined from the dot plots between forward- 
scattered light (FSC) and side-scattered light (SSC). FSC is a parameter proportional 
to cell size and SSC indicates the cell granularity or internal complexity. In the 
histogram of events at different fluorescence intensity control group, the fluorescence 
intensity range (Mi) was set as a constant range throughout the experiments. For
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EGFP detection, the % fluorescence cells sorting events in the established range (Mi) 
was reported with the correction of the background fluorescence of the control 
sample.
Cytotoxicity (MTT) assay for the lipoplex formed
The MTT assay is a colorimetric assay to evaluate the metabolic activity of 
viable cells to convert a soluble tetrazolium salt [3-(4, 5-dimethylthiazol-2-yl)-2,5- 
diphenyltetrazolium bromide (MTT)] into an insoluble formazan crystal. The MTT 
assay is used to investigate the cytotoxic effects of lipopolyamines and lipoplexes 
(pEGFP complexes). Six primary cell lines were used in the cytotoxicity 
experiments, FEK4, FCP4, FCP5, FCP7 and FCP8  cells are human primary 
fibroblasts derived from newborn foreskin explants, which were used as a model for 
human primary cells (mortal cell line), and these cells were cultured in Earle’s 
Minimal Essential Medium (EMEM) with a final serum concentration of 15 % v/v. 
HtTA was used as a model for carcinoma cells (an immortal cell line), and these 
HtTA cells were cultured in Earle’s Minimal Essential Medium (EMEM) with a final 
FCS concentration of 10 % v/v.
Lipopolyamines used in the cell viability assay were the liposomal 
formulations Lipofectin (DOTMA/DOPE 1:1 w/w) and Lipofectamine 
(DOSPA/DOPE 3:1 w/w) and the non-liposomal formulations Transfectam®
(DOGS), A^^-distearoyl spermine, A^^-dioleoyl spermine and A^^-dilinoleoyl 
spermine. They were used either complexed or as free lipopolyamine.
For DNA-vector complex formation, two solutions were prepared for each 
well (96-well plate), solution A (DNA) and solution B (condensing agent). Solution 
A was prepared by diluting DNA solution (0.2 |Lig/well) to 10 (il using Opti-MEM, a 
serum free media (Gibco), in a sterile 1.5 ml micro-centrifuge tube obtained from 
Eppendorf Ltd., gently mixed using a vortex, for 2 secs and incubated for 30 mins at 
room temperature. Solution B was prepared by diluting transfection agent solution to 
10 pl/well using Opti-MEM, serum free media, in a sterile 1.5 ml micro-centrifuge 
tube, gently mixed using a vortex, for 2 secs and incubated for 30 mins at room 
temperature. The complex was then prepared by mixing solution A and B with
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vortex for 1 sec then incubated for 20 mins at room temperature. Each transfection 
agent used in solution B was at a different volume according to the required N/P ratio 
for 0.2 fig DNA/well, as described before in the N/P determination section for EthBr 
assay.
For primary fibroblasts and carcinoma cells toxicity study, 8  x 103 cells/well 
were seeded in 96-well plates, obtained from NUNC, in 200 pi of 15 % v/v FCS 
EMEM and 10 % v/v FCS EMEM in the case of primary fibroblasts and HtTA, 
respectively. Cells were incubated at 37 °C and 5 % v/v CO2 in a CO2 incubator for 
24 h to reach 50-60 % confluency. The adherent cells were washed twice with PBS 
solution, and then washed once with Opti-MEM. Washed medium was removed and 
replaced with 80 pi of Opti-MEM to which 20 pi of either the transfection complex 
(lipoplex), the free lipopolyamine, or the free DNA (naked DNA) was added to the 
plates except for control cells where 100 pi of Opti-MEM was added (no DNA 
complex solution). The plates were incubated for 4 h at 37 °C in an atmosphere of 5 
% v/v CO2. After that, the Opti-MEM in the incubated plates was aspirated and 
replaced with 200 pi of 15 % v/v FCS EMEM and 10 % v/v FCS EMEM in the case 
of primary fibroblasts and HtTA, respectively. Then, incubated for a further 44 h at 
37 °C in an atmosphere of 5 % v/v CO2.
After incubation for 44 h, the media was replaced with 90 pi of fresh media 
and 10 pi of sterile filtered MTT solution (Sigma-Aldrich) (5 mg/ml) to reach a final 
concentration of 0.5 mg/ml. Then the plates were incubated for a further 4 h at 37 °C 
in an atmosphere of 5 % v/v CO2. After incubation, the media and the un-reacted dye 
were aspirated and the formed blue formazan crystals were dissolved in 2 0 0  pl/well 
of DMSO. The produced colour was measured using a plate-reader (VERSAmax™) at 
wavelength 570 nm. The % viability related to control wells containing cells without 
DNA and/or polymer and is calculated as follow (200):
% cell viability =
^A570 sample ^  
yA 570 control j
x 1 0 0  [1 0 ]
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Characterization of the formed nanoparticles
Particle size
The average particle size for the lipoplexes formed (at their optimum charge 
ratio of transfection), after mixing with a vortex mixer, was determined using a 
Malvern Zetasizer Nano S (Malvern Instruments) All measurements were carried out 
on lipoplexes with 5 (ig/ml plasmid DNA in HEPES buffer at pH 7.4 and 20 °C.
For pEGFP lipoplex formation, two solutions were prepared for each well, 
solution A (DNA) and solution B (lipopolyamine). Solution A was prepared by 
diluting DNA solution (10 jLig/ml) in sterile Falcon polypropylene tubes (15 ml), 
obtained from Falcon, gently mixed using a vortex for 2 secs, and then incubated for 
30 mins at room temperature. Solution B was prepared by diluting the lipopolyamine 
solution to 1.0 ml using HEPES buffer, in sterile Falcon polypropylene tubes (15 ml), 
gently mixed using a vortex for 2 secs, and then incubated for 30 mins at room 
temperature. The complex was then prepared by mixing solutions A and B by vortex 
for 1 sec, and then incubated for 2 0  mins at room temperature.
Each lipopolyamine used in solution B was at a different concentration from 
the required N/P ratio for 5 pg DNA/ml as described before in the N/P determination 
section for EthBr assay. The charge ratio was calculated according to the 
ammonium/phosphate (+/-) charge ratio of the investigated lipopolyamines to DNA. 
For DNA it was calculated as 330 g/mole is DNA that contains one negative charge 
(5). In case as of A^^-distearoyl spermine, it was calculated as 735.7g/mole that 
contains two primary amino groups that are protonated (positively charged) at pH 7.4. 
For AT^^-dioleoyl spermine it was calculated as 731.26 g/mole that contains two 
primary amino groups that are protonated (positively charged) at pH 7.4.
Dilinoleoyl spermine was calculated as 727.7g/mole that contains two primary amino 
groups that are protonated (positively charged) at pH 7.4. In the case of the 
commercially available lipopolyamine (DOGS, Transfectam®) it was calculated as 
1263 g/mole that contains three nitrogens that are protonated at pH 7.4. In the non- 
liposomal formulations, Transfectam® carries 3 positive charges (185).
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The mean hydrodynamic diameter of the particles, dh (from 10 measurements 
per sample) was computed from the intensity of the scattered light using the Malvern 
software package based on the theory of Brownian motion and the Stokes-Einstein 
equation (2 0 1 ).
kT
D = ———  [11]
3 m jd h
where D is the diffusion coefficient, k is the Boltzmann constant, T is the 
temperature, and r\ is the solvent viscosity.
Zeta potential
^-Potential measurements were determined using a Malvern Zetasizer Nano 
ZS (Malvern Instruments). All measurements were carried out on lipoplexes with 5 
|Lig/ml plasmid DNA in HEPES buffer at pH 7.4 and 20 °C.
For pEGFP lipoplex formation, two solutions were prepared for each well, 
solution A (DNA) and solution B (lipopolyamine). Solution A was prepared by 
diluting DNA solution (10 pg/ml) in sterile Falcon polypropylene tubes (15 ml), 
gently mixed using a vortex for 2 secs, and then incubated for 30 mins at room 
temperature. Solution B was prepared by diluting the lipopolyamine solution to 1.0 
ml using HEPES buffer, in sterile Falcon polypropylene tubes (15 ml), gently mixed 
using a vortex, for 2 secs and incubated for 30 mins at room temperature. The 
complex was then prepared by mixing solution A and B with vortex for 1 sec then 
incubated for 2 0  mins at room temperature.
Each lipopolyamine used in solution B was at a different concentration to the 
required N/P ratio for 5 pg DNA/ml, as described before in the N/P determination for 
the particle size and EthBr experimental sections. In the non-liposomal formulations, 
Transfectam® carries 3 positive charges (185), while A^^-distearoyl spermine, 
A ^^-dioleoyl spermine and A^^-dilinoleoyl spermine each carry 2 positive
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charges. The ^-potential measurements of the nanoparticles were computed from the 
electrophoretic mobility using the Malvern software package based on the Henry 
equation:
v  2 £ £ /(* b )  
3/7
where Ue is the electrophoretic mobility (velocity of the nanoparticle in a unit electric 
field), C, is the zeta potential, 8  is the dielectric constant, r\ is the solvent viscosity and 
f (Ka) is Henry’s function, which in aqueous media and electrolyte is equal to 1.5 
known as Smoluchowski approximation.
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CHAPTER 3
Formulation and Delivery of DNA Condensed by a 
Synthetic Lipospermine, A^A^-Dioleoyl Spermine
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Introduction
Non-viral delivery systems can be defined to include the use of plasmid DNA 
alone (so-called “naked DNA”) (10) as well as DNA complexed to synthetic carriers 
such as cationic lipids (202, 203) or polymers (204). The design of an efficient 
formula for the delivery of genetic material requires a detailed understanding of the 
mechanism of gene delivery to the nucleus. Since the design and formulation of 
Lipofectin by Feigner and co-workers, reported in 1987 (16), the focus on non-viral 
vectors for DNA delivery has shown a remarkable increase worldwide (205-207).
Efficient non-viral formulation should be able to deliver safely the required 
DNA across the various cellular barriers to the nucleus. Cationic lipids are 
considered to be the major gene carriers among the non-viral delivery systems. They 
have the ability to conderiseDNA into particles that can be readily endocytosed by 
cultured cells, and facilitate endosomal escape leading to efficient delivery to the 
nucleus (208). They can be classified as liposomal and non-liposomal non-viral 
delivery vectors. Liposomal delivery vectors usually contain two types of lipids, a 
cationic lipid (positively charged amphiphile) for DNA condensation and cellular 
membrane interaction, and a neutral helper lipid (phospholipid), most use 
dioleoylphosphatidyl-ethanolamine (DOPE) (Fig. 1) to increase transfection 
efficiency as it has a membrane fusion promoting ability (16,108, 209). Non- 
liposomal cationic-lipid delivery vectors combine both the characteristics of cationic 
and helper lipids.
The synthesis of the lipopolyamine dioctadecylamidoglycylspermine (DOGS) 
by Behr and co-workers (179) as a promising transfecting agent, encouraged several 
laboratories to focus on the synthesis of novel cationic lipids based on the naturally 
occurring polyamine spermine e.g. RPR120535 (182) and l,3-dioleoyloxy-2-(6- 
carboxyspermine) DOSPER (177) (Fig. 1). The design of a novel lipopolyamines 
formula for DNA condensation and cellular delivery relies on previous and 
continuing studies of the structure-activity relationships of DNA binding and 
condensation by polyamines (19,171, 210, 211). Although lipopolyamines are less 
efficient in comparison with viral vectors, their promising lower toxicity than viral
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vectors ensures a continuous effort to design novel lipopolyamines with improved 
transfection efficiency.
In this chapter, we have synthesized and formulated a novel lipospermine, in 
which a di-amine derived from spermine (the cationic moiety) and dioleoyl chains 
(the lipophilic moiety), that are reported to improve the transfection efficiency by 
fusion with cellular membrane (2 1 2 ), these unsaturated chains are linked by amide 
bonds at the secondary amino groups of spermine to form A^^-dioleoyl spermine. 
These amide linkers have the advantages of being both biodegradable and less toxic 
than the ether bonds in DOTMA (213, 214). A^^-Dioleoyl spermine was only 
previously reported by Kirby and his colleagues (187) who synthesized A4^V9- 
dioleoyl spermine as an intermediate for the synthesis of the gemini surfactants 
A^A^-d^Lys-Lys-Lys-Se^-A^^-dioleoylspermine) and N l iN n -di-Lys-N4 JV9- 
dioleoylspermine). In the same work, similar spermine conjugates were synthesized 
by replacing the hydrocarbon chains position on spermine from the (A4 and A9) to 
(A1 and A12) with the basic amino acid residues position. Publications from their 
research work did not report any intention to use A4,A9-dioleoyl spermine as an 
NVGT vector (186, 187). Also, no other research group has reported the 
investigation of A ^^-dioleoyl spermine as an NVGT vector.
The ability of this synthetic lipopolyamine to condense DNA was studied 
using ethidium bromide (EthBr) fluorescence quenching and light scattering assays. 
Transfection efficiency was studied in an immortalized cancer cell line (HtTA), and 
in primary skin cells (FEK4) for the first time. The results are compared with two 
commercially available (liposomal) transfection formulations, Lipofectin® and 
Lipofectamine™ that incorporate such oleoyl or oleyl (C l8 ) chains. Lipofectamine™ is 
available as a mixture of the cationic lipid DOSPA and the neutral helper lipid DOPE 
as 3/1 w/w, respectively. While Lipofectin® is available as a mixture of the cationic 
lipid DOTMA and the helper lipid DOPE as 1/1 w/w, respectively (Fig. 1). The 
cytotoxicity of these compounds was studied in both primary skin and immortalised 









Figure 1. DOTMA, DOPE and spermine based lipopolyamines.
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Synthesis of A^^-dioleoyl spermine
As indicated in the material and methods chapter, spermine was used as the 
starting material for the synthesis process ( 2 1 5 ) ,  outlined in Fig. 2 . Spermine was 
protected on the primary amino functional groups with ethyl trifluoroacetate (2 .2  eq.) 
in methanol and the reaction mixture was stirred for 1 8  h at 2 5  °C. The solvent was 
evaporated to dryness in vacuo to form A ^^^-ditrifh ioroacetyl-l^-diam ino-^- 
diazadodecane, R f  0 .7  (CFkCb-MeOH-conc. aq. NH3 2 5 :1 0 : 1  v/v/v) with a yield of 
about 93 % as previously reported ( 2 1 6 ) .
For oleic acid conjugation, dicyclohexylcarbodiimide (DCC, 2.5 eq), 1- 
hydroxybenzotriazole (HOBt, 0.2 eq) and oleic acid (2.2 eq) were added to the 
diprotected spermine solution (used without purification) in CH2CI2 and methanol 
(1:1). The solution was stirred for 18 h at 25 °C. The solvent was evaporated to 
dryness in vacuo. The residue was dissolved in CH2CI2 and the solution filtered and 
evaporated to dryness in vacuo to form A^^-dioleoyl-A /1 ,A/12-ditrifluoroacetyl-1,12- 
diamino-4,9-diazadodecane.
For the removal of the di-trifluoroacetyl groups, the tetra-amide was dissolved 
in methanol and the pH of the solution was increased by saturating with ammonia 
gas, then it was left (18 h) and evaporated to dryness in vacuo to give a residue which 
was purified over silica gel (C^Ch-M eOH 5:3 v/v, then CH2Cl2-MeOH-conc. aq. 
NH3 25:10:1 v/v/v) to afford A^^-dioleoyl spermine (Fig. 2) homogenous on silica 
gel thin-layer chromatography as a colourless oil ( R f  0.44) (CH2Cl2-MeOH-conc. aq. 
NH3 25:10:1 v/v/v) with a 9 % overall yield, characterized by high resolution accurate 
mass spectroscopy (HRMS), C46H91N4O2 found (m/z [M+H]+) 731.7115, requires 










25 °C for 18h
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Saturation with NH3 
25 °C for 18h
Figure 2. Synthesis of A^^-dioleoyl spermine.
68
DNA condensation studies
The use of an efficient carrier for nucleic acid delivery is considered to be a 
determinant factor for the successful application of gene therapy (217). This carrier is 
responsible for the complex process of gene delivery to the nucleus (26). Within the 
prerequisites for delivery of DNA across intact cytoplasmic membrane are 
condensation and masking the negative charge of the phosphate backbone. 
Condensation of DNA occurs when 90 % of the charge on DNA is neutralised (19, 
22). To investigate the neutralization of the negative charges of the phosphate groups 
on the DNA back bone that leads to collapse of DNA into a more compact structure 
(nanoparticles). Two experiments were carried out, these are:
1. Ethidium bromide fluorescence quenching assay
2. Light scattering assay
The ability of the synthetic lipopolyamine A^^-dioleoyl spermine to 
condense both calf thymus DNA and circular plasmids DNA was investigated. Two 
plasmids were used in this study. pSV-p-galactosidase (pp-gal, 6 .8  kbp) with SV40 
early promoter and enhancer that drive the transcription of LacL gene which encodes 
the P-galactosidase enzyme. pEGFP encoding for enhanced green fluorescent protein 
(4.7 kbp) under CMV promoter. A^^-Dioleoyl spermine was compared with the 
natural polyamine spermine (Fig. 3). Also, the cationic polymers polyethylenimine 
(PEI) and poly-L-lysine (PLL) (Fig. 3) were used as model for their well known DNA 
condensation ability to compare with the lipopolyamine A^^-dioleoyl spermine 
ability to condense DNA. Also, the ability of our novel polyamine conjugate A 
dioleoyl spermine to condense DNA, leading to the formation of nanoparticles (that 
are suitable for gene delivery), was compared with the commercially available 
liposomal transfection formulations Lipofectin® and Lipofectamine™.
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Figure 3. Spermine, PLL and PEL
Ethidium bromide fluorescence quenching assay
Ethidium bromide (EthBr) (2,7-diamino-9-phenylphenanthridinium- 10-ethyl 
bromide, Fig. 4) a cationic dye that displays a marked increase in the fluorescence 
upon binding with DNA and RNA through the intercalation between the EthBr 
phenanthridinium moiety and adjacent base pairs of specific DNA sequences (193, 
218-220). The increase in the fluorescence of EthBr upon binding with DNA making 
EthBr a useful probe to measure drug-DNA interactions (193, 218). The binding of 
cationic molecules with DNA is not entirely responsible for the release of EthBr, but 
alteration of the molecular flexibility of DNA through cationic compaction facilitated 
the release of bound EthBr (193, 221, 222).
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Figure 4. Structure of ethidium bromide.
The significant enhancement of fluorescence when EthBr intercalates DNA is 
attributed to the hydrophobic environment surrounding the EthBr molecule leading to 
longer life time for the excited state (218, 223). On the other hand, free EthBr (in 
solution) is strongly quenched by aqueous solvent, so it exhibits a weak fluorescence 
relative to that from intercalated dye (223). The fluorescence intensity of free EthBr 
(no DNA) in HEPES buffer solution (20 mM NaCl, 2 mM HEPES, 10 pM EDTA, 
pH 7.4) was usually small (background). On the other hand, the fluorescence 
intensity of the EthBr solution was significantly increased after the addition of DNA 
solution, as a result of EthBr intercalation between DNA base-pairs. The 
fluorescence was expressed as the percentage of the maximum fluorescence when 
EthBr was bound to the DNA in the absence of competition for binding and was 
corrected for background fluorescence of free EthBr in solution.
We started DNA condensation studies through investigating the effect of 
spermine to condense calf thymus DNA, plasmid p-galactosidase, pEGFP and the 
synthetic polynucleotides poly(dA-dT).poly(dA-dT) and poly(dG-dC).poly(dG-dC). 
The charge ratio was calculated according to the ammonium/phosphate (+/-) charge 
ratio for spermine as 202.35 g/mole is spermine that contains four nitrogens that can 
be protonated. Spermine has a pKa values of 10.9, 10.1, 8.9 and 8.1, and according to 
Henderson-Hasselbach equation, spermine has 3.8 charges / molecule at pH 7.4 
(145).
From these results, it was found that spermine caused a decrease in the 
fluorescence intensity with the studied polynucleotides. In the case of the synthetic 
polynucleotides poly(dA-dT).poly(dA-dT) and poly(dG-dC).poly(dG-dC) there is a
71
lower decrease in fluorescence intensity of EthBr-poly(dG-dC).poly(dG-dC) complex 
in comparison with the fluorescence intensity of EthBr-poly(dA-dT).poly(dA-dT) 
complex (Fig. 5) which may be attributed to the bending of poly(dA-dT) major 
groove interacted with spermine that leads to widening of minor groove of the 
alternating A-T sequences that increase EthBr mobility in this minor groove which is 
not the case of poly(dG-dC) due to stiffness of the structure due to the presence of 
more hydrogen bonds (222, 224). These results were in accordance with the previous 








0 2 3 4 5 61
charge ratio
Figure 5. Plot of EthBr displacement assay of spermine with poly(dA-dT).poly(dA- 
dT) and poly(dG-dC).poly(dG-dC).
Fig. 6 shows the decrease in fluorescence intensity of EthBr for both calf 
thymus DNA and pp-gal interacted with spermine. These results show the ability of 
spermine to condense, both linear calf thymus DNA and circular plasmid DNA 
through quenching of EthBr fluorescence by up to 17 % and 23 %, respectively, at 
charge ratio 6. Also, in the case of the interaction of spermine with calf thymus DNA 
and plasmid p-galactosidase, there is no significant difference in the decrease of the 
fluorescence intensity.
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Figure 6 . Plot of EthBr displacement assay of calf thymus DNA and pp-gal with 
spermine at different N/P charge ratios.
To study the ability of poly-L-lysine (PLL) (225) and polyethylenimine (PEI) 
(95) (Fig. 7) to condense calf thymus DNA as well as compared this effect with the 
effect of spermine to condense DNA. In the case of polyethylenimine, two different 
molecular weights were investigated, PEI average molecular weight 2,000 Da (PEI 
2k) and 60,000 Da (PEI 60k). In the case of PLL, two different molecular weights 
were investigated, PLL average molecular weight 9,600 Da (PLL 9.6k) and 27,000 
Da (PLL 27k). In the case of PEI 2k and PEI 60k, the charge ratio was calculated by 
assuming that 43.1 g/mol is the repeating unit of PEI that contains one nitrogen atom 
that can be protonated (75, 113).
It seems to be that there is no agreement in the literature for the calculation of 
the PEI/DNA charge ratio. While it is calculated as PEI nitrogen/DNA phosphate 
(95) not as charge ratio, it is reported that every third nitrogen atom of PEI polymer is 
a protonatable nitrogen (95), but one in five of the protonatable nitrogens in PEI are 
protonated at pH 7 (226). PEI charge ratio was calculated as 25 % of the amino 
groups in the polymer that can be protonated at pH 7.4 (75, 113). However, Wagner 
(206) reported that one of every seven nitrogens within PEI polymer is protonated at 
pH 7. In our studies, the charge ratio of PEI 2k and PEI 60k were calculated by 
multiplying the weight ratio of PEI to DNA by 1.9 (75). The value 1.9 indicated that
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25 % of the amino groups in the polymer are protonated at pH 7.4. In the case of 
PLL 9.6k and PLL 27k, the charge ratio was calculated as one nitrogen (as one 
positive charge) that can be protonated/lysine monomer.
The results in Fig. 7 show that the studied polyamines, PEI and PLL 
polycations, are able to condense and displace EthBr from DNA efficiently at a 
significantly low charge ratio compared to spermine. These results show that the 
efficiency of DNA condensation was in the order of PEI > PLL > spermine according 
to the charge ratio. PEI are the most efficient by completely condensing DNA (less 
than 90 % fluorescence quenching) at a lower charge ratio, PEI 2k completely 
condense calf thymus DNA (less than 10 % residual fluorescence intensity) at charge 
ratio 0.3, and PEI 60k completely condense calf thymus DNA (less than 90 % 
fluorescence quenching) at charge ratio (N/P) 0.2 (Fig. 7). PLL 9.6k and PLL 27k, 
displace intercalated EthBr from calf thymus DNA by less than 90 % fluorescence 
quenching at charge ratios 1.8 and 1.3, respectively. The tetra-amine spermine shows 
lower ability in DNA condensation in comparison with the polycations PEI and PLL, 
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Figure 7. Plot of EthBr fluorescence quenching assay of calf thymus DNA with PLL 
9.6k, PLL 27k, PEI 2k, PEI 60k and spermine.
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These results confirmed that, both the number of positive charges and their 
distribution on the surface of the molecule have profound effects on DNA 
condensation as indicated in refs (49, 210, 227). Also, spermine is not considered as 
an efficient condensing agent. Although PEI and PLL show more efficiency in DNA 
condensation, but their well known toxicity limits their use in DNA formulation as 
non-viral gene delivery vectors (228, 229).
On studying the effect of each condensing agent on different DNAs, calf 
thymus DNA and herring testes DNA were used as an example of linear DNA and 
plasmid p-gal was used as an example of circular plasmid DNA. These results 
showed that there is no significant variation in the condensation ability of the studied 
polyamines on calf thymus DNA and herring testes DNA using PEI 60k (Fig. 8 A), 
PEI 2k (Fig. 8 B) or PLL 27k (Fig. 8 C). Also, there is no significant difference 
between calf thymus (linear) DNA and plasmid P-galactosidase using PLL 9.6 as 
indicated in Fig. 8 D. Similarly, in the case of the interaction of spermine with calf 
thymus DNA and plasmid p-galactosidase, there is no significant difference in the 
decrease of the fluorescence intensity (Fig. 6 ).
The ability of the synthetic A^^-dioleoyl spermine to condense calf thymus 
DNA and pEGFP as well as compared this effect with the effect of different known 
polycations spermine, PLL (225) and PEI (95) (Fig. 9) for DNA condensation was 
investigated using EthBr fluorescence quenching assay. Charge ratio was calculated 
as two positive charges/ A^^-dioleoyl spermine molecule (731.2 g/mol) at pH 7.4. 
The binding ability was in the order PEI > A^^-dioleoyl spermine > PLL > spermine 
according to the charge ratio.
On the other hand, the results revealed that A^^-dioleoyl spermine is able to 
condense DNA at a lower charge ratio than PLL 9.6K and spermine (Fig. 9), and 
produces a 50 % fluorescence decrease at charge ratio 0.52. These results showed the 
ability of the cationic lipid A^^-dioleoyl spermine (derived from spermine by 
conjugation with two oleoyl moieties on the secondary amino groups of spermine) to 
condense DNA efficiently compared to the natural polyamine spermine and the 
efficient DNA condensing agents, PLL and PEI cationic polymers, that are used as 
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Figure 8 . Plot of EthBr displacement assay of A PEI 60k, B PEI 2k, C PLL 27k with 
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Figure 9. Plot of EthBr fluorescence quenching assay of calf thymus DNA with PLL 
9.6K, PLL 27K, PEI 2K, PEI 60K, spermine and A^^-dioleoyl spermine.
To quantify the ability of the investigated polyamines in condensing DNA, the 
binding constant of these polyamines with DNA was estimated (Table 1) and 
compared using EthBr assay that has been shown to be a valid method for comparison 
of DNA binding affinity (144, 194, 221). The drug concentration producing 50 % 
inhibition of fluorescence is approximately inversely proportional to the binding 
constant (194).
From Table 1 data, the concentrations of condensing agents producing 50 % 
fluorescence inhibition were calculated (equation 1) as shown in the experimental 
chapter. The “apparent” equilibrium constant (ATapp) of polyamine binding was 
calculated taking into account that the binding constant of ethidium to be 107 M'1 
(194) and the concentration of EthBr is 1.3 pM. From these results it was found that 
PEI 60k has the highest binding affinity {Km  6.5x109 M 1) between the compared 
polyamines and spermine the lowest with binding affinity (^app 4xl06 M'1) which 
could be attributed to the higher number of positive charges and the charge 
distribution on PEI 60k compared with spermine.
Kb (vector) [1]
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Table 1. Calf thymus DNA binding data
Condensing agent Drug concentration at 50 % 
fluorescence quenching (|iM)
/^ app*
Spermine 3.295 4xl06 M' 1
PLL 9.6k 0.125 10s M ' 1
PLL 27k 0.028 4.6x108 M' 1
PEI 2k 0.063 2.1xl08 M' 1
PEI 60k 0 .0 0 2 6.5xl09 M' 1
dioleoyl spermine 1.7 0.8xl07 M' 1
* “apparent” equilibrium binding constant of condensing agent to calf thymus DNA
Also, to extend our investigation to validate the ability of our novel polyamine 
conjugate A ^^-dioleoyl spermine to condense DNA, condensation results were 
compared with two commercially available cationic lipid (liposomal) transfection 
formulations, Lipofectin® (DOTMA/DOPE 1/1 w/w) and Lipofectamine™ 
(DOSPA/DOPE 3/1 w/w). Fig. 10 shows DNA condensation ability of 
dioleoyl spermine in comparison with the commercially available, cationic lipid 
formulations Lipofectin® and Lipofectamine™. All three cationic lipid formulations 
have the ability to condense completely DNA through the displacement of EthBr 
leading to fluorescence quenching. At lower charge ratios, A^^-dioleoyl spermine 
has better ability to suppress fluorescence, which produces 50 % fluorescence 
decrease at N/P charge ratio 0.52, than Lipofectin®, which produces 50 % 
fluorescence quenching at charge ratio 2.0 and Lipofectamine™ which produces 50 % 
fluorescence decrease at charge ratio 1.0. Also, Lipofectin was able to completely 
condense DNA (less than 10 % fluorescence quenching) at charge ratio 4.5, while 
Lipofectamine at charge ratio 1.8 and A^^-dioleoyl spermine at charge ratio 1.4.
On studying the effect of A^^-dioleoyl spermine on the type of DNA (calf 
thymus DNA, and plasmid pEGFP), it was found that there is no significant variation
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in the condensation ability of the studied lipopolyamine on the type of DNA as shown 
in Fig. 11. These results are also in agreement with the previous results that were 
carried out by interaction of linear and circular plasmid DNA with the cationic 










Figure 10. Plot of EthBr displacement assay of calf thymus DNA complexed with 
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Figure 11. Plot of EthBr fluorescence quenching assay of A^A^-dioleoyl spermine 
with calf thymus DNA and pEGFP.
79
EthBr fluorescence quenching results show the ability of the cationic lipid 
A ^^-dioleoyl spermine to compact DNA more efficiently than both spermine and 
the powerful condensing agent cationic polymer PLL (Fig. 10). These results show 
the importance of the lipid moieties that have been bound to the cationic polyamine in 
order to achieve improvements in its ability to condense DNA, cellular entry, and 
lowering the toxicity of the polyamine conjugate (69, 206, 230).
DNA is condensed by neutralizing the DNA phosphate negative charges by 
the two primary amines that are positively charged at pH 7.4 and coated by the 
dioleoyl lipophilic moiety of A^^-dioleoyl spermine. In addition, the formation of 
A ^^-dioleoyl spermine-DNA lipoplex at lower charge ratio decreases the toxicity of 
the DNA delivering lipopolyamine. In addition, as the mammalian cell membrane is 
a semi-permeable membrane formed of phospholipids bilayer that allows the 
transport of macromolecules by endocytosis, neutralization of the negative charges on 
the DNA by polycations will improve the delivery of DNA through the cell 
membrane because of the presence of negative charges on both DNA and cell 
membrane. Also, the positively charged lipid complex will mediate transfection by 
fusion with cell membrane (69, 93). These results also showed that both the number 
of positive charges and their distribution on the surface of the molecule have 
profound effects on DNA condensation, which are also in agreement with the 
published literature (49, 210, 227).
In addition, in a study on the transfection activity of cholesterol carbamate 
cationic lipids, Blagbrough and co-workers reported (210) that the carbamate with a 
spermine polyamine moiety has the highest transfection activity with its ability to 
condense DNA efficiently. Our findings are in agreement with the literature (210), 
the cationic liposomal formulation Lipofectin®, with its cationic moiety DOTMA 
containing one positively charged quaternary ammonium group, has lower ability to 
displace the EthBr from DNA than Lipofectamine™ formulation that contains DOSPA 
(Fig. 1) with its four positively charged nitrogens (185) and A^^-dioleoyl spermine 
with its two positively charged nitrogens.
The higher ability of A^^-dioleoyl spermine (two positive charges) over 
Lipofectamine™ (four positive charges) in DNA condensation, though A^^-dioleoyl
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spermine has a lower number of positive charges/molecule, may be attributed to the 
distribution of the positive charges on the molecule allowing a higher affinity of the 
vector for DNA and leading to the efficient displacement of EthBr. Another variable 
is the liposomal formulation of Lipofectamine™ compared to the non liposomal 
formulation of A^^-dioleoyl spermine, where the addition of the neutral helper lipid 
DOPE to the liposomal formulae could affect the condensation ability of the cationic 
lipid used in the formulation.
Light scattering assay
This experiment has been carried out to investigate the condensation of DNA 
by polyamines and the formation of particles (20). The apparent UV absorbance at 
320 nm (where there is no DNA absorbance above 300 nm) was measured (21, 210, 
231) showing light scattering. The formation of DNA nanoparticles causes scattering 
of light that reduces light intensity at the UV detector. The results from Fig. 12 
indicated the formation of particles upon interaction of spermine, PLL 9.6K, PLL 27k 
PEI 2K and PEI 60K.
Fig. 13 shows the increased in apparent absorbance by increased light 
scattering of the formed particles as a result of interaction of A^^-dioleoyl spermine 
with calf thymus DNA. The maximum apparent absorption was reached at a charge 
ratio of 1.7.
Also, light scattering and particle formation results of the lipoplex formed by 
interaction of A ^^-dioleoyl spermine with calf thymus DNA were compared with 
the results of the interaction of calf thymus DNA with PLL, PEI and spermine (Fig. 
14). These results indicate improved ability of A^^-dioleoyl spermine to condense 
DNA and form particles over PLL 9.6K, PLL 27K and spermine, which were also 
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Figure 12. Light scattering assay (relative maximum apparent absorbance at X = 320 
nm) of calf thymus DNA with PLL 9.6k, PLL 27k, PEI 2k, PEI 60k and spermine.
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Figure 13. Light scattering assay (relative maximum apparent absorbance at X = 320 
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Figure 14. Light scattering assay (relative maximum apparent absorbance at X = 320 
nm) of calf thymus DNA with PLL 9.6k, PLL 27k, PEI 2k, PEI 60k, spermine and 
A^^-dioleoyl spermine.
In addition, Fig. 15 shows that the light scattering due to particle formation 
increases with the increase in the displaced EthBr and reaches the maximum at 
approximately the same charge ratio at which there is a maximum EthBr 
displacement, although the concentration of DNA used in light scattering experiments 
is ten times the concentration used in fluorescence quenching experiments which is 
related to the lack of sensitivity of the light scattering experiment in comparison with 
EthBr fluorescence assay.
Also, from light scattering results, there is a decrease in the % relative 
maximal apparent absorbance (% rel. max. app. abs.) after reaching the maximum 
absorbance, which could be attributed to the formation of polyamine-DNA aggregates 
as reported by Gosule and Schellman (232) where any DNA intra-chain binding 
agents will also act as inter-chain segment binders. The formation of aggregates at 
high charge ratio, at the relatively high concentration of DNA in comparison with 
EthBr assay, will decrease the scattering light that will decrease the apparent 
absorption value.
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Figure 15. Comparison of EthBr displacement and light scattering assays of calf 
thymus DNA with TV^A^-dioleoyl spermine.
Transfection experiments
Following to the promising DNA condensation results of A^^-dioleoyl 
spermine shown in Figs. 9 and 10, the ability of the lipopolyamine to deliver DNA 
efficiently to living cells was investigated. Two cell lines have been used in the 
transfection experiments in this study, primary skin fibroblast cells, FEK4 derived 
from an infant foreskin explant (passage dependent cell line) and human cervix 
carcinoma, HeLa derivative and transformed cell line (HtTA) was used as a model for 
carcinoma cells (an immortal cell line).
Transfection results and cell viability studies are considered indicative 
measures of the ability of the lipopolyamine to be used for in-vivo investigation of 
non-viral gene delivery vectors. A^^-Dioleoyl spermine transfection results were 
compared with two commonly used and commercially available transfection 
formulations Lipofectin® and Lipofectamine™. Both are available as liposomal 
formulations Lipofectin® (DOTMA/DOPE 1/1 w/w) and Lipofectamine™ 
(DOSPA/DOPE 3/1 w/w).
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Transfection experiments were carried out using pEGFP, encoding for 
enhanced green fluorescent protein as a reporter gene, either complexed with DNA 
condensing agents, or free (naked DNA) as a negative control. DNA was used at a 
concentration of 2 fig/well. The transfection efficiency of the delivered pEGFP, i.e. 
levels of green fluorescent protein (EGFP positive cells) in the transfected cells, were 
detected using a fluorescence activated cell sorting (FACS) machine (A«x = 480 nm 
and A*m = 530 nm). Transfection efficiency was expressed as % transfection 
representing % of EGFP-containing fluorescent cells. A^^-Dioleoyl spermine and 
both the commercially available liposomal formulations were used according to the 
required N/P ratio for 2 jig DNA/well, as described before in the N/P determination 
and the same protocol for transfection as mentioned in the materials and methods 
chapter.
Primary skin cell transfection studies
Primary cell lines are characterized as difficult to transfect cell lines (233, 
234). Promising primary cell transfection results were achieved by electroporation 
technique where DNA is directly delivered to the nucleus (233, 234). Electroporation 
is used to overcome both extracellular and intracellular barriers that hinder a 
successful delivery of the gene to the nucleus. FEK4 cells were cultured in Earle’s 
Minimal Essential Medium (EMEM) with foetal calf serum (FCS) serum 
concentration of 15 % v/v. The primary cells were seeded at a concentration of 1 x 
106 cells/flask (T150) that have 25 ml culture media and were passaged by 
trypsinisation technique.
Fig. 16 shows the transfection results of pEGFP into FEK4 cells using 
Lipofectin at different charge ratios. Results show that Lipofectin achieves a 
maximum of only 20 %. Lipofectin is unable to deliver DNA to primary cells 
efficiently. Also, at charge ratios higher than 1.2 there was a marked decrease in the 
number of cells due to toxic effects of the cationic lipid that was not sufficient for 












Figure 16. Lipofection of FEK4 cells transfected with pEGFP complexed with 
Lipofectin at different charge ratios. The data show 3 different experiments (3 
replicates each) and the error bars are the standard deviation.
Lipofectamine was investigated at different charge ratios in order to identify 
the optimum charge ratio for transfection. The results in Fig. 17 show that increasing 
the charge ratio will improve the transfection efficiency up to charge ratio 3.7 where 
there is no significant increase in the transfection efficiency. In addition 
Lipofectamine achieves higher transfection efficiency than Lipofectin formulation. 
Lipofectamine achieves a transfection efficiency of about 67% and 70% at charge 
ratios 3.7 and 7.3 respectively.
The transfection results of pEGFP into FEK4 using A^A^-dioleoyl spermine 
indicated a high transfection ability of A^A^-dioleoyl spermine (around 75 %) at 
charge ratios 2.5, 5.0,and 10. Also, there is no significant increase in the transfection 
ability of the lipoplex above charge ratio 2.5, as indicated in Fig. 18. The non- 
liposomal formulation A^A^-dioleoyl spermine achieves higher transfection 










Figure 17. Lipofection of FEK4 cells transfected with pEGFP complexed with 
Lipofectamine at different charge ratios. The data show 3 different experiments (3 










Figure 18. Lipofection of FEK4 cells transfected with pEGFP complexed with 
A^A^-dioleoyl spermine at different charge ratios. The data show 3 different 
experiments (3 replicates each) and the error bars are the standard deviation.
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Cancer cell line transfection studies
HtTA cells used in this study are a HeLa derivative and transformed cell line. 
The cancer cell line Hela cells are the first continuous cancer cells (cervical cancer 
cells) isolated in 1951 from the cervix of a 30-year-old mother lady called Henrietta 
Lacks, at The Johns Hopkins Hospital in Baltimore, Maryland by George Gey (235). 
The HtTA cells being stably transfected with a tetracycline-controlled transactivator 
(tTA) consisting of the tet repressor fused with the activating domain of virion 
protein 16 of the herpes simplex virus (HSV) (236). The tTA sequence stimulates 
transcription from a minimal promoter sequence and it is sensitive to the 
concentration of tetracycline (236, 237). HtTA cells were cultured in EMEM 
supplemented with FCS 10 %, penicillin and streptomycin (50 IU/ml each), 
glutamine (2 mM), and sodium bicarbonate (0.2 % w/v).
Transfection results of HtTA with the lipoplex (Lipofectin®-pEGFP) at 
different charge ratios show increase in the transfection efficiency by increasing the 
charge ratio (Fig. 19). Lipofectin shows transfection efficiency more than 50 % at 
charge ratios 0.3,0.6 and 1.2. Lipofectin achieves higher levels of EGFP expression 
in the case of cancer cell line HtTA compared to the primary cell line FEK4 
transfection results.
Also, in the case of the commercially available liposomal formulation 
Lipofectamine™ with pEGFP to form lipoplexes at different charge ratios show 
increase in the transfection efficiency by increasing the charge ratio (Fig. 20). The 
increase in the transfection efficiency is up to charge ratio 3.7 where there is no 
significant improvement in the transfection efficiency at higher charge ratios.
The same results were achieved with the lipofection of the non-liposomal 
A^jA^-dioleoyl spermine-pEGFP lipoplexes at different charge ratios. These results 
show increase in the transfection efficiency by increasing the charge ratio up to 
charge ratio 2.5 (75 %) (Fig. 21). There is no significant increase in the transfection 












Figure 19. Lipofection of FEK4 cells transfected with pEGFP complexed with 
Lipofectin at different charge ratios. The data show 3 different experiments (3 
replicates each) and the error bars are the standard deviation.
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Figure 20. Lipofection of FEK4 cells transfected with pEGFP complexed with 
Lipofectamine at different charge ratios. The data show 3 different experiments (3 











Figure 21. Lipofection of HtTA cells transfected with pEGFP complexed with 
A^A^-dioleoyl spermine at different charge ratios. The data show 3 different 
experiments (3 replicates each) and the error bars are the standard deviation.
To compare the transfection results of the lipoplexes in both the primary and 
cancer cell lines, Fig. 22 show the comparison of the expression levels in both FEK4 
and HtTA cells. Expression levels results of Lipofectin-pEGFP lipoplex in HtTA 
were higher than the transfection level achieved by the lipoplex in the primary cell 
line FEK4 at the same charge ratio investigated. It is shown in the literature that the 
cancer cell line are generally transfected easily compared with the primary cell lines 
(238, 239).
On the other hand, Lipofectamine and A^A^-dioleoyl spermine lipoplexes 
with pEGFP transfection results show almost no significant improvement in the 
expression levels of green fluorescent protein in HtTA cells in comparison with the 
results achieved in FEK4 cells (Fig. 22). This could be attributed to the high 
efficiency of Lipofectamine and A^A^-dioleoyl spermine in transfecting the primary 
cell line FEK4, transfection efficiency levels in the case of FEK4 were about 70 % 
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Figure 22. Comparison of the transfection efficiency at different charge ratios of 
FEK4 and HtTA cells transfected with pEGFP complexed with A Lipofectin, B 
Lipofectamine or C A^A^-dioleoyl spermine. The data show 3 different experiments 
(3 replicates each) and the error bars are the standard deviation.
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In-vitro cytotoxicity
Mosmann (240) has developed a rapid colorimetric assay that is widely used 
for analysing the cytotoxic effect of the gene delivering agents. The living cells when 
incubated with (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
produced a dark blue insoluble formazan crystal that is solubilzed in 
dimethylsulfoxide (DMSO) and measured spectrophotometrically (570 nm) as shown 
in Fig. 23.
The cytotoxicity of A^A^-dioleoyl spermine and the liposomal formulations 
Lipofectin and Lipofectamine were studied in FEK4 and HtTA cells. The IC50 values 
(the concentration at which cell growth is inhibited by 50 % (113)) for the 
investigated lipopolyamines were calculated. Mikos and his research group reported 
(228) that the free PEI is more toxic than the DNA complexed form. So, the 
cytotoxicity studies were carried out on both the free and complexed form to 
investigate if there is a significant difference in the toxic effects (IC50) of the free 
cationic lipid over the lipoplex form in the case of HtTA cells and FEK4 cells.
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Figure 23. MTT and the reaction product formazan.
The cytotoxicity of Lipofectin, as free or complexed with pEGFP, was studied 
in FEK4 and HtTA cells as shown in Fig. 24. The IC50 values for the free polycation 
in FEK4 and HtTA cells were 11 |Lig/ml, and for the lipoplex were 9.5 and 6.5 pg/ml 
respectively. The results indicate that there is no significant difference in the toxic 
effect (IC50) of the free polycation over the lipoplex in the case of HtTA cells and 
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Figure 24. Viability of HtTA cells (above) and FEK4 primary skin cells (below) 
after application of different concentrations of Lipofectin either free or complexed 
with pEGFP.
In the case of Lipofectamine, the cytotoxicity as free or complexed with 
pEGFP, was studied in FEK4 and HtTA cells are shown in Fig. 25. The IC50 values 
for the free cationic lipid in FEK4 and HtTA cells were 19 and 21 pg/ml respectively, 
and for the lipoplex were 25 and 21 pg/ml respectively. The results indicate that 
there is no significant difference in the toxic effect (IC50) of the free polycation over 
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Figure 25. Viability of HtTA cells (above) and FEK4 primary skin cells (below) 
after application of different concentrations of Lipofectamine either free or 
complexed with pEGFP.
In the case of A^A^-dioleoyl spermine, the IC50 values for the free 
lipopolyamine in FEK4 and HtTA cells were 20.47 and 6.31 Jig/ml respectively, and 
for the lipoplex were 19.82 and 8.35 |ig/ml respectively (Fig. 26). The results 
indicate that there is no significant difference in the toxic effect (IC50) of the free 
polycation over the lipoplex in the case of HtTA cells and FEK4 cells for the studied 
lipopolyamine. The results show that cell viability levels in the case of FEK4 are 
higher than in HtTA cells. These results also revealed that A/^A^-dioleoyl spermine 
toxicity is higher (lower concentrations) in the case of HtTA cells more than with the 
primary cell line FEK4 which could be attributed to the ease of transfection of 
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Figure 26. Viability of HtTA cells (above) and FEK4 primary skin cells (below) 
after application of different concentrations of A^A^-dioleoyl spermine either free or 
complexed with pEGFP.
Figs. 27 and 28 show the transfection efficiency results in relation to cell 
viability levels at different concentrations of Lipofectin, Lipofectamine and A^iV9- 
dioleoyl spermine for both the primary cell line FEK4 and the cancer cell line HtTA. 
These figures were plotted in order to determine the optimum charge ratio 
(concentration) of transfection. The optimum charge ratio of transfection is selected 
based on the best transfection results a cationic lipid can achieve in relation to 
acceptable cytotoxic levels at the same charge ratio. The results in Figs. 27 and 28 
show that the optimum charge ratios selected are 0.6, 3.7 and 2.5 for Lipofectin, 
Lipofectamine and V4,^ 9-dioleoyl spermine, respectively. Although the cationic 
lipids achieve higher transfection results at higher charge ratios, but this accompanied 
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Figure 27. Lipofection and cytotoxicity studies of FEK4 cells transfected with 
pEGFP complexed with A Lipofectin®, B Lipofectamine™ or C A^A^-dioleoyl 
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Figure 28. Lipofection and cytotoxicity studies of HtTA cells transfected with 
pEGFP complexed with A Lipofectin®, B Lipofectamine™ or C A^A^-dioleoyl 
spermine at different N/P charge ratios.
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Fig. 29 shows the cytotoxic effect of the investigated cationic lipids at their 
optimum charge ratio of transfection. From these results it was found that, A^ TV9- 
dioleoyl spermine show a significant difference in the % viability comparing to either 
Lipofectin® and Lipofectamine in the primary skin cell line FEK4, but there is no 
difference in the case of the cancer cell line HtTA (Fig. 10). These results also 
revealed that A^A^-dioleoyl spermine toxicity is higher (at lower concentrations) in 
the case of HtTA cells more than with the primary cell line FEK4 which could be 
attributed to the ease of transfection of immortalized cancer cell lines over primary 
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Figure 29. Cytotoxicity effect of pEGFP (2 pg/ml) complexed with either A^A9- 
dioleoyl spermine (5.54 pg/ml), Lipofectin® (5 fig/ml) or Lipofectamine™ (10 jLig/ml) 
in FEK4 and HtTA cells.
Also, the transfection efficiency of the cationic lipids at their optimum charge 
ratio of transfection were compared with the transfection results of “naked” DNA, as 
negative control, as indicated in Fig. 30. The transfection results of pEGFP into 
FEK4 indicated higher transfection ability of A^A^-dioleoyl spermine (75 %) and 
Lipofectamine™ (66 %) formulations over Lipofectin® (18 %). On the other hand, 
there is no significant difference in the transfection activity between A^A^-dioleoyl
TMspermine and Lipofectamine (Fig. 30).
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Figure 30. Lipofection of FEK4 and HtTA cells transfected with pEGFP either free 
(naked) or complexed with Lipofectin®, Lipofectamine™ or A^A^-dioleoyl spermine 
(at their respective N/P ratio for best transfection). The data show 3 different 
experiments (3 replicates each) and the error bars are the standard deviation.
While in the case of HtTA transfection results, A^A^-dioleoyl spermine and 
Lipofectamine™ formulations show a similar transfection activity (about 70 %), 
higher than Lipofectin® (58 %) (Fig. 30). A^A^-Dioleoyl spermine transfects the 
cells best at charge ratio (+/-) 2.5 (5.54 |ig/ml), Lipofectin® at charge ratio 0.6 (5.0
TM
|ig/ml), while Lipofectamine transfect both cell lines at charge ratio 3.7 (10.0 
pg/ml).
These results revealed that the difficulties found in efficiently transfecting 
primary cell lines were largely overcome with the non-liposomal formulation A/4,^ 9- 
dioleoyl spermine comprising a vector with two covalently bound oleoyl chains. The 
helper lipid DOPE which is the second component of the cationic liposomal 
formulations is used to increase the transfection activity of the cationic liposomes 
through its ability to destabilise lipid bilayer leading to endosomal destabilisation 
with subsequent increase in the total cellular uptake of the delivered DNA (91, 209).
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Lipospermines (Fig. 2) with their cationic head-group sometimes form 
micelles (in the absence of DNA) rather than the bilayer produced by the small 
cationic quaternary ammonium head-group of DOTMA (Lipofectin® formulation) 
(226, 241). /V^A^-Dioleoyl spermine combines in its structure the two oleoyl chains 
that have the characteristics of the fusogenic lipid DOPE and the cationic polyamine 
spermine (Fig. 2). Thus, DNA is condensed by the two primary amines and coated by 
the dioleoyl lipophilic moiety. The DNA condensation results obtained with N*J\P- 
dioleoyl spermine (Fig. 10) show a higher efficiency than either liposomal 
formulation.
The transfection results reveal higher transfection ability (levels of 
expression) of A^A^-dioleoyl spermine compared to Lipofectin® (Fig. 30) in FEK4 
and HtTA cells. These results indicate the roles of both number and distribution of 
positive charges along the polyamine backbone on the ability of the compound to 
condense DNA. On the other hand, there is no significant difference in the 
transfection activity between A^JN^-dioleoyl spermine and Lipofectamine™ in both 
FEK4 and HtTA cell lines, which indicates the importance of lipid coating over the 
DNA molecule on both the condensation and cellular delivery of DNA in the case of 
the liposomal and non-liposomal formulations (241). A^^-Dioleoyl spermine 
achieved high levels of transfection in both a cancer cell line and a primary skin cell 
line (73 %) which indicates the ability of this vector to deliver DNA.
Cell viability results revealed improved FEK4 viability more than the cancer 
cells HtTA (Fig. 29). Also, A^^-dioleoyl spermine showed a significant 
improvement in primary FEK4 cell viability over the liposomal formulations (Fig.
29), but no significant difference in HtTA cells. In conclusion, in this chapter, a 
lipopolyamine vector has been developed for DNA delivery. This new non-liposomal 
formulation has the ability to transfect primary skin cells more efficiently than the 
commercially available liposomal Lipofectin® formulation. These promising results 
draw our attention to the role of the degree of unsaturation of the lipospermine lipid 
moiety in the transfection efficiency and therefore whether a change in the lipid 
hydrophobic domain could improve the interactions of the lipospermine with DNA 
and/or with cellular components (e.g. for endosome escape). In chapter 4, we 
investigate changes in the shape of the C l8  lipid moieties.
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CHAPTER 4
Efficient Non-Viral Gene Delivery Using 
C18-Lipid Conjugates of Spermine
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Introduction
As viral gene therapy continues to suffer significant problems with 
mammalian toxicity (7, 8 , 242), the possibility of reaching the goal of intracellular 
protein levels at therapeutic concentrations moves even more towards utilising non- 
viral gene therapy (NVGT). Within this broad term, we are concentrating on 
lipopolyamines composed either of a lipophilic steroid attached to a polyamine chain 
(145, 171, 210, 243, 244), or to a single or double long-carbon chain covalently 
bound to a polyamine e.g. spermine (A^A^-diamino^^-diazadodecane) (241, 245). 
Other research groups are investing in a variety of alternative approaches classified 
under the NVGT umbrella, including: naked DNA (246), gene gun (bound to gold 
particles) (115, 247), electroporation (248), polycation-mediated DNA delivery, and 
the use of a wide variety of cationic lipids (lipoplexes) (63), e.g. bolaamphiphiles 
(69), and cationic polymers (polyplexes) (206, 249, 250), for reviews see: (10, 30, 
251-253).
For gene therapy to realise its potential and become an efficient medicine for 
the treatment of diseases such as cancer, cystic fibrosis, inflammation, or for 
vaccination, key obstacles must be overcome. The essential requirements for gene 
delivery are the transport of DNA through the cell membrane and ultimately to the 
nucleus. The design of an efficient formula for the delivery of genetic material 
requires a detailed understanding of the barriers that hinder this process.
Thus, efficient formulations, lipoplexes (63, 69) polyplexes (206, 249, 250), 
must be able to deliver safely the required DNA across the various cellular barriers to 
the nucleus. Barriers to DNA delivery also include complex formation between the 
DNA and the lipopolyamine leading to DNA nanoparticle formation by electrostatic 
charge neutralisation (to about 90 % of the total negative charge) and overall packing 
as condensed DNA nanoparticles (22). So, a key first step in this method of gene 
formulation is masking the negative charges of the phosphate backbone. This 
titration with a lipopolyamine causes alleviation of charge repulsion between remote 
phosphates along the DNA helix leading to collapse into a more compact structure 
that facilitates cell entry.
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For NVGT, except for naked (free, uncomplexed) DNA being trapped inside 
cells by direct association with the chromatin during mitosis, the (prodrug) DNA 
must be formulated. Small molecule synthetic cationic lipids are one of the major 
gene carriers for NVGT, often classified as liposomal and non-liposomal non-viral 
delivery vectors. They condense DNA into nanoparticles that are readily endocytosed 
by cultured cells, and facilitate endosomal escape leading to efficient delivery to the 
nucleus presumably crossing through the nuclear pore complex. After nuclear entry, 
the payload DNA should ultimately be able to give the desired protein through 
transcription and translation.
The first cellular barrier for the delivery of the DNA nanoparticles is the 
eukaryotic cell membrane which is composed mainly of phospholipids (50-90 % of 
total lipid content, most phospholipids are derivatives of diacyl-glycerol-3- 
phosphate), sterols (5-25 %), and glycol-lipids (usually less than 5 %). The diacyl- 
glycerol chains (C14 to C24) are derived from linear fatty acids with varying degrees 
of unsaturation (254). In NVGT, cationic lipids which interact with the DNA payload 
also mediate cell-membrane transport, typically through adsorptive endocytosis or 
mediated by cations (157, 158, 255), both routes leading to internalization of the 
DNA complex nanoparticles. Such endocytosis is via the clathrin-coated pits (250- 
300 nm) (256), followed by fusion of the early endosome and sorting to the late 
endosomal compartment, hence avoiding degradation in the lysosome.
One of the important factors to improve the release of free DNA or the 
lipoplex into the cytoplasm is the influence of the cationic lipid chain. Xu and Szoka 
(93) have reported that unsaturated hydrocarbon chains increase the transfection 
efficiency of the lipoplex by decreasing the rigidity of the bilayer and favouring a 
higher inter-membrane transfer rate and lipid mixing, compared to their saturated 
counterparts. However, Engberts, Hoekstra, and co-workers recently reported that, in 
certain cases, saturated fatty chains afforded better results than unsaturated chains 
(257). Also, Heyes et al. (176) showed that, among the cationic lipid analogues they 
synthesized with variation in the degree of saturation, the saturated C l8  conjugates 
were internalized in to the cells more, although they are less efficient in gene 
silencing (siRNA delivery).
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In this chapter, we investigate the effects on DNA formulation of a circular 
plasmid with variation in the degree of unsaturation in the two Cl 8 fatty chains in our 
lipospermines, the saturated iV^A^-distearoyl spermine, the alkenoic A^A^-dioleoyl 
spermine, and the dienoic fatty acyl spermine conjugate A^A^-dilinoleoyl spermine 
(Fig. 1). We report the synthesis of the lipopolyamines and characterisation of the 
lipoplexes nanoparticles formed, transfection results with the synthesized 
lipospermine formulations in a panel of both primary and cancer cell lines, and 
compare these results with those obtained with the commercially available non- 






Figure 1. Spermine based lipopolyamines, A^A^-distearoyl spermine, A^A^-dioleoyl 
spermine, A^A^-dilinoleoyl spermine and Transfectam®.
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Figure 2. Synthetic scheme of spermine based cationic lipids: TV^A^-distearoyl 
spermine 1, A^A^-dioleoyl spermine 2, and A^A^-dilinoleoyl spermine 3. Reagents: 
i) ethyl trifluoroacetate, methanol, 18 h at 20 °C; ii) fatty acyl chloride, R = (stearoyl 
1, oleoyl 2, and linoleoyl 3), triethylamine, CH2CI2 and methanol (1:1), 72 h at 20 °C; 
iii) methanol saturated with ammonia gas, 18 h at 20 °C.
Synthesis of lipospermines A^^-dilinoIeoyl spermine, A^^-dioleoyl spermine, 
and A^^-distearoyl spermine
The tetra-amine spermine was used as the starting material for the synthesis of 
the three desired lipopolyamines: A^A^-distearoyl spermine 1, A^A^-dioleoyl 
spermine 2 ,  A^A^-dilinoleoyl spermine 3 ,  outlined in Fig. 2. The tetra-amine was 
protected on both the primary amino functional groups with ethyl trifluoroacetate (2 .2  
eq.) in methanol and the reaction mixture was stirred for 18 h at 20 °C to form Nl JV12- 
ditrifluoroacetyl-l,12-diamino-4,9-diazadodecane R f  0.7 (CTkCk-MeOH-conc. aq. 
NH3 25:10:1 v/v/v).
Each corresponding fatty acyl chloride (stearoyl, oleoyl, or linoleoyl) (2.2 eq) 
was used as the acylating agent together with triethylamine (2.5 eq) to the diprotected 
spermine solution in CH2CI2 and methanol (1:1). The solution was stirred for 72 h at 
20 °C, and then evaporated to dryness in vacuo. The residue was dissolved in C H 2 C I 2  
and the solution filtered and evaporated to dryness in vacuo to form A^^V9- 
(dilinoleoyl, dioleoyl (187), or distearoyO-AT^^-ditrifluoroacetyl-l^-diamino-^- 
diazadodecane.
For the removal of the di-trifluoroacetyl protecting groups, the tetra-amide 
was dissolved in methanol and the pH of the solution was increased by saturating 
with ammonia gas, then it was left for 18 h at 20 °C, and then evaporated to dryness 
in vacuo to give a residue which was purified over silica gel (C^Cfc-MeOH 5:3 v/v, 
then CH2Cl2-MeOH-conc. aq. N H 3 25:10:1 v/v/v) to afford the three desired 
lipopolyamine conjugates as their free bases. Flash column chromatography afforded 
the three target lipospermines, homogenous on silica gel thin-layer chromatography 
and characterized by high-resolution mass spectroscopy (HRMS).
A^A^-Distearoyl spermine 1 Rf = 0.41 (CH2Cl2-MeOH-conc. aq. NH3 25:10:1 
v/v/v), C46H95N4O2 found (m/z [M+H]+) 735.7458, requires 735.7455 (A ppm -0.4), 
C4513CH95N4C>2 found 736.7500, requires 736.7489 (A ppm -1.5), C46H952HN4C>2 
found 736.7500, requires 736.7533 (A ppm 4.6). A^^-Dioleoyl spermine 2  R f  =
0.44 (CH2Cl2-MeOH-conc. aq. NH3 25:10:1 v/v/v), C46H91N4O2 found (m/z [M+H]+)
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731.7115, requires 731.7142 (A ppm 3.7), C4513CH9iN4C>2 found 732.7145, requires 
732.7176 (A ppm 4.1). A^^-Dilinoleoyl spermine 3  R f  = 0.49 (CFkCk-MeOH-conc. 
aq. NH3 25:10:1 v/v/v), C46H87N4O2 found (m/z [M+H]+) 727.6846, requires 
727.6829 (A ppm -2.3), C4513CHg7N4 0 2  found 728.6857, requires 728.6863 (A ppm 
0.7).
Preparation of plasmid DNA
We have chosen to deliver a 4.7 kbp plasmid encoding for enhanced green 
fluorescent protein (pEGFP), with a molecular weight of about 3.1 MegaDa (given an 
average of 330 Da per nucleotide, 660 Da per bp (5), carrying 9,400 negative charges. 
DNA plasmid pEGFP, purchased from Clontech, was transformed into Escherichia 
coli JM 109 bacterial strain (Promega) and purified by a Qiagen Maxi kit (Qiagen). 
DNA yields and purity were determined spectroscopically (OD260/OD280 = 1.80-1.90 
OD, optical density) and by agarose gel (1 %) analysis.
DNA condensation
In this study, we have investigated the change in the degree of unsaturation of 
the di-C18 fatty chain formulation of lipospermine on DNA condensation and 
formation of nanoparticles. DNA condensation was monitored using an ethidium 
bromide (EthBr) fluorescence quenching and light scattering assays as described in 
detail in the materials and methods chapter. The results were compared with the 
commercially available lipospermine Transfectam®.
Ethidium bromide fluorescence quenching assay
DNA ( 6  pg) was diluted to 3 ml with buffer (20 mM NaCl, 2 mM HEPES, 10 
pM EDTA, pH 7.4) in a glass cuvette stirred with a micro-flea. EthBr solution (3 pi, 
0.5 mg/ml) was added to the stirring solution and allowed to equilibrate for 10 min. 
Separately, lipopolyamine aliquots (5 pi, according to the ammonium/phosphate (+/-) 
charge ratio required) were then added to the stirring solution and the fluorescence 
measured after 1 min equilibration using a Perkin-Elmer LS 50B luminescent
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spectrometer (A*XCit = 260 nm and XemiSS = 600 nm with slit width 5 nm) while stirring 
using an electronic stirrer (Rank Bros. Ltd.). The fluorescence was expressed as the 
percentage of the maximum fluorescence when EthBr was bound to the DNA in the 
absence of competition for binding and was corrected for background fluorescence of 
free EthBr in solution.
Behr, Vierling and co-workers (185) showed that the commercially available 
non-liposomal formulation Transfectam® (DOGS, Fig. 1) has a pKa values of 10.5, 
9.5, 8.4 and 5.5, and according to Henderson-Hasselbach equation, Transfectam® has 
3 positive charges / molecule (more accurately 2.92) at pH 7.4. They also indicate 
that the lowest nitrogen has the same pKa value of the lysosome pH (5.5) which will 
have a role to improve the transfection efficiency of the lipospermine through 
buffering the decrease in the pH inside the endosome.
Fig. 3 shows the DNA condensation ability of the synthesized lipopolyamine 
formulations in comparison with the commercially available Transfectam® in an 
EthBr fluorescence quenching assay. Three cationic lipid formulations A4,N9- 
dilinoleoyl spermine, A^A^-dioleoyl spermine, and the commercially available 
Transfectam® show similar DNA condensing ability. Also, they are able to condense 
DNA completely (defined as more than 90 % EthBr fluorescence quenching (19, 22)) 
at N/P charge ratio 2, while N4, A^-distearoyl spermine is only able to displace around 
80 % of EthBr at the same charge ratio.
To quantify the ability of the investigated lipopolyamines in condensing 
DNA, the binding constant of these polyamines with DNA was estimated (Table 1) 
and compared using EthBr assay that has been shown to be a valid method for 
comparison of DNA binding affinity (144, 194, 221). The drug concentration 
producing 50 % inhibition of fluorescence is approximately inversely proportional to 
the binding constant (194). From Table 1 data, the concentrations of condensing 
agents producing 50 % fluorescence inhibition were calculated as shown in the 
experimental chapter. The Kapp of lipopolyamines (A^^-distearoyl spermine, iV4,^ 9- 
dioleoyl spermine, TV^A^-dilinoleoyl spermine and Transfectam®) binding was 
calculated taking into account that the binding constant of ethidium is 107 M 1 (194) 
and the concentration of EthBr is 1.3 juM. From these results it was found that
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Transfectam® has the highest binding affinity (A'app 1.1 x 107 M'1) between the 
compared polyamines and A^A^-distearoyl spermine the lowest with binding affinity 
(A^aPp 0.4x107 M'1) which could be attributed to the higher number of positive charges 
(+3.0) and the charge distribution on Transfectam® compared with A^A^-distearoyl 
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Figure 3. Plot of EthBr fluorescence quenching assay of calf thymus DNA 
complexed with A^^-distearoyl spermine, TV^A^-dioleoyl spermine, A^A9- 
dilinoleoyl spermine, or Transfectam®.
Table 1. Calf thymus DNA binding data
Condensing agent
Drug concentration at 50 % 
fluorescence quenching (pM)
ATapp*
A^A^-distearoyl spermine 3.3 4xl06 M'1
A^A^-dioleoyl spermine 1.7 8xl06 M 1
A^A^-dilinoleoyl spermine 1.8 7xl06 M'1
Transfectam® 1 .2 l.lxlO 7 M 1
* “apparent” equilibrium binding constant of condensing agent to calf thymus DNA
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Light scattering assay
The apparent UV absorbance at 320 nm showing light scattering was 
measured to investigate the condensation of DNA by lipopolyamines and the 
formation of particles (20). The formation of DNA nanoparticles causes scattering of 
light that reduces light intensity at the UV detector.
Fig. 4 shows the increase in apparent absorbance by light scattering of the 
formed particles as a result of interaction of A^A^-distearoyl spermine, A^V9- 
dioleoyl spermine and A^A^-dilinoleoyl spermine with calf thymus DNA. The 
maximum apparent absorption was reached at a charge ratio of 2.5, 1.7 and 1.5 in the 
case of A^A^-distearoyl spermine, A^A^-dioleoyl spermine and A^A^-dilinoleoyl 
spermine, respectively. These results indicate improved ability of A^A^-dioleoyl 
spermine and A^A^-dilinoleoyl spermine to condense DNA and form particles over 
A^A/9-distearoyl spermine, which were also similar with the results concluded from 
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Figure 4. Light scattering assay (relative maximum apparent absorbance at X = 320 
nm) of calf thymus DNA with the lipospermines: A^A^-distearoyl spermine V4,^9- 
dioleoyl spermine and A^A^-dilinoleoyl spermine.
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Fig. 5 shows the plot of EthBr fluorescence quenching and light scattering 
data of A^A^-dilinoleoyl spermine interacted with calf thymus DNA. These results 
reveal that the light scattering due to particle formation increases with the increase in 
the displaced EthBr and reaches the maximum at approximately the same charge ratio 
region (1.5-1.7) at which there is a maximum EthBr displacement. This comparison 
show that the validity of both experiments to investigate DNA condensation studies, 
although the concentration of DNA used in light scattering experiments is ten times 
the concentration used in fluorescence quenching experiments which is related to the 
lack of sensitivity of light scattering experiment in comparison with EthBr 
fluorescence assay.
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Figure 5. Comparison of EthBr fluorescence quenching and light scattering assays of 
calf thymus DNA with A^A^-dilinoleoyl spermine.
Cell culture and transfection experiments
Six cell lines were used in the transfection experiment, FEK4 (196), FCP4, 
FCP5, FCP7 and FCP8 cells are human primary fibroblasts derived from newborn 
foreskin explants (198). HtTA cells are a human cervical carcinoma, HeLa derived 
and transformed cell line. Cells were cultured in Earle’s Minimal Essential Medium 
(EMEM) supplemented with foetal calf serum (FCS) 15 % in the case of FEK4 and 
FCP cells and 10 % in the case of HtTA cells, penicillin and streptomycin (50 IU/ml
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each), glutamine (2 mM), and sodium bicarbonate (0.2 %). Primary cells were 
passaged once a week, and used between passages 7-15.
For the transfection (gene delivery) and the resultant gene activity 
(transfection efficiency), cells were seeded in 6 -well plates at a density of 1 x 1 0 5 
cells/well (in 4 ml EMEM with FCS) for 24 h to reach a 50-60 % confluency on the 
day of transfection. The complex was prepared by mixing pEGFP (2 |ng/ml/well) 
with each lipopolyamine in Opti-MEM (serum free media, Gibco BRL) according to 
the charge ratio at 20 °C for 30 mins, and then incubated with the cells for 4 h at 37 
°C in 5 % CO2. Then the cells were washed and cultured for a further 44 h in growth 
medium at 37 °C in 5 % CO2.
Levels of EGFP in the transfected cells were detected and corrected for 
background fluorescence of the control cells using a fluorescence activated cell 
sorting (FACS) machine (Becton Dickinson FACS Vantage dual Laser Instrument, 
argon ion laser 488 nm). The transfection efficiency was calculated based on the 
percentage of the cells that expressed EGFP (positive cells) in the total number of 
cells.
Primary skin cell transfection studies
A panel of five primary skin cell lines were used in the transfection 
experiment, FEK4, FCP4, FCP5, FCP7 and FCP8  cells are human primary fibroblasts 
derived from newborn foreskin explants. The use of a group of primary cell lines is 
to validate the transfection efficiency results of the investigated lipopolyamines as 
primary cell lines are well known as a difficult to transfect cell lines (233, 234).
The synthesized lipopolyamines and Transfectam® were investigated for their 
gene delivery ability in FCP4 cells using pEGFP as a reporter gene. Fig. 6  shows the 
transfection results of pEGFP into FCP4 using A^A^-distearoyl spermine at different 
charge ratios. These results show that A^^-distearoyl spermine is unable to achieve 
high transfection efficiency in FCP4 cell line up to charge ratio 20. Fig. 6  shows that 
A^^-distearoyl spermine achieves a maximum of 21 % transfection efficiency from 
charge ratio 20. In the case of Transfectam®, results shown in Fig. 7 revealed that
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commercially available lipopolyamine achieves higher transfection efficiency 
compared to A^A^-distearoyl spermine. Transfectam® shows the highest gene 











Figure 6 . Lipofection of FCP4 cells transfected with pEGFP complexed with TV4^ /V9- 
distearoyl spermine at different charge ratios. The data show 3 different experiments 
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Figure 7. Lipofection of FCP4 cells transfected with pEGFP complexed with
Transfectam® at different charge ratios. The data show 3 different experiments (3
replicates each) and the error bars are the standard deviation.
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On the other hand, A/^A^-dilinoleoyl spermine show higher transfection 
efficiency levels in comparison with A^A^-distearoyl spermine, Transfectam® and 
A^A^-dioleoyl spermine that achieves 62 % transfection efficiency at the optimum 
charge ratio of transfection (N/P 2.5). A^A^-Dilinoleoyl spermine achieves 
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Figure 8 . Lipofection of FCP4 cells transfected with pEGFP complexed with iV4,^9- 
dilinoleoyl spermine at different charge ratios. The data show 3 different experiments 
(3 replicates each) and the error bars are the standard deviation.
In the case of FCP5 cell line, transfection results of A^A^-distearoyl spermine 
show that the lipopolyamine was only able to achieve 31 % of transfection efficiency 
at charge ratio 15 (Fig. 9). Transfectam® was able to achieve higher green fluorescent 
protein expression levels of more than 60 % from charge ratio 5.9 as shown in Fig.
10. Similarly, A^A^-dioleoyl spermine achieves 68 % transfection efficiency at 
charge ratio 2.5. On the other hand, A^A^-dilinoleoyl spermine shows a significant 
improvement in the transfection efficiency over the investigated lipopolyamines. The 
double unsaturated C l8 spermine conjugate achieves more than 90 % transfection 
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Figure 9. Lipofection of FCP5 cells transfected with pEGFP complexed with A^N9- 
distearoyl spermine at different charge ratios. The data show 3 different experiments 
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Figure 10. Lipofection of FCP5 cells transfected with pEGFP complexed with
Transfectam® at different charge ratios. The data show 3 different experiments (3
replicates each) and the error bars are the standard deviation.
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Figure 11. Lipofection of FCP5 cells transfected with pEGFP complexed with 
A^A^-dilinoleoyl spermine at different charge ratios. The data show 3 different 
experiments (3 replicates each) and the error bars are the standard deviation.
In the case of FCP7 cell line, A/^A^-distearoyl spermine is not able to transfect 
the cells efficiently. The results in Fig. 12 show that A^A^-distearoyl spermine is 
able to transfect FCP7 cell line by 24 % at charge ratio 15. Also, the transfection 
results show that the lipopolyamine is not able to transfect the cell line at charge 
ratios lower than N/P 10. While in the case of Transfectam®, the results revealed that 
the commercially available lipopolyamine achieves higher transfection levels by more 
than 54 % from charge ratio 5.9, as shown in Fig. 13. A^A^-Dioleoyl spermine 
transfects the cell line by 61 % at charge ratio 2.5. Also similar to FCP5 cells 
transfection results, A^A^-dilinoleoyl spermine continues to show a significant 
improvement in the transfection levels Fig. 14. The cationic lipid achieves more than 
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Figure 12. Lipofection of FCP7 cells transfected with pEGFP complexed with 
A^A^-distearoyl spermine at different charge ratios. The data show 3 different 
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Figure 13. Lipofection of FCP7 cells transfected with pEGFP complexed with
Transfectam® at different charge ratios. The data show 3 different experiments (3
replicates each) and the error bars are the standard deviation.
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Figure 14. Lipofection of FCP7 cells transfected with pEGFP complexed with 
A^A^-dilinoleoyl spermine at different charge ratios. The data show 3 different 
experiments (3 replicates each) and the error bars are the standard deviation.
Transfection results of the primary skin cell line FCP8 show that N4,7V9- 
distearoyl spermine is not able to transfect the cells efficiently. The results revealed 
in Fig. 15 show that A^A^-distearoyl spermine is able to transfect FCP8 cell line by 
22 % at charge ratio 20. While Transfectam® achieves higher transfection levels by 
up to 52 % at charge ratio 9.8 (Fig. 16). A^A^-Dioleoyl spermine transfects the cell 
line by 65 % at charge ratio 2.5. The transfection results of pEGFP into FEK4 using 
TV^A^-dilinoleoyl spermine indicated a high transfection ability of TV^A^-dioleoyl 
spermine more than 75 % transfection efficiency from charge ratio 5.5 (Fig. 17). 
Also, there is no significant increase in the transfection ability of A^A^-dilinoleoyl 












Figure 15. Lipofection of FCP8 cells transfected with pEGFP complexed with 
A^A^-distearoyl spermine at different charge ratios. The data show 3 different 
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Figure 16. Lipofection of FCP8 cells transfected with pEGFP complexed with
Transfectam® at different charge ratios. The data show 3 different experiments (3
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Figure 17. Lipofection of FCP8 cells transfected with pEGFP complexed with 
A^A^-dilinoleoyl spermine at different charge ratios. The data show 3 different 
experiments (3 replicates each) and the error bars are the standard deviation.
Fig. 18 shows the transfection results of pEGFP into FEK4 cells using A4,7V9- 
distearoyl spermine at different charge ratios. Results show that A^^-distearoyl 
spermine achieves a maximum of only 30 % at charge ratio 20. The di-Cl 8 saturated 
spermine conjugate is unable to deliver DNA to primary cell lines efficiently. On the 
other hand Transfectam®-DNA lipoplex shows a significant increase in the 
transfection efficiency by up to 79 % at charge ratio 5.9 (Fig. 19). As shown in the 
previous chapter, A^A^-Dioleoyl spermine transfects the cell line by 76 % at charge 
ratio 2.5. In addition, A^A^-dilinoleoyl spermine cationic lipid achieves more than 85 
% transfection efficiency levels from charge ratio 5.5 as shown in Fig. 20. These 
results revealed that TV^A^-dilinoleoyl spermine is the most efficient cationic lipid 
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Figure 18. Lipofection of FEK4 cells transfected with pEGFP complexed with 
A^A^-distearoyl spermine at different charge ratios. The data show 3 different 












Figure 19. Lipofection of FEK4 cells transfected with pEGFP complexed with 
Transfectam® at different charge ratios. The data show 3 different experiments (3 
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Figure 20. Lipofection of FEK4 cells transfected with pEGFP complexed with 
A^A^-dilinoleoyl spermine at different charge ratios. The data show 3 different 
experiments (3 replicates each) and the error bars are the standard deviation.
Cancer cell transfection studies
HeLa derivative and transformed cell line HtTA was used as a model for 
continuous cancer cell line to investigate the transfection ability of the studied 
lipopolyamines. Expression levels results of A^A^-distearoyl spermine-pEGFP 
lipoplex in HtTA at different charge ratios show that the cationic lipid achieves a 
maximum of 26 % at charge ratio 15 (Fig. 21). The expression levels were improved 
by the use of the lipopolyamine Transfectam® lipoplex to 79 % (Fig. 22).
Transfectam® show a significant improvement in the transfection levels of the 
cancer cell line HtTA compared to the primary cell lines at different charge ratios, 
from 61 % at charge ratio 2.9 to up to 80 % transfection levels at charge ratio 9.8 
(Fig. 22). A^A^-Dioleoyl spermine achieves 75 % transfection efficiency at the 
optimum charge ratio of transfection 2.5 as indicated in the previous chapter. The 
lipofection A^A^-dilinoleoyl spermine-pEGFP lipoplexes at different charge ratios 
show a significant increase in the transfection efficiency by increasing the charge 
ratio (Fig. 23) up to charge ratio 5.5 (99 %). There is no significant increase in the 
transfection efficiency at higher charge ratios than 5.5.
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Figure 21. Lipofection of HtTA cells transfected with pEGFP complexed with 
TV^A^-distearoyl spermine at different charge ratios. The data show 3 different 
experiments (3 replicates each) and the error bars are the standard deviation.
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Figure 22. Lipofection of HtTA cells transfected with pEGFP complexed with 
Transfectam® at different charge ratios. The data show 3 different experiments (3 




Figure 23. Lipofection of HtTA cells transfected with pEGFP complexed with 
A^A^-dilinoleoyl spermine at different charge ratios. The data show 3 different 
experiments (3 replicates each) and the error bars are the standard deviation.
In-vitro cytotoxicity
A panel of five primary skin cell lines FEK4, FCP4, FCP5, FCP7 and FCP8 
cells and cancer cell line HtTA used in the transfection experiment were used for the 
cytotoxicity studies. The cytotoxicity of the synthesized lipopolyamines and the 
commercially available lipopolyamine Transfectam® was studied. The cytotoxicity of 
A^A^-distearoyl spermine complexed with pEGFP was studied in the primary cell 
lines FCP4, FCP5 and FCP7 cells at different charge ratios as shown in Fig. 24. The 
lipoplex show high levels (more than 50 %) cell viability up to charge ratio 20 in the 
investigated cell lines. The results indicate 76 %, 63 % and 73 % cell viability at 
charge ratio 20 in the case of FCP4, FCP5 and FCP7, respectively. This could be 
related to the inability of the lipoplex to cross the cellular membrane, one of the main 
gene delivery barriers, which clear from the low transfection levels and higher 
viability levels.
In the case of the primary cell line FCP8 and FEK4 and the cancer cell line 
HtTA, A^A^-distearoyl spermine lipoplex with pEGFP show high levels (more than 




































Figure 24. Viability of primary skin cell lines A FCP4, B FCP5 and C FCP7 cells 
after application of iV^A^-distearoyl spermine complexed with pEGFP at different 
charge ratios. The data show 3 different experiments (3 replicates each) and the error 
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Figure 25. Viability of primary skin cell lines A FCP8 and B FEK4 and the cancer 
cell line C HtTA cells after application of A^A^-distearoyl spermine complexed with 
pEGFP at different charge ratios. The data show 3 different experiments (3 
replicates each) and the error bars are the standard deviation.
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Fig. 26 shows cell viability of FCP4, FCP5 and FCP7 primary cells after 
application of Transfectam® lipoplex at different charge ratios. The results show that 
44 %, 39 %, 31 % cell viability at charge ratio 9.8 in the case of FCP4, FCP5 and 
FCP7, respectively Fig. 26. In the case of FCP8  and FEK4, Transfectam® lipoplex 
shows 49 % and 31 % cell viability at charge ratio 9.8, as shown in Fig. 27. In the 
case of HtTA cell line, as in the case of the primary cell lines, cell viability decreases 
with increase in the charge ratio and the lipoplex show 43 % at charge 9.8 Fig. 27.
In the case of A4 JN^-dilinoleoyl spermine lipoplexes, viability of FCP4, FCP5 
and FCP7 primary cells at different charge ratios show a decrease with increase in the 
charge ratio (Fig. 28). The results show FCP4 cell viability of 29 % at charge ratio 
7.5 and 44 % and 54 % cell viability at charge ratio 6.5 in the case of FCP5 and FCP7 
respectively (Fig. 28). The increased toxicity levels of the lipoplex could be 
attributed to the high efficiency of the lipopolyamine in transfecting the primary and 
cancer cell lines investigated.
In the case of the primary cell lines FCP8  and FEK4, cell viability results in 
Fig. 29 show 41 % and 43 % at charge ratio 7.5, respectively. In the case of HtTA 
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Figure 26. Viability of primary skin cell lines A FCP4, B FCP5 and C FCP7 cells 
after application of Transfectam® complexed with pEGFP at different charge ratios. 












































Figure 27. Viability of primary skin cell lines A FCP8 and B FEK4 and the cancer 
cell line C HtTA cells after application of Transfectam® complexed with pEGFP at 
different charge ratios. The data show 3 different experiments (3 replicates each) and 
























Figure 28. Viability of primary skin cell lines A FCP4, B FCP5 and C FCP7 cells 
after application of A^A^-dilinoleoyl spermine complexed with pEGFP at different 
charge ratios. The data show 3 different experiments (3 replicates each) and the error 
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Figure 29. Viability of primary skin cell lines A FCP8 and B FEK4 and the cancer 
cell line C HtTA cells after application of A^A^-dilinoleoyl spermine complexed with 
pEGFP at different charge ratios. The data show 3 different experiments (3 replicates 
each) and the error bars are the standard deviation.
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Fig. 30 shows the transfection efficiency results in relation to cell viability 
levels at different charge ratios A^A^-distearoyl spermine for both the primary cell 
lines and the cancer cell line HtTA in order to determine the optimum charge ratio 
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Figure 30. Lipofection and cytotoxicity studies of the primary cells A FCP4, B
FCP5, C FCP7, D FCP8 and E FEK4 and F the carcinoma cell line HtTA transfected
with pEGFP complexed with A^A^-distearoyl spermine at different N/P charge ratios.
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In the case of Transfectam lipoplexes, the transfection efficiency results in 
relation to cell viability levels at different charge ratios show that the optimum charge 
ratio of transfection is 5.9 (15.0 Jig/ml) as shown in Fig. 31.
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Figure 31. Lipofection and cytotoxicity studies of the primary cells A FCP4, B
FCP5, C FCP7, D FCP8 and E FEK4 and F the carcinoma cell line HtTA, transfected
with pEGFP complexed with Transfectam® at different N/P charge ratios.
133
The optimum N/P charge ratios (and corresponding concentrations) for 
transfection for A^A^-dilinoleoyl spermine lipoplexes in primary and HtTA cell lines 
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Figure 32. Lipofection and cytotoxicity studies of the primary cells A FCP4, B FCP5,
C FCP7, D FCP8 and E FEK4 and F the carcinoma cell line HtTA, transfected with
pEGFP complexed with /V^A^-dilinoleoyl spermine at different N/P charge ratios.











The transduction of pEGFP into a series of primary skin cell lines (FEK4, 
FCP4, FCP5, FCP7, and FCP8) and a cancer cell line (HeLa derived HtTA) was 
investigated using our novel lipopolyamines. The transfection results at their 
optimum charge ratio of transfection indicate the improved transfection ability of 
A^A^-dilinoleoyl spermine, greater than 85 % in many of the studied primary cell 
lines (80 % for FCP8 cells) and 99 % in the case of the cancer cell line HtTA 
compared to the saturated A^A^-distearoyl spermine (18-32 %), the mono­
unsaturated A4,A9-dioleoyl spermine (62-75 %), and the commercially available 
Transfectam® (46-79 %) (Fig. 33).
As a negative control, naked (uncomplexed circular) pEGFP DNA typically 
gave 1-2 % transfection of these cell lines. Also, the shift in the EGFP positive cells 
compared to the untransfected cells in FACS analysis (Figs. 34 and 35), show the 
high efficiency of A^A^-dilinoleoyl spermine of transfecting both primary (e.g. 










Figure 33. Lipofection of the primary skin cell lines (FEK4, FCP4, FCP5, FCP7, and 
FCP8) and the cancer cell line HtTA transfected with pEGFP complexed with N4,A9- 
distearoyl spermine, A^A^-dioleoyl spermine, A^A^-dilinoleoyl spermine, and 
Transfectam® (at their respective N/P ratios for best transfection). The data show 3 
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Figure 34. FACS analysis of FEK4 cells after 48 h transfection of pEGFP either A 
free or complexed with B A^A^-distearoyl spermine, C A^A^-dioleoyl spermine, D 
A^A^-dilinoleoyl spermine or E Transfectam®: ■  untransduced cells, □  e g f p  
positive cells, Mi is the fluorescence intensity range.
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Figure 35. FACS analysis of HtTA cells after 48 h transfection of pEGFP either A 
free or complexed with B A^A^-dilinoleoyl spermine (at the optimum charge ratio of 
transfection, 5.5): ■  untransduced cells, □  EGFP positive cells, Mi is the 
fluorescence intensity range.
Cell viability (MTT assay (240)) results indicate that there is no significant 
difference in lipoplex toxicity, at the respective N/P ratios for best transfection, in the 
case of HtTA and FCP8 primary skin cells for all four studied lipopolyamines, A/4,^ 9- 
distearoyl spermine, A^A^-dioleoyl spermine, A^A^-dilinoleoyl spermine and 
Transfectam® with percentage cell viability about 70 % and 75 % in the case of the 
cancer cell line HtTA and the primary skin cells FCP8, respectively (Fig. 36). Only 
small differences were observed across the other four primary skin cell lines (FEK4, 
FCP4, FCP5 and FCP7) often with percentage cell viability about 80 %.
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The lipopolyamine A^A^-dilinoleoyl spermine that show the best transfection 
results of the investigated lipopolyamines, typically shows 70 % cell viability in most 
of the studied cell lines, and such a value has recently been reported to be acceptable 
for a safe DNA delivery vector (258). The cytotoxicity results of the lipoplexes were 
compared with the viability of both primary and cancer cell lines transfected with 
uncomplexed (naked) pEGFP (Fig. 36).
HtTA FEK4 FCP4 FCP5 FCP7 FCP8
□  N4,N9-Distearoyl spermine D N4,N9-Dioleoyl spermine H N4,N9-Dilinoleoyl spermine
□  Transfectam  ■  Naked DNA
Figure 36. Cytotoxicity effect of pEGFP (2 pg/ml) free (naked DNA) or complexed 
with A^A^-distearoyl spermine (33.4 pg/ml), A^A^-dioleoyl spermine (5.5 |ig/ml), 
TVV^-dilinoleoyl spermine (12.1 fig/ml) and Transfectam® (15.0 pg/ml) in the tested 
cells.
Characterization of the lipoplex formulations 
Lipoplex particle size and zeta potential measurement
Condensation of DNA into nanoparticles is a way to decrease the size of the 
delivered gene in order to facilitate cellular membrane entry by endocytosis and 
subsequent trafficking to the nucleus. Zeta potential characterizes the stability of the 
formulation. Romoren et al. (141) investigated the long-term stability of chitosan- 
based polyplex solutions (25 mM sodium acetate buffer, pH 5.5) at different
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temperatures (4 °C, 25 °C, 45 °C) over a period of up to 1 year. They showed the 
relation between the change in the physicochemical characteristics of the polyplexes 
(particle size and zeta potential) and the change in the transfection efficiency.
Lipoplex particle size measurement
The average particle size for the lipoplexes formed (at their optimum charge 
ratio of transfection) between plasmid DNA and our novel synthetic lipopolyamines, 
after mixing with vortex mixer was determined using Malvern Zetasizer (Nano S, 
Malvern Instruments). All measurements were carried out on lipoplexes having a 5 
|ig/ml plasmid DNA in HEPES buffer at pH 7.4 at room temperature.
The characterization of particle size by dynamic light scattering revealed that 
the average particle size of both A^A^-dilinoleoyl spermine and Transfectam® were 
considerably smaller (71 and 62 nm, respectively) than that of A^^-distearoyl 
spermine and A ^^-dioleoyl spermine that show increased average particle size of 
217 and 366 nm, respectively, as indicated in Table 2. Polydispersity of size ranged 
from 0.15 in the case of TV^A^-dilinoleoyl spermine and Transfectam, to 0.4 in the 
case of A^^-distearoyl spermine and A^^-dioleoyl spermine (Table 2). All the 
particle size measurements were carried out on the lipoplexes at their optimum charge 
ratio of transfection.
The results of pEGFP (4.7 kbp) condensation and formation of 62 nm 
nanoparticles with Transfectam® were in agreement with the results found by Dunlap 
et al. in their study of the commercial lipospermine condensation of plasmid DNA (5- 
7 kbp) that induced condensates of 50-70 nm in diameter (259).
It was noticed from the titration of the cationic lipids A^A^-dioleoyl spermine 
and A^,A^-dilinoleoyl spermine with pEGFP that the complexes formed were small 
(about 100 nm) at low charge ratio (+/-, N/P) and grew to more than lpm  with 
increasing the charge ratio (about 2 ) for both cationic lipids , followed by a decrease 
in the particle size with a further increase in the charge ratio.
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These results were in agreement with the results of using cationic polymers by 
Pouton et al. (260), the lipopolyamines RPR128522 and RPR120535 (2-(3-[4-(3- 
amino-propylamino)-butylamino]-propylamino)-A-dioctadecylcarbamoylmethyl- 
acetamide) by Byk et al. (50), DOTMA (2,3-dioleyloxypropyl-l-trimethylammonium 
chloride)/DOPE (dioleoyl phosphatidylethanolamine) liposomes by Sakurai et al. 
(261) that show increase in the particle size (up to a micron size level) of the 
condensed DNA with increase in the ratio of the condensing agent to DNA, followed 
by decrease in the particle size with further increase in the ratio.
The appearance of large particles reflected an aggregated form of the 
lipoplexes formed. Choosakoonkriang et al. (262) reported that the size of the 
cationic lipids/DNA complexes, DOTAP and DDAB
(dioctadecyldimethylammonium bromide), was constant (150 nm) until ratio 0.5 
followed by a gradual increase in the size until ratio 1.5 then a large increase (>1 pm) 
in particle size above 1.5 (lipid/DNA), the same was noticed after incorporation of the 
helper lipids cholesterol and DOPE.
Table 2. Particle size and polydispersity of DNA lipoplexes of A ,^ A^-distearoyl 
spermine, iV^A^-dioleoyl spermine, A^A^-dilinoleoyl spermine and Transfectam® at 








A^A^-Distearoyl spermine 15.0 217(21) 0.46
A^A^-Dioleoyl spermine 2.5 366 (73) 0.32
A^A^-Dilinoleoyl spermine 5.5 71 (2.5) 0.19
Transfectam® 5.9 62 (3.2) 0 .2 2
Each lipoplex diameter value shows the mean ± S.D.
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Zeta potential measurement
The average ^-potential measurement for the lipoplexes formed (at their 
optimum charge ratio of transfection), after mixing with vortex mixer, was 
determined using a Malvern Zetasizer (Nano ZS, Malvern Instruments). All 
measurements were carried out on lipoplexes having a 5 pg/ml plasmid DNA in 
HEPES buffer at pH 7.4 at room temperature.
The results revealed that the surface charge, as determined by ^-potential 
measurements, was +43 and +32 mV for N*^-dilinoleoyl spermine (at N/P charge 
ratio of 5.5) and A^^-dioleoyl spermine (at N/P charge ratio of 2.5) lipoplexes, 
respectively. Transfectam® lipoplex shows a ^-potential of +20 mV (at N/P charge 
ratio of 6 ) in Phosphate Buffered Saline (PBS) solution (Remy and Behr, personal 
communication). Also, from the titration of the cationic lipids A^-dioleoyl 
spermine and /V^A^-dilinoleoyl spermine with pEGFP, these results show that the 
complexes show a negative ^-potential at low charge ratio (+/-, N/P), -45 mV at 
charge ratio 1 in the case of N4,A^-dioleoyl spermine and -50 mV at charge ratio 0.9 
in the case of A^^-dilinoleoyl spermine. Then, the ^-potential increases with the 
increase in charge ratio up to charge ratio about 2  where the ^-potential reaches the 
charge neutrality (zero). After that, the ^-potential increases to positive values with 
increase in the charge ratio more than charge ratio 2, as shown in Fig. 37.
From these titration results, it is revealed from both particle size and £- 
potential measurements that the appearance of large particle sizes, more than 1 pm at 
charge ratio about 2 , reflected an aggregated form of the lipoplexes formed that could 
be explained from ^-potential results as a result of charge neutrality on the surface of 
the lipoplexes nanoparticles. The value of the ^-potential was close to zero (Fig. 37) 














Figure 37. Zeta potential measurements of pEGFP with A^A^-dioleoyl spermine and 
A^A^-dilinoleoyl spermine measured at different (+/-) charge ratios.
Zeta potential is an important parameter helping to predict the stability of the 
formulation as well as the ability of the positively charged particles to interact with 
cell membranes (263, 264). Zeta potential depends on several factors including: pH, 
ionic charge, ion size, and concentration of ions in solution (265). The interaction of 
DNA with cationic lipids leads to the formation of net charge on the surface of the 
formed nanoparticles, either positive or negative according to the DNA- cationic lipid 
charge ratio, which attracts counter ions close to the surface of the formed 
nanoparticles (an electrical double layer). Ions close to the surface of the particle are 
bound relatively strongly to the surface until the hydrodynamic plane of shear (Fig. 
38). After this plane, ion distribution is determined by a balance of electrostatic 
forces and random thermal motion. The potential in this region, therefore, decays as 
the distance from the surface increases until, at sufficient distance, it reaches the bulk 
solution value (zero). The potential at this imaginary surface, the hydrodynamic 
plane of shear, which separates the thin layer of liquid bound to the solid surface and 





Hydrodynamic plane of shear
Condensed DNA particle (C potential)
Figure 38. Diagram indicating the distribution of charges from the surface of the 
condensed DNA nanoparticle and the C, potential.
The formed nanoparticles are considered to be stable when they have 
pronounced (^-potential values, either positive or negative, but the tendency to 
aggregate is higher when the ^-potential is close to zero. Charge neutrality (£ = 0) 
occurred at an N/P charge ratio of about 2 for both lipopolyamines TV^A^-dilinoleoyl 
spermine and TV^A^-dioleoyl spermine (comparable with our EthBr results, Fig. 3).
Martini and co-workers found neutralization N/P charge ratios of 6 and 2 with 
intact liposomes (265). Similarly, also working with liposomes, Middaugh and co­
workers reported that neutralization charge ratios of cationic lipid-DNA complexes 
occurred at N/P charge ratios of 1.5, 2.5, and 3.5 (266, 267). These results are in 
agreement with the studies of Yi et al. (268) and Sakurai et al. (261) where they used 
DOTAP (A-[l-(2,3-dioleoyloxy) propyl]-A/A/A-trimethylammonium methyl sulfate) 
as the cationic lipid, and also in agreement with the results from an artificial 
lipoprotein used by Alanazi et al. (269) and with the results of Tang and Szoka found 
with their cationic polymers (270).
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Agarose gel electrophoresis
The complex formation of our three synthetic lipopolyamines and the 
commercially available lipospermine Transfectam® with polyanionic DNA (pEGFP) 
was examined by analysis of the electrophoretic mobility of the circular plasmid 
DNA-lipopolyamine complex within an agarose gel (1 %) stained with EthBr. The 
unbound free DNA in the agarose gel was visualized under UV using GeneGenius 
(Syngene).
All four spermine conjugates (including Transfectam®) were able to condense 
pEGFP DNA efficiently (as a result of the interactions between the lipopolyamine 
ammonium ions and the DNA phosphate charges) at their optimised respective charge 
ratios (N/P) of transfection (see: Table 2) leads to immobilization and reduction of 
EthBr intercalation with DNA. All the tested lipopolyamines were able to completely 
inhibit the migration of the circular plasmid DNA from lipoplexes in the agarose gel 
at their respective charge ratio of transfection as indicated in Fig. 39.
Figure 39. Gel retardation assay of pEGFP either free (pEGFP lane) or complexed 
with A^A^-distearoyl spermine (lane A), A^A^-dioleoyl spermine (lane B), N4,A9- 
dilinoleoyl spermine (lane C), and Transfectam® (lane D) at their respective N/P 
ratios for best transfection.
Also, Fig. 40 shows the interaction of pEGFP with /V^A^-dilinoleoyl spermine 
at different (N/P) charge ratios of 0.25, 0.5, 1.0, 1.5, 2, 3 and 5. The results revealed
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the ability of A^A^-dilinoleoyl spermine to completely immobilize pEGFP at higher 
charge ratios (charge ratio 3 and 5). While at lower charge ratios (< 2) a moderate 
inhibition of pEGFP in the agarose gel was observed (Fig. 40). These results were in 
agreement with the EthBr fluorescence intensity (DNA condensation) results (Fig. 3) 
that showed more than 90 % fluorescence quenching was achieved by pEGFP-A^/V9- 
dilinoleoyl spermine charge ratio of 2. This value (more than 90 % fluorescence 
quenching) achieved by A^A^-dilinoleoyl spermine indicates the complete 
condensation of pEGFP (19, 22).
Figure 40. Gel retardation assay of pEGFP either free (pEGFP lane) or complexed 
with A^A^-dilinoleoyl spermine at different lipopolyamine/ DNA ratios (N/P ratios), 
N/P 0.25 (lane 1), N/P 0.5 (lane 2), N/P 1.0 (lane 3), N/P 1.5 (lane 4), N/P 2.0 (lane 
5), N/P 3.0 (lane 6) and N/P 5.0 (lane 7).
In this study, we have investigated the change in the degree of unsaturation of 
the di-C18 fatty chain formulation of lipospermine on DNA condensation and cellular 
delivery. The results from pEGFP condensation, investigated by EthBr fluorescence 
quenching assay, revealed that two of our synthetic lipopolyamines and the 
commercial formulation Transfectam® were able to condense DNA to less than 10 % 
EthBr fluorescence, where DNA is defined as condensed (19), however /V^ /V9- 
distearoyl spermine had not reduced (quenched) the EthBr fluorescence to 10 % by 
N/P charge ratio 3.5 (Fig. 3). Particle size of the final gene formulation is also an 
important factor in improving gene delivery (141, 271). Particle size results (Table 2)
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showed larger particles with both A^^-dioleoyl spermine and A^^-distearoyl 
spermine formulations over those obtained with A^^-dilinoleoyl spermine and 
Transfectam®. These results are in concordance with the improvement in transfection 
achieved with TV^A^-dilinoleoyl spermine over our other two formulations.
On the other hand, although Transfectam® has the smallest particle size (62 
nm), the saturation of the di-C18 fatty chains could possibly contribute to the lower 
transfection efficiency of this spermine conjugate in comparison to our formulation 
results with A^A^-dilinoleoyl spermine. Gao and Huang (272) reported that the 
addition of poly-L-lysine (PLL) or protamine to DC-Chol liposomes reduces the size 
of the complex as well as its heterogeneity in all ratios of lipid/DNA that improve 
transfection efficiency. Noguchi et al. (63), also working with protamine, reported 
that smaller sized particles transfect cells efficiently. The incorporation of protamine 
as a nuclear localization signal to liposomes incorporating a cationic cholesterol 
derivative reduced the size of the formed particles from 0.4-1.8 pm, for the DNA- 
liposome complex, to 0.1-0.8 pm for the DNA-protamine-liposome complex.
On the relationship between particle size and transfection efficiency, there are 
no definite limits to the nanoparticle size that are suitable for transfection (205). 
Nanoparticles have relatively higher intracellular uptake than microparticles (273). 
Also, on the nanoscale, smaller size polyplexes are more able to enter cells and 
thereby increase the efficiency of transfection (123). Similarly, in 2004, Hoekstra 
and co-workers showed with fluorescently labelled nanospheres (latex beads) that 
size itself can determine the pathway of entry (274). Wagner and co-workers 
reported larger particles ( 1 0 0 0  nm) exceeding the transfection efficiency achieved 
with smaller particles (40 nm) using DNA/transferrin-polyethylenimine complexes at 
physiological salt concentration (275). With a different DNA condensation system, 
they also reported that small toroid structures of DNA/transferrin-PLL complexes 
(80-100 nm) showed high transfection efficiency as their diameters are in the range of 
the coated pits involved in the endocytosis process (276).
We have previously reported (145, 171, 241, 243-245) the importance of the 
substituents in the lipid moiety conjugated to the cationic polyamine in order to 
achieve improvements in DNA condensation efficiency for non-liposomal
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formulations where the lipid moiety must be considered in shape (volume) and 
substituent pattern, as well as the polyamine moiety and its pKa values. The design 
and synthesis of novel cationic lipids based upon the tetra-amine spermine, as non- 
liposomal formulations, where the lipid moiety is a long carbon chain was largely 
instigated by Behr and co-workers with their design and preparation of the highly 
efficient lipopolyamine dioctadecylamidoglycylspermine (DOGS, Transfectam®) 
(179, 185). A leading non-viral vector following from such structure-activity 
considerations is RPR 120535 (182) where the di-C18 saturated alkyl chains are 
substituents pendant from a diamide at one end of the tetra-amine spermine, used as 
the cationic moiety to take advantage of DNA binding by polyamines (211).
Unsaturated chains have also been incorporated as the lipophilic moiety in 
lipopolyamine vectors. Kirby and co-workers (187) have used two covalently bound 
oleoyl chains in non-liposomal formulations for improved transfection efficiency by 
fusion with cellular membranes. They attached basic amino acids (Lys) to the 
primary groups (compounds type A, 1 and 2) or to the secondary amino groups of the 
lipospermine surfactants (compounds type B, 3 and 4) (Fig. 41). They found that 
Type B compounds with the same short peptides show higher transfection efficiency 
compared to type A compounds. Also, the use of unsaturated Cl 8 oleoyl fatty chains 
shows the highest transfection efficiency and increasing the number of positive 
charges improves the ability of the compound as a non-viral gene delivery vector 
(187).
A I R  =LysLysLysSer, 2 R = Lys
B 3 R =LysLysLysSer, 4 R = Lys
R














0-P -O x’Vs^ NH3 • _o
“o o
Figure 42. Spermine conjugates together with DOTMA (cationic) and neutral helper 
lipids, gene delivery formulation excipients.
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In liposomal formulations, dioleoylphosphatidyl ethanolamine (DOPE) is 
often used as a helper lipid for liposomal formulation and for its fusogenic ability as it 
has the characteristics of non-bilayer forming activity leading to destabilisation of the 
lipid bilayer (209). Oleoyl and oleyl chains have also been bound as esters and ethers 
in liposomal formulations: l,3-dioleoyloxy-2-(6-carboxyspermine) DOSPER (177), 
DOSPA-DOPE (3/1 w/w, Lipofectamine ™), DOTMA-DOPE (1/1 w/w, Lipofectin®) 
(Fig. 42).
Non-liposomal cationic-lipid delivery vectors combine both the characteristics 
of cationic and of helper lipids. So a factor that is important for both facilitating cell 
entry and the efficient intracellular release of free DNA (or lipoplexes) into the 
cytoplasm is the influence of the cationic lipid chain. The lipid moiety in our cationic 
lipids interacts with the phospholipid bilayer of the cell membrane, and that, either in 
crossing the membrane bilayer and/or in helping to weaken the endosomal bilayer, 
thereby aids escape into the cytosol.
Cationic lipids in aqueous solutions exhibit different polymorphic phases.
The two most important organizational forms are La (lamellar organization with fluid 
hydrocarbon chains) and Hu (two-dimensional hexagonal state) (Fig. 43) (277). 
Huang and co-workers have reported that the replacement of DOPE with a 
trimethylated structural analogue dioleoylphosphatidyl choline (DOPC) (Fig. 42), in 
cationic liposomal formulations, abolishes most of the transfection activity of the 
lipoplex, as DOPE exhibits a high tendency to form the inverted hexagonal (Hn) 
phase particularly at acidic pH (209).
Figure 43. Typical diagram of the change in lipid phase structure from the lamellar 
La phase to the inverted hexagonal Hn phase.
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Lipids that are cylindrical in solution shape prefer bilayer formations, while 
lipids with large head-groups and small diameter hydrocarbon chains (inverted cones) 
form micellar structures (277). Lipids with small head-groups and long hydrocarbon- 
chains e.g. (saturated) phosphatidyl ethanolamine (PE) and DOPE (Fig. 42), due to 
their solution cone shape, favour phase transition to an inverted hexagonal phase, as a 
result of steric factors (278). Also, increasing the degree of unsaturation of the acyl 
chain (especially in the c/s-configuration) favours hexagonal phase formation 
(La — phase transition) and potentially improves the fusogenic characteristics of 
the lipid. The actual significance of maximising such fusogenic characteristics in 
NVGT remains to be proven.
Gaucheron, Santaella, and Vierling, in their detailed study on fluorinated 
lipospermines (Fig. 44), that are close analogues to Transfectam, speculated the 
improved transfection with the unsaturated over the saturated counterparts could be 
due to “their greater ability to promote membrane fusion with and destabilization of 
the endosomal membrane allowing optimal DNA release in the cytosol” and “related 
to the fluidification effect of the C=C bonds” (184). Vierling et al. have also reported 
(279) that unsaturated fluorinated lipids showed lower lamellar phase transition 
temperatures than the corresponding fluorinated saturated lipids. These results are in 
agreement with the higher transfection levels of the monounsaturated C 18 (oleoyl 
group) over the saturated C l8 (stearoyl) achieved by Feigner and his research group 
that was related to the possibility of the decrease in bilayer stiffness by introducing 







R1 = R2 = CH3(CH2)17 DOGS (Transfectam)
n h 2
Figure 44. Fluorinated lipospermines (DOGS analogues).
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In addition, the effect of degree of saturation of cationic lipid analogues was 
investigated to identify the fusogenic and transfection ability of these compounds in 
relation to their degree of unsaturation by Heyes and co-workers (176). The saturated 
cationic lipid (l,2-distearyloxy-A,A-dimethyl-3-aminopropane (DSDMA)) (Fig. 45) 
was more readily internalized to the cells, despite its almost no ability of gene 
silencing (siRNA delivery). While the unsaturated cationic lipids, the mono­
unsaturated (1,2-dioleyloxy -7V,A-dimethyl-3-aminopropane (DODMA)), the di­
unsaturated (l,2-dilinoleyloxy-A,A-dimethyl-3-aminopropane (DLinDMA)) and the 
tri-unsaturated (1,2-dilinolenyloxy-A,A-dimethyl-3-aminopropane (DLenDMA))
(Fig. 45) show higher efficiency in gene silencing compared to the saturated DSDMA 
cationic lipid. Gene silencing increased with the increase of the degree of 
unsaturation, as a result of the increase in the fusogenic ability, lower transition 
temperature from La (lamellar organization) to Hu (two-dimensional hexagonal state), 
of the cationic lipid (176).
N ^ O
Figure 45. The cationic lipids, DSDMA A, DODMA B, DLinDMA C and 
DLenDMA D.
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The fusogenic characteristics of our synthetic non-liposomal lipopolyamines 
were taken under consideration to account for the observed difference in gene 
delivery. The two factors head-group and chain-length are held constant among our 
investigated compounds. The degree of unsaturation of the C l8 fatty chain may be a 
key factor that explains the increase in the transfection efficiency of the lipoplex.
This may be a result of the improved fusogenic characteristics of A^^-dilinoleoyl 
spermine with its (di-ds-configuration) dienoic fatty acyl residue, more than the 
mono-unsaturated A^A^-dioleoyl spermine and the saturated A^A^-distearoyl 
spermine.
In conclusion, in this chapter we have designed, synthesized and characterised 
novel gene carriers. DNA condensation, particle size, transfection efficiency and 
cytotoxicity results revealed that A^^-dilinoleoyl spermine is a promising DNA 
delivery formulation with its increased degree of unsaturation in both of the 
lipospermine fatty chains. The dienoic C l8 A^^-dilinoleoyl spermine achieves 
a high (85-90 %) transfection efficiency in primary cell lines and (99%) transfection 
efficiency in cancer cell line. The Transfection efficiency was in the order of the 
dienoic fatty acyl spermine conjugate A^^-dilinoleoyl spermine > the alkenoic 
A^^-dioleoyl spermine > the saturated A^^-distearoyl spermine. The increase in 
the degree of unsaturation (number of double bonds) in the fatty chains, due to the 
fluidification effect of the C=C bonds, improves the ability of the lipospermine to 
promote membrane fusion and destabilization of the endosomal membrane that 
ultimately increase the transfection efficiency of the cationic lipid.
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Conclusions
From this thesis it can be concluded that new medicines can potentially be 
used to formulate and efficiently deliver DNA as the drug. In formulation terms, 
DNA is a medicinal substance that is difficult to formulate. This is because of the 
nature of both its size that is usually in Mega-Daltons and the many thousands of 
negative charges on the phosphate backbone of the polynucleotide. The use of an 
efficient carrier (delivery vehicle) responsible for the complex process of successful 
DNA delivery to the nucleus is a determinant factor for the successful application of 
gene therapy. DNA is condensed naturally by basic proteins, histones and by 
positively charged polyamines spermine and spermidine. Therefore, polycationic 
compounds (polyamines) were utilized in the design of our gene carriers.
Delivery vehicles for DNA formulation are either viral or non-viral vectors 
relying on (poly)cationic compounds. Non-viral formulation has to overcome 
cellular barriers to achieve a successful delivery of the prodrug DNA. These barriers 
include: DNA condensation, cell targeting, cell membrane entry, endosomal escape, 
nuclear entry, decomplexation, and transcription and translation. To overcome these 
barriers, several investigations were carried out to improve the delivery of DNA 
through several approaches including: the use of novel carriers, the delivery and 
internalisation to specific cells, incorporating moieties to improve the endosomal 
escape (e.g. proton sponge effect) or fusogenic lipids.
In these studies, the condensation of DNA and formation of nanoparticles 
was monitored using ethidium bromide (EthBr) fluorescence quenching, light 
scattering and gel electrophoresis assays. In addition, EthBr was used to determine 
the binding affinity of the condensing agents for DNA. The binding of cationic 
molecules with DNA is not entirely responsible for the release of EthBr, but 
alteration of the molecular flexibility of DNA through cationic compaction facilitated 
the release of bound EthBr. The number and/or the distribution of the positive 
charges on the molecule could have a significant effect on the affinity of the vector 
for DNA that leads to the efficient displacement of EthBr. A simple light scattering 
assay is useful for the detection of (nano)particle formation.
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Transfection efficiency and cell viability (toxicity) experiments were carried 
out using pEGFP as a reporter gene, encoding for enhanced green fluorescent protein, 
either complexed with DNA condensing agents, or free (naked) DNA as a negative 
control. pEGFP was transformed and propagated in E. coli JM 109 bacterial strain. 
DNA yields and purity were determined spectroscopically (OD260/OD280 = 1.80-1.90) 
and by agarose gel (1 %) analysis. Six primary cell lines were used in the 
transfection and cytotoxicity experiments, FEK4, FCP4, FCP5, FCP7 and FCP8 cells 
are human primary fibroblasts derived from newborn foreskin explants used as 
models for human primary cells. HeLa derivative and transformed cell line (HtTA) 
was used as a model for an immortal cancer cell line. The cytotoxicity (cell viability) 
of these compounds was studied in both primary skin and immortalised cancer cell 
lines using an MTT assay. The formed lipoplexes (nanoparticles) were characterized 
by both average particle size and ^-potential measurements.
A^A^-Dioleoyl spermine was synthesized from the naturally occurring 
polyamine spermine by primary amine protection using ethyl trifluoroacetate. DNA 
condensation and binding affinity results, using EthBr fluorescence quenching assay 
for A ^^-dioleoyl spermine compared with model polyamines (spermine, PEI 
average molecular weight 2,000 Da (PEI 2k) and 60,000 Da (PEI 60k) and PLL 
average molecular weight 9,600 Da (PLL 9.6k) and 27,000 Da (PLL 27k)), revealed 
that addition of lipophilic moieties to the polyamine spermine improves its ability to 
condense DNA. No significant difference was detected in the condensation of linear 
(readily available calf thymus and herring testes) and circular plasmid (pEGFP and 
pP-gal, which includes the gene LacX encoding for p-galactosidase) DNA using 
EthBr fluorescence quenching assay. However, the type of formulation of the 
cationic lipid (liposomal or non-liposomal) could affect the DNA condensation 
efficiency. The results showed that A^A^-dioleoyl spermine is able to condense 
DNA at a lower charge ratio than PLL 9.6K and spermine and produces a 50 % 
fluorescence decrease at charge ratio 0.52. A^A^-Dioleoyl spermine showed 
improved DNA condensation ability in comparison with the commercially available, 
cationic lipid formulations Lipofectin® (DOTMA/DOPE 1/1 w/w) and
TM
Lipofectamine (DOSPA/DOPE 3/1 w/w).
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The transfection of pEGFP (analysed by FACS) showed a higher transfection 
efficiency of A^A^-dioleoyl spermine (at N/P charge ratio of 2.5) than that obtained 
using commercially available liposomal Lipofectin® formulation in FEK4 primary 
skin fibroblast and HtTA cell lines. On the other hand, there is no significant 
difference in the transfection activity between non-liposomal A^A^-dioleoyl 
spermine and the commercially available standard liposomal formulation
T  .  -  t mLipofectamme .
Cell viability results for A^A^-dioleoyl spermine revealed improved FEK4 
viability more than the cancer cells HtTA. Also, TV^A^-dioleoyl spermine showed a 
significant improvement in primary FEK4 cell viability over the liposomal 
formulations, but no significant difference in HtTA cells. A^^-Dioleoyl spermine 
shows promising transfection results in tissue cultured cancer and skin fibroblast 
primary cell lines. Therefore, we investigated the effects on DNA formulation with 
variation in the degree of unsaturation in the two C l8 fatty chains of the 
lipospermine, preparing the novel saturated A^^-distearoyl spermine, alkenoic 
A ^^-dioleoyl spermine, and the dienoic fatty acyl spermine conjugate N^JV9- 
dilinoleoyl spermine as synthetic lipopolyamines aimed at more efficient NVGT.
DNA condensation was studied using an EthBr fluorescence-quenching assay 
(A** = 260 nm, Xem = 600 nm) (5). A^A^-Dilinoleoyl spermine induced a marked 
decrease in intercalated EthBr fluorescence intensity from 100 % (EthBr-DNA 
complex without cationic lipid) reduced to 10 % at N/P charge ratio of 1.5. Light 
scattering by condensed DNA nanoparticles was detected at X = 320 nm and a 
maximum (100 %) relative apparent absorption (UV scattered light) at N/P charge 
ratio of about 1.5. The transfection efficiencies of the synthesized lipopolyamines 
were studied in primary skin cells (FEK4 and FCP cells) and in an immortalized 
(HeLa derived HtTA) cancer cell line using pEGFP as the reporter macromolecule 
with its fluorescent imidazolidinone moiety analysed by FACS. The results revealed 
high transfection efficiencies with TV^A^-dilinoleoyl spermine, typically 85-90 % in 
primary cell lines, higher values than were obtained with the saturated N4,!^ !9- 
distearoyl spermine (about 25-40 %) or with A^A^-dioleoyl spermine (about 60-75 
%).
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The cytotoxicity of these compounds was studied in both primary skin and 
immortalised cancer cell lines using an MTT assay. A^A^-Dilinoleoyl spermine 
achieves (about 70 %) viability at N/P charge ratio 5.5. These transfection and cell 
viability results were compared with non-liposomal cationic lipid Transfectam® that 
achieved about 46-79 % transfection and 75 % cell viability in the various cell lines at 
N/P charge ratio 5.9 (cf Fig. 31). Naked (uncomplexed circular) pEGFP DNA 
typically gave 1-2 % transfection of these cell lines. The results show that an increase 
in the number of double bonds in the long Cl 8  fatty chain of the cationic lipid 
improves the ability of the non-viral vector to deliver the DNA payload to the cultured 
cells.
Condensation of DNA into nanoparticles is a way to decrease the size of the 
delivered gene in order to facilitate cellular membrane entry by endocytosis and 
subsequent trafficking to the nucleus. The characterization of particle size by 
dynamic light scattering revealed that the average particle sizes of both /vVv9- 
dilinoleoyl spermine and Transfectam® were considerably smaller (71 and 62 nm, 
respectively) than that of A^^-distearoyl spermine and A^^-dioleoyl spermine that 
show increased average particle size of 217 and 366 nm, respectively.
Zeta potential is an important parameter helping to predict the stability of the 
formulation as well as the ability of the positively charged particles to interact with 
cell membranes. ^-Potential results revealed that the surface charge was +43 and 
+32 mV for A^^-dilinoleoyl spermine (at N/P charge ratio 5.5) and A^^-dioleoyl 
spermine (charge ratio 2.5) lipoplexes, respectively. In addition, gel electrophoresis 
results revealed that all four spermine conjugates (including Transfectam®) were able 
to condense pEGFP DNA and completely inhibit the migration of the circular 
plasmid DNA from lipoplexes in the agarose gel at their respective charge ratio of 
transfection.
The results show that an increase in the number of double bonds in the long 
C18 fatty chain of the cationic lipid improves the ability of the non-viral vector to 
deliver the DNA payload to cultured cells. A^^-Dilinoleoyl spermine shows high 
efficiency in DNA condensation and was the most efficient non-viral gene carrier 
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CHAPTER 16
SPERMINE AND LIPOPOLYAMINES AS GENE DELIVERY AGENTS
I.S. BLAGBROUGH, N. ADJIMATERA, O.A.A. AHMED, A.P. NEAL and C. POURZAND 
Department o f Pharmacy and Pharmacology, University o f Bath, Bath, BA2 7AY, U.K.
1. INTRODUCTION TO SPERMINE AND LIPOPOLYAMINES
Polyamines are polycationic at physiological pH and play a variety of important biological 
roles. Many mammalian cells also possess an active polyamine uptake system, although little 
is known about its function.1 Spermine (Fig. li) (3.4.3 methylene count between the amine 
groups) and spermidine (Fig. lii) (4.3 methylene spacings) were first discovered in the nuclei 
of sperm, where these polycations help histone proteins to package DNA by charge 
neutralization of the phosphate anions along the DNA backbone. Most cells use histone 
proteins and polyamines to condense DNA in the nucleus. The histones found in chromatin 
are categorized as core histone (subunit H2A, H2B, H3, H4) (Fig. 1) and linker histone (HI), 
forming an octomer (108kDa) that binds to DNA. Lysine (Lys, K) and arginine (Arg, R), the 
most important of the positively charged amino acids, are found in significant sequences 
along most histone proteins. Lys has its (CH2)4NH3+ (basic) side-chain, and Arg is the 
naturally occurring (mammalian) amino acid containing a guanidine functional group, the 
most basic functional group in biological chemistry. Thus, the side-chains of these amino 
acids (together with ornithine and histidine) can be positively charged in the cell. The p ^ as of 
Lys and Arg (side-chains) are 10.5 and 12.5 respectively. DNA-histone complexes are 
dissociated on treatment with acids or dilute salt solutions.2 This is evidence of ionic and 
non-covalent interactions; the phosphate anions are titrated by the ammonium cations. Of 
course, there also has to be some consideration of spermine (i) and spermidine (ii) and their 
conjugates as neurotoxins; such neurotoxication can be due to high levels of free polyamines, 
or similar effects achieved by polyamine amides in the mammalian brain by mechanisms 
involving glutamate receptors. This latter process parallels the modes of action of the spider 
and wasp polyamine amide (invertebrate) neurotoxins.
2. OVERVIEW OF NON-VIRAL GENE THERAPY (NVGT)
Gene therapy is a new treatment strategy for some difficult-to-cure diseases, introducing a 
therapeutic gene into body cells and aiming for desired gene expression. The therapeutic 
outcome is not only limited to missing proteins in patients (such as a chloride ion channel in
147
Neurotox'03: Neurotoxicological Targets for Functional Genomics and Proteomics
the lungs of patients with cystic fibrosis), but also an inhibitory protein signal to stop the 
progression of disease, especially as a potential treatment for certain cancers 4 The design and 
synthesis of efficient DNA delivery vectors are major research areas in non-viral gene therapy 
(NVGT). Lentiviral and other viral vectors show efficient transfection, however, there is the 
possibility of severe toxicity from the viral genome, as well as immunogenicity, and there is 
the drawback of a limited DNA payload. Naked DNA is used even in current clinical trials. 
NVGT vectors have been produced to retain or to improve upon the performance of viral 
vectors and to provide a safe alternative for clinical gene therapy.4 Recently, Feigner et al. 
reported a system of NVGT nomenclature guidelines to aid in NVGT research, dividing the 
vectors into the two major synthetic gene delivery systems: lipoplex (cationic lipid-nucleic 
acid complex) e.g. lipopolyamines, cationic liposomes, and polyplex (cationic polymer- 
nucleic acid complex) e.g. polyethylenimine (PEI), poly-L-lysine (PLL) etc.5 Gene therapy is 
a complex drug (DNA) delivery strategy which must overcome intracellular barriers. The 
contributions from these barriers in blocking efficient NVGT are not well understood. We are 
aiming to understand (Fig. 2) and, thereby, to design a significant improvement over current 
transfection yields.
Figure 1 Spermine (i), spermidine (ii) and histone 2A (iii) K(13)AKTRSSR(20) (underlined 




Figure 2 Barriers to NVGT (I -  DNA condensation and particle formation, II -  endocytosis, 
III -  endosome escape, IV  - nuclear localization, V - nuclear entry and VI - gene expression).
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Negatively charged DNA (due to the phosphate anions), when neutralized by salt formation 
with positively charged lipopolyamine vectors, results in condensed nanometer-sized particles 
typically 50-150nm in outer diameter (Fig. 4). Nanoparticles, toroidal in shape, were 
observed in polyamine-induced DNA condensation.6,7 This DNA compaction facilitates its 
stability in extracellular compartments, cellular uptake, and other intracellular process such as 
nuclear entry.7,8 The electrostatic interactions between the surface of DNA particles and cell 
membranes is expected to be an initial process leading to internalization by endocytosis of 
DNA nano-complexes, with the involvement of clathrin-coated pits on the cell membrane.9,10 
It has been shown that endosome escape of the DNA is one major critical barrier to efficient 
transfection.8 Early endosomes are formed by the inversed cell membrane upon DNA 
particles endocytosis, which are eventually degraded into late endosomes by internalization 
into lysosome vesicles. The “proton sponge” hypothesis has been proposed for endosome 
escape of NVGT cationic polymer. The protons are pumped into endosomes (at pH 7.4) by 
V-ATPase proton pump at their membrane, while polycations (the pKa of a primary amine is 
around 10.5)11 work as a pH buffer material. This results in an increased proton/water flux 
and lower pH at 5.5. Membrane disruption by swelling and finally osmotic lysis allows DNA 
complexes to escape from these vesicles prior to enzymatic degradation. Alternatively, the 
mechanism of lipid membrane mixing between endosomal membrane and lipidic gene carrier 
has also been hypothesized as an alternative means by which cationic lipids/liposomes might 
facilitate the endosome escape process, although this process is not well understood.8'12,13
Also, the mechanism of DNA nuclear translocation is not well understood. However, the 
transport through nuclear pores has been considered as the most likely possible route in 
conjunction with help from nuclear localization signals (NLS). NLS are peptides that help 
DNA complexes (which are typically bigger than 50kDa and cannot pass through the nuclear 
pore complex) to reach the nucleus. NLS binds with the a-subunit of the cytosolic importin 
receptor, then the p-subunit of the importin binds to the nuclear pore complex with the help of 
GTP binding protein (called Ran). The (3-subunit will be retained at the inner face of pore 
complex.14 Based on amino acid sequence analysis of NLS such as SV40 T-antigen, HIV-tat 
protein etc., positively charged amino acids are also found as their unique characteristic.14 
The nuclear envelope contains double phospholipid layers, with the membrane space directly 
connecting to the endoplasmic reticulum lumen. The inner and outer membranes join 
together at the nuclear pore complex (NPC). The NPC is a large structure with an assembly 
of eight spokes attached to rings on the cytoplasmic and nuclear sides of the nuclear envelope, 
accordingly named “the cytoplasmic ring” and “the nuclear ring”, with a formed central 
channel approximately 40nm in diameter for the transportation of large particles across the 
nuclear membrane. The pore diameter is 120nm and the molecular mass is about 125 million 
Da. The small molecules (size of 9nm diameter, size less than 50kDa), for example, ions, 
metabolites and small proteins, use passive diffusion to get in and out of the nucleus freely. 
Bigger molecules, including DNA, are transported by an energy-dependent mechanism 
through this NPC. The selective transport of these macromolecules to and from the nucleus 
requires a NLS to direct their traffic through the NPC.14
3. SPERMINE MEDIATED DNA CONDENSATION AND PARTICLE FORMATION
Spermine (i) is a natural biomolecule involved in cell growth and differentiation control. In 
vitro studies have shown that the binding of spermine to DNA induces structural changes in 
DNA. The spermine cations neutralize the negatively charged phosphodiester groups of 
DNA, initiating the DNA helix’s axis bending resulting in DNA condensation. This gene
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packing enables efficient gene therapy by non-viral vectors. The results show that the 
nanoparticle (50-150nm) is able to go across the cell membrane and lead to the gene 
expression of delivered DNA.7'15 The ethidium bromide (EthBr) assay was used to measure 
DNA condensation. EthBr is a cationic dye (Fig. 3) that intercalates between DNA base 
pairs. This intercalation increases the fluorescence yield of EthBr (excitation 546nm, 
emission 595nm). Many compounds that bind to DNA, including spermine, can displace 
EthBr from the EthBr-DNA complex. The EthBr displacement by these chemicals is related 
to DNA bases as well as environmental conditions (e.g. buffer composition, ionic strength). 
So, EthBr fluorescence quenching can be used to measure the DNA-polyamine binding 
efficiently.15,16
NH
> = N  Br
Figure 3 Ethidium bromide.
The EthBr assay method is a modified literature protocol of Cain and co-workers’7, regarded 
as an “exclusion assay” requiring the pre-forming of DNA and DNA binding drugs, before 
EthBr is added. The excitation wavelength used is 546nm, which is based on the excitation of 
EthBr. In 2000, the modified reproducible EthBr “displacement assay” was reported by Geall 
and Blagbrough.16 The excitation wavelength was optimized at 260nm, so (only) intercalated 
EthBr is indirectly excited by energy transfer from the DNA. The proposed protocol also 
allows the experiment to be run without pre-complexing DNA and its binding molecule. This 
method is named as “displacement assay”.16 Additionally, the EthBr-DNA complex 
formation restricts the internal rotational freedom of EthBr. The fluorescence polarization is 
calculated from the emission intensity from polarizer and analyzer in a spectrofluorimeter. 
The polarization increase is observed when DNA is condensed due to the limited movement 
of EthBr. The measurement of steady-state fluorescence polarization can be used to indicate 
the EthBr-DNA complex conformation upon binding of spermine.15
In addition to the intercalating assay using EthBr, the UV absorbance at over 300nm (e.g. 
320nm) was useful in confirming the formation of nanoparticles. The double helix DNA was 
bound by polyamines and formed the nanoparticles which scatter the light resulting in the UV 
absorbance increase above 300nm.18 So, light scattering (LS) is being measured rather than 
(apparent) UV absorption. Some precipitation of the DNA may be visible, but it does not 
increase the absorption above 300nm. However, the DNA concentration used in this assay 
was in a 10-fold excess compared to the EthBr assay given the low sensitivity of this 
experiment and the lack of fluorescent indicator.11
DNA used in gene therapy research is normally prepared as plasmids, usually with a protein 
marker that can be followed in the gene expression quantification. pEGFP 9 (4.7 
kilobasepairs) is the plasmid encoding for enhanced green fluorescent protein, under CMV 
(cytomegalovirus) promoter, obtained from Clontech. Successfully transfected cells with 
pEGFP shows the distinct fluorescence detectable by a Fluorescent Activated Cell Sorter 
(FACS). Modified firefly (Photinus pyralis) luciferase pGL3 control vector20 (5.2 
kilobasepairs), with SV-40 promoter, was from Promega. In this luciferase assay, luciferin 
was added to transfected cells that underwent oxidation and generated the yellow light, 
measured by a luminometer.
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Figure 4 Detailed NVGT mechanism. A: endocytosis process. B: nuclear entry and gene 
expression process.
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pEGFP and pGL3 were condensed by spermine to about 50%, measured using the EthBr 
assay (Fig. 5). Particle formation was also confirmed by the LS assay, with significantly 
increased apparent absorbance at an N/P ratio > 3.00. We conclude that (simple) spermine- 
mediated condensation may provide less compacted particles; also these are only really 
significant at high N/P ratios. Additionally, the condensation profiles of both plasmids were 
found to be similar, possibly relative to their similar plasmid sizes. We and others have shown 
that lipopolyamines are more efficient DNA condensers (though not necessarily NVGT 































— -  EthBr
10.00 0.005
0.00 0.000
3.00 3.500.00 0.50 1.00 1.50 2.00 2.50
N/P charge ratio
Figure 5 DNA condensation and light scattering o f  nanoparticles (above -  pEGFP plasmid vs 
spermine, below -pG L 3 vs spermine).
4. DEVELOPMENT OF POLYCATION VECTORS IN NVGT
A variety of polycations, but nevertheless small molecules compared to histones or DNA, 
have now been reported for studies in NVGT (Fig. 6). The examples chosen serve to 
illustrate the current range of molecular diversity within lipopolyamines. From one of the 
earliest steroid conjugates, DC-Chol containing only one positively charged N-atom, through
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Genzyme’s GL#67, Behr’s Transfectam (DOGS), Scherman and co-workers’ RPR-120535 
and DOSPA (all containing spermine in different ways), through to vitamin D and modified 









Figure 6 A selection o f lipopolyamine-based NVGT vectors (lipoplex).
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Polymer polycationic NVGT vectors (Fig. 7) for the formation of polyplexes are based upon 
linear and branched polyethylenimines, PLL, poly-L-arginine and poly-L-histidine. These 
representative examples demonstrate the distribution of positive charge in the presence of a 
lipid region, cationic lipids.


































Figure 7 Polymer polycationic NVGT vectors (polyplex).
5. PHYSICOCHEMICAL PROPERTIES OF POLYAMINES-BASED DNA CONDENSING 
AGENTS
The effects of the regiochemical distribution of positive charges along the polyamine moiety in 
DNA condensing agents were studied by Geall et a l.11 27 DNA condensation is dependent upon
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three characteristic properties of polyamines: the number of positive charges, the regiochemical 
distribution of charges (determined by the pKa of each amino group), and the local salt 
concentration. From the pKa investigation and calculation, spermine (i) carries 3.8 charges and 
its cholesterol conjugate has a positive charge distribution similar to that found in spermidine 
(ii) (4.3) (Fig. 8). Such spermidine mimics (lipospermidines) are still effective as DNA 
condensing agents, significantly more so than spermidine itself, which is but a weak DNA 
condensing agent.
pK =8.1 pKa = 10.1
pK, = 8.9pK, = 10.9
H,N
pK = 10.1 pKa = 7.3
PKa = 8.6 O
'N ^  'N  O' 
H„ H H
Figure 8 pK a o f  spermine and a cholesteryl lipopolyamine. 11
We have designed and prepared lipopolyamines (Fig 9) and monitored their efficiency in 
DNA condensation into particles by LS and their salt-dependent binding affinity for DNA by 
fluorescence quenching.11,27 Lipopolyamines were prepared from cholesterol, lithocholic and 
cholic acids (5p-cholanes) by acylation of tri-Boc-protected tetra-amines spermine and 
thermine. These ligands are polyammonium ions at physiological pH.28
LipoGen (^/V^-dioleoylsperm ine)
Figure 9 Lipopolyamines based on cholesterol11. bile acids28 and fa tty  acids.
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LipoGen (from InvivoGen) is an example of a lipopolyamine with two oleoyl groups at TV2 
and TV3 of spermine, therefore with only two positively charged nitrogens. Modifying the 
lipophilicity of spermine (3.4.3) led to efficient DNA condensation (15% residual 
fluorescence at N/P charge ratio 2.5) comparing to the tetracationic spermine (50% at charge 
ratio more than 3.50) (Fig 10). According to Vijayanathan et a l 29 the 7,-phage DNA 
condensed particles (by spermine) are in the size range 50-100 nm. Lipospermine was shown 
to condense pSfiSVneo, pSifiSV19 and pCISfi-ylFN DNA to smaller particle sizes at 50- 
70nm.30 The efficient condensation of DNA by lipospermine over spermine, resulting in 















2.00 2.500.00 0.50 1.00 1.50 3.00
N/P charge ratio
Figure 10 pEGFP condensation by LipoGen vs spermine.
6. TRANSFECTION IN HUMAN SKIN FIBROBLAST CELLS (FEK4)
LipoGen (Invivogen) is a lipospermine with two oleoyl groups at N2 and N3 of spermine (i) 
and, therefore, only two positively charged primary amines. It was prepared as a non- 
liposomal formulation. The lipophilic modification aims to facilitate the transfection process 
(e.g. potentially through enhanced DNA condensation, cell entry, endosomal escape). This 
lipophilic modification of the spermine structure resulted in a more efficient pEGFP DNA 
condensation (15% residual fluorescence, in the EthBr assay, at N/P charge ratio 2.5) 
compared to tetracationic spermine (50% at N/P charge ratio 3.0). The in vivo transfection of 
pEGFP (2pg/well) with LipoGen was carried out using FEK431 (2.5 x 104 cells/well at 50% 
confluence), incubated for 4h, then the transfection was stopped by removal of the DNA 
complex and replacement with foetal-calf serum containing media; FACS analysis was 
performed 48h post-transfection. By using pEGFP as delivered DNA, the EGFP 
chromophore (a substituted 4-hydroxybenzylidene imidazolidinone) was detected in 
successfully transfected cells by FACS (fluorescent-activated cell sorting). The EGFP amino 
acid sequence L(64)TYGV(68) transcribed from pEGFP was cyclised in the post-translational
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steps (at amino acids 65-67) forming an EGFP fluorophore with X ex = 488nm (red-shifted 
from wild GFP protein) and X em = 507nm.19 Lipofectin (DOTMA/DOPE =1:1 w/w, 
Invitrogen), the commonly used transfection liposomal reagent containing cationic lipid (with 
one positive charge) and helper lipid (DOPE), was also used in this experiment for a 
comparison. The fluorescent cell counts observed in all N/P ratios were higher in LipoGen- 
mediated transfection. Thus, the lipid moiety in lipospermine is playing an important role in 
in vitro transfection. The optimal charge ratio for FEK.4 transfection with pEGFP-LipoGen 
complex is around 2.5, which corresponds to the optimal DNA condensation N/P ratio (from 
the EthBr assay)- However, from Fig. 11 it appears that increased condensation leads to 
higher transfection efficacy. The high N/P ratio (more than 5.0) results in less efficient gene 
delivery overall. A similar relationship between N/P charge ratio and transfection efficiency 
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7. CONCLUSIONS
v
Our research has advanced neurotoxic polyamine amides from spider and wasp natural 
products,32 with their exquisite sensitivity in modulating glutamate receptors, from 
pharmacological tools towards therapeutic neurochemistry,33 thereby highlighting their 
potential as therapeutic agents.34 So, whilst polyamines and polyamine amides are potent and 
selective receptor probes for a variety of voltage- and especially for ligand-gated cation 
channels,35 they also are now seen to have potential as synthetic vectors and can be exploited
91 'ISin NVGT. ’ Using our designed steroidal lipopolyamine probes (Fig. 9), we are studying 
DNA-lipopolyamine complexes with respect to their formation by DNA condensation. 
Comparable DNA-binding efficiency to that of the unlabelled lipopolyamines and robust 
fluorescent spectral properties across the varying cellular pH range are desirable properties in 
fluorescent ligands, but this requires experimental verification. Have we designed and 
prepared fluorophore-substituted lipopolyamines or lipopolyamine-substituted fluorophores? 
Only time and experimental results will tell. However, we have achieved a controlled chain 
extension of suitably protected polyamines using reductive alkylation to mimic spermine (i) 
rather than spermidine (ii) in the target molecules.21 A practical method for the efficient 
hydroboration of cholesteryl carbamates has allowed us to prepare our designed trans-AB 
steroidal lipopolyamines, together with the corresponding czs-AB ring junction as the minor 
product of hydroboration or from naturally occurring bile acids.21 We are able to introduce 
fluorophores of choice by our Fmoc-chemistry route. The design in our versatile synthetic 
route to Fmoc protected aminoesters of cholesteryl carbamate and lithocholic acid polyamine 
amides allows a range of selected fluorophores to be readily incorporated. The design and 
synthesis of these novel fluorescent lipopolyamines allows us to study the intracellular events 
during transfection. As well as our studies on lipopolyamine-mediated DNA condensation, 
we are optimising these probes to employ them monitoring the intracellular hurdles to NVGT. 
At present, a poor understanding of the molecular mechanisms of action of non-viral vectors 
remains an important, but unresolved issue. With a greater knowledge of these mechanisms, 
new (possibly spermine based) lipopolyamine vectors with improved transfection efficiency 
can be rationally designed and used as gene delivery agents in vivo.
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N  , N  -Dioleoyl Spermine Is a Novel Nonviral Lipopolyamine Vector for 
Plasmid DNA Formulation
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Purpose. To study the effect of synthesized N 4,N9-dioleoyl spermine on DNA condensation and then 
measure its transfection efficiency in cell culture.
Methods. The lipopolyamine was synthesized from the naturally occurring polyamine spermine. The 
ability of this novel compound to condense DNA was studied using ethidium bromide fluorescence 
quenching and light scattering assays. Transfection efficiency was studied in primary skin cells (FEK4) 
and in an immortalized cancer cell line (HtTA), and compared with the commercially available 
transfection formulations Lipofectin and Lipofectamine.
Results The synthesized N4y/V9-dioleoyl spermine formula is efficient at condensing calf thymus and 
circular plasmid DNA and effectively transfects both primary skin cells and cancer cell lines at low 
charge ratios of (+ /-  ammonium/phosphate) 2.5.
Conclusions N AJ49-Dioleoyl spermine condenses DNA and achieves high transfection levels in 
cultured cells.
KEY WORDS: FEK4; gene delivery; lipopolyamine; jV4jV9-dioleoyl spermine; transfection.
INTRODUCTION
It is widely believed that gene therapy will become an 
efficient medicine for the treatment of diseases such as 
cancer, cystic fibrosis and for vaccination. The essential 
requirements for gene delivery are the transport of DNA 
through the cell membrane and ultimately to the nucleus. 
The design of an efficient formula for the delivery of genetic 
material requires a detailed understanding of the mechanism 
of gene delivery to the nucleus. Different strategies have 
been used for the delivery of genetic material into target 
cells, classified as viral or non-viral delivery systems (1-3). 
Viral delivery systems depend on the development of 
genetically-modified viruses to utilize their capability of 
efficiently delivering DNA into cells without their pathogenic 
characteristics (3). Although high efficiency is achieved by 
viral vectors, there are concerns about their use which 
include: a limit in the size of the DNA delivered (the 
“payload”), endogenous viral recombination, unexpected 
anti-vector immune response, and oncogene activation
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ABBREVIA TIO NS: DCC, dicyclohexylcarbodiimide; DOGS,
dioctadecylamidoglycylspermine; DOSPER, l,3-dioleoyloxy-2-(6-
carboxyspermine; EGFP, enhanced green fluorescent protein;
EMEM, E arle ’s minimal essential medium; E thB r, ethidium
bromide; FCS, fetal calf serum; HOBt, hydroxybenzotriazole; NPC,
nuclear pore complex; PEI, polyethylenimine; PLL, poly-L-lysine.
(4-7). Since the design and formulation of Lipofectin by 
Feigner and co-workers, reported in 1987 (8), the focus on 
nonviral vectors for DNA delivery has shown a remarkable 
increase worldwide (9-15).
Efficient nonviral formulation should be able to deliver 
safely the required DNA across the various cellular barriers 
to the nucleus. These barriers that hinder the delivery of 
DNA to its physical site of action (the nucleus) have been 
summarized in Fig. 1. They include complex formation 
between the DNA and cationic lipid or polymer that leads 
to condensation of DNA into nanoparticles. Cell-membrane 
entry is thought to be mediated by cationic substances, which 
interact with the DNA payload, and can then cause 
adsorptive endocytosis and internalization of the complex. 
Also, the lipid moiety in cationic lipids interacts with the 
phospholipid bilayer of the cell membrane that facilitates cell 
entry. The internalized material is fused with early endo- 
some. That leads to sorting to the late endosomal compart­
ment, at this stage the DNA complex should escape the 
endosomal vesicle before the later stage of the lysosome 
where the DNA will be degraded. After endosomal escape, 
the DNA (either complexed or dissociated from the con­
densing agent) should find its way to the nucleus and cross 
the nuclear membrane which is thought to occur through the 
nuclear pore complex (NPC) or by direct association with the 
chromatin during mitosis. After nuclear entry, the payload 
DNA should successfully be able to give the desired protein 
through the processes of transcription and translation.
For drug formulators, it is difficult to deliver a drug 
molecule of 3.3 kDa molecular weight carrying 10 negative 
charges, but in the case of the (prodrug) DNA, a 5 kbp
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Fig. 1. Steps in the process of nonviral gene therapy by endocytosis showing the barriers for DNA 
nanoparticles, from the formation of the DNA-polycation complex (condensed DNA particles) to 
protein synthesis.
plasm id has a m olecular weight of about 3.3 m egadaltons and 
carries 10,000 negative charges. So the first key step  in gene 
form ulation is D N A  condensation into a nanopartic le  form 
through m asking the negative charges of the  phosphate 
backbone  which causes a lleviation  of charge  repu lsion  
betw een rem ote phosphates on the D N A  helix leading to 
collapse into a m ore com pact structure (2,16). T he im por­
tance of D N A  condensation is a ttribu ted  to  the  corre lation  of 
the transfection  efficiency w ith the fo rm atio n  of D N A  
nanoparticles that are essential for the  delivery of D N A 
through the  cell m em brane (16-20).
Cationic lipids are considered to be  the  m ajor gene 
carriers am ong the non-viral delivery systems. T hey  have the 
ability to  condense D N A  in to  particles th at can be readily 
endocytosed by cultured  cells, and facilita te  endosom al 
escape leading to  efficient delivery to the  nucleus (21). They 
can be classified as liposomal and non-liposom al nonviral 
delivery vectors. Liposomal delivery vectors usually contain 
two types o f lipids, a cationic lipid (positively  charged 
am phiphile) for D N A  condensation and cellu lar m em brane 
in teraction, and a neutral helper lipid (phospholip id), most 
use dioleoylphosphatidyl-ethanolam ine (D O P E ) (Fig. 2) to  
increase transfection efficiency as it has a m em brane  fusion 
prom oting ability (8,22,23). Nonliposom al cationic-lipid de­
livery vectors com bine both the  characteristics of cationic 
and helper lipids.
The synthesis of the lipopolyam ine dioctadecylam ido- 
glycylspermine (D O G S) by B ehr and co-w orkers (24) as a 
prom ising transfecting agent, encouraged several laboratories 
to focus on the  synthesis of novel cationic lipids based on the 
n a tu ra lly  o ccurring  po lyam ine sp e rm in e , fo r  exam ple, 
RPR120535 (25) and l,3-dioleoyloxy-2-(6-carboxysperm ine) 
D O SPE R  (26) (Fig. 2). The design of a novel lipopolyam ine 
form ula for D N A  condensation and cellular delivery relies 
on previous and continuing studies of the  structure-activity
relationships of D N A  bind ing  and condensation by poly­
amines (1627-30). A lth o u g h  lipopolyam ines are less efficient 
in com parison w ith viral vectors, their promising lower 
toxicity than viral vectors ensures a continuous effort to  
design novel lipopo lyam ines with im proved transfection 
efficiency. In  this study, w e synthesized and formulated a 
novel liposperm ine in w hich the tetra-am ine spermine (the 
cationic m oiety) and  dioleoyl chains (the lipophilic moiety) 
that is reported  to  im prove the transfection efficiency by 
fusion with cellular m em b ran e  (31). These unsaturated chains 
are linked by am ide bonds a t the  secondary amino groups of 
sperm ine to  form  7V4,A/9-dioleoyl sperm ine (commercially 
available as L ipoG en) (32). T hese amide linkers have the 
advantages o f being bo th  biodegradable and less toxic than 
the e ther bonds in D O T M A  (33,34). T he ability of this 
synthetic lipopolyam ine to  condense D N A  was studied using 
ethidium  brom ide (E th B r) fluorescence quenching and light 
scattering assays. T ransfec tion  efficiency was studied in an 
im m ortalized cancer cell line  (H tT A ). and in primary skin 
cells (FEK 4) for the  first tim e. The difficulties found in 
effic ien tly  tran sfec tin g  p rim a ry  cell lines were largely 
overcom e with this non liposom al form ulation comprising a 
vector with two covalently  bound oleoyl chains. The results 
are com pared with tw o com m ercially available (liposomal) 
transfection form ulations, Lipofectin®1 and Lipofectamine 
that incorporate such oleoyl o r oleyl (C l8) chains.
MATERIALS AND METHODS 
Materials
Chemicals, including poly  amines sperm ine, polyethyle- 
nimine (PE I), and poly-L-lysine (PLL). reagents, solvents, 
buffers, and D N A  were rou tinely  purchased from Sigma- 
Aldrich, U K , except w here  indicated. Lipofectin and Lipo-
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Fig. 2. Chemical structures of spermine, PEI, PLL. DOPE, DOTMA, and spermine based lipopolyamines.
fectam ine reagen ts from  Inv itrogen  (L ife  Technologies 
Gibco B R L ) and cell cultures m aterials from  Life T echnol­
ogies (Paisley. Scotland).
Synthesis o f  A,4JV9-D io leo y l Sperm ine
Sperm ine was used as the starting m ateria l for the syn­
thesis process (35), outlined  in Fig. 3. Sperm ine was protected  
on the prim ary am ino functional groups w ith ethyl trifluoro- 
acetate (2.2 eq) in m ethanol and the  reac tion  m ixture was 
stirred for 18 h at 25°C. The solvent was evaporated to 
dryness in vacuo to  form  N 1 JV12-d itriflu o ro ace ty l-l,1 2 - 
d iam in o -4 ,9 -d iaz ad o d e c an e . D ic y c lo h e x y lc a rb o d iim id e  
(DCC, 2.5 eq). 1 -hydroxybenzotriazole (H O B t. 0.2 eq) and 
oleic acid (2.2 eq) were added to the  d ip ro tected  sperm ine 
solution in CH2C12 and m ethanol (1:1). T h e  solution was 
stirred for 18 h at 25°C. The solvent was evaporated to
dryness in vacuo. T he residue was dissolved in C tL C L  and 
the solution filtered  an d  evaporated  to  dryness in vacuo to 
form  N 4,Af9-dioleoyl-7V1 JV12-ditrifluoroacetyl-l,12-diam ino- 
4,9-diazadodecane. F o r  the rem oval of the di-trifluoroacetyl 
groups, the te tra-am id e  was dissolved in m ethanol and the 
pH  of the solution was increased by saturating with am m onia 
gas, then it was left (18 h) and evaporated to dryness in 
vacuo to  give a residue which was purified over silica gel 
(C H 2Cl2-M eO H  5:3 v/v, then  C H 2Cl2-M eOH-conc. aq. N H 3 
25:10:1 v/v/v) to  affo rd  /V4,/V9-dioleoyl sperm ine R f 0.3 
(C H 2Cl2-M eO H -conc. aq. N H 3 25:10:1 v/v/v).
A m plification and P urification o f  Plasm id D N A  (pE G FP )
D N A  plasm id encoding  enhanced green fluorescent 
protein (pE G FP) purchased  from  Clontech was transform ed 
into Escherichia coli JM  109 bacterial strain (Prom ega). T he
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Fig. 3. Synthesis of A'4,A'9-dioleoyl spermine.
transform ed cells were grown in larger quantities of Luria- 
B ertani (LB) broth  supplem ented with 125 m g/L ampicillin. 
pE G FP  plasmid was produced in large-scale using HiSpeed 
plasmid purification Maxi k it (Q iagen) according to  the 
m anufacturers protocol. D N A  yields and purity' were de te r­
m ined spectroscopically (O D 26o/O D 2ko = 1.80 to  1.90 OD, 
optical density) and by agarose gel (1%  agarose) analysis.
Ethidium  Brom ide F luorescence Q uench ing A ssay
Each concentration  of the  D N A  stock solutions (ap­
proximately 1 pg/pl, 1 ml) was de term ined  spectroscopically 
(M ilton Roy Spectronic 601 spectrom eter. 1 cm path length, 
3 ml cuvette) (2) and 6 pg (approxim ately 6 pi) of D N A  was 
diluted to 3 ml with buffer (20 m M  NaCl. 2 mM H EPES, 
10 pM E D T A , pH  7.4) in a glass cuvette  stirred with a m icro­
flea. Im m ediately p rio r to analysis, E th B r solution (3 pi, 
0.5 mg/ml) was added to  the stirring solution and allowed to 
equilibrate for 10 min. Separately fo r each polyam ine or 
lipopolyamine (sperm ine, poly-L-lysine (average m olecular 
weight 9600 D a. PL L  9.6k), po lyethy len im ine (average 
m o lecu la r w e ig h t 2000 D a . P E I 2 K ), A ^A ^-d io leo y l 
sperm ine, L ipofectin, and L ipofectam ine) aliquots (5 pi, 
according to  the am m onium /phosphate ( + / - )  charge ratio  
required) were then added to  the stirring solution and the 
fluorescence m easu red  a fte r 1 m in eq u ilib ra tio n  using 
Perkin-Elm er LS 50B lum inescent spectrom eter (Xexcjl = 260 
nm and ?^miss = 600 nm with slit w idth 5 nm ) while stirring 
using an electronic stirrer (R ank Bros. L td .) (36). The total 
polyamine solution added to  the  D N A  solution did not 
exceed 5% of the total volume of the solution, so no cor­
rection was m ade for sample dilution. T he  fluorescence was 
expressed as the percentage of the m axim um  fluorescence
when E th B r was bound to  the D N A  in the absence o f 
com petition  fo r b inding and was corrected for background  
fluorescence o f free  E thB r in solution.
Light Scattering A ssay
D N A  (60 pg, 60 pi of 1 mg/ml solution) was d ilu ted  to  
3 ml w ith H E P E S  buffer (2 mM H EPES, 20 mM  N aC l, 
10 pM E D T A , p H  7.4) in a cuvette with a micro-flea, and the  
co n cen tra tio n  d e te rm in ed  spectroscopically (M ilton  R o y  
Spectronic 601 spectrom eter, 1 cm pa th  length, 3 ml cuvette). 
T hen a liquots (5 pi, according to  the  am m onium /phosphate 
(+ /—) charge ra tio ) of the  tested polyam ines were then  ad ded  
to  the stirring so lu tion  and the absorbance (light scattering) 
at 320 nm  was m easu red  after 1 min stirring to allow the  
m ixture to  reach  equilibrium . The increase in absorbance d ue  
to  the sca ttered  light was expressed as the percentage of re l­
ative m axim um  ap paren t absorbance (%  rel. max. app. abs.) 
due to  light scattering  of the bound polyamine with D N A .
Cell Culture and T ransfection  Experim ents
Two cell lines w ere used in the transfection experim ent, 
a hum an prim ary  skin fibroblast cells FEK4 (37) derived  
from a foreskin exp lan t and a hum an cervix carcinom a, H eL a 
derivative and transform ed cell line (H tTA ). The H tT A  cells 
being stably transfec ted  with a tetracycline-controlled tran s­
activator (tT A ) consisting of the tet repressor fused with the  
activating dom ain  of virion protein  16 of the herpes sim plex 
virus (HSV). Cells w ere cultured in E arle ’s minimal essentia l 
m edium  (E M E M ) supplem ented  with foetal calf se rum  
(FCS) 15% in the  case of FEK 4 and 10% in the  case o f 
H tT A  cells, penicillin and streptom ycin (50 IU/m l each), 
glutam ine (2 m M ), and sodium bicarbonate (0.2%).
For the  transfection  (gene delivery) and the resu ltan t 
gene activity (transfection efficiency), FEK4 and H tT A  cells 
were seeded a t 1 x 105 cell/well in 6 well plates in 4 ml E M E M  
media with FC S for 24 h to  reach a plate confluency of 
50-60%  on the  day of transfection. The complex was p repared  
by mixing 2 pg of p E G F P  with the cationic liposomes o r  
lipopolyamine in O pti-M EM  (serum free media, G ibco B R L ) 
according to  the  charge ratio  at room tem perature for 30 m in 
and then incubated  with the cells for 4 h a t 37°C in 5%  C 0 2. 
Then the cells w ere washed and cultured for further 44 h in 
growth m edium  at 37°C in 5%  C 0 2 before the assay.
Levels of enhanced  green fluorescent protein (E G F P  
positive cells) in the transfected cells were detected  and  
corrected for background  fluorescence of the contro l cells 
using a fluorescence activated  cell sorting (FACS) m achine 
(Becton D ickinson FA C S V antage dual Laser In strum en t, 
argon ion laser 488 nm ). T he transfection efficiency was 
calculated based on the percentage of the cells that expressed  
E G FP  (positive cells) in the  total num ber of cells.
C ytotoxicity (M T T ) A ssay o f  the Formed Lipoplexes
FEK 4 and H tT A  cells were seeded in 96 well p lates a t 
8000 cell/well and incubated  for 24 h at 37°C in 5%  C 0 2. 
W4JV9-D ioleoyl sperm ine com plexed with pEG FP was ad d ed  
in the sam e way as the  transfection protocol. A fter in cubation  
for 44 h. the m edia  was replaced with 90 pi of fresh m edia and
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10 pi o f sterile  filtered M T T  solu tion  (Sigm a-Aldrich, U K ) 
(5 mg/ml) to  reach a final concen tra tion  of 0.5 mg/ml. T hen 
the plates were incubated fo r a fu rth er 4 h at 37°C in an 
atm osphere  of 5%  v/v COo. A fte r  incubation, the m edia and 
the un reac ted  dye were a sp ira ted  and  the form ed blue 
form azan crystals were dissolved in 200 gl/well of dimethyl 
sulfoxide (D M SO ). The produced  color was m easured using 
a p la te -reader (V E R SA m ax) a t w avelength 570 nm . The % 
viability re la ted  to  control wells containing cells w ithout 
D N A  and /o r polym er and is calculated  by (test absorbance/ 
control absorbance) x 100 (38). T he sam e protocol was 
app lied  in  case of the com m erc ially  available reag en ts  
L ipofectin and  L ipofectam ine.
R E SU LTS
Synthesis o f A1"4, Ar9-Dioleoyl Sperm ine
The synthesized /V47V9-dioleoyl sperm ine (Fig. 3) was 
hom ogenous on silica gel th in -layer chrom atography and was 
fully characterized  by XH -N M R  (a t 400 M H z) and 13C-NM R 
and high-resolution accurate m ass spectroscopy.
Ethidium  B rom ide F luorescence Q uenching Assay
To study the ability of/V4.Ar9-dioleoyl spermine to  condense 
calf thymus D N A  and p E G F P  as well as compared this effect 
with the effect of different know n polycations spermine, PLL 
(39) and PE I (40) (Fig. 2) to  condense DN A. Figure 4 shows 
the ability of the studied polyam ines to displace E thB r from 
DNA. T he binding ability was in the  order PEI 2K > /V4JV9- 
dioleoyl sperm ine > PLL 9.6K > spermine according to the 
charge ratio. The charge ratio was calculated according to the 
ammonium/phosphate (+ /—) ratio  for: spermine. 202.35 g/mole 
with four nitrogen atoms that can be protonated; PLL 9.6K. one 
positive charge/lysine m onom er: Ar4JV9-dioleoyl spermine, with 
two positive charges. In the case of PET 2K the charge ratio was 
calculated as 25% of the am ino groups in the polymer that can 
be protonated, assuming that 43.1 g/mol is the repeating unit of 
PEI that contains one nitrogen atom  (41,42). It seems to be that 
there is no  agreem ent in the literature for the calculation of the 
PEI/D N A  ratio. A lthough it is calculated as PE I nitrogen/DNA
PLL 9.6K
100 -A—  PEI 2K
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Fig. 4. Plot of E thB r displacement assay of calf thymus DNA 
complexed with PLL 9.6K, PEI 2K, A 4,/V9-dioleoyl spermine, and 
spermine.
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Fig. 5. Plot of E thB r displacement assay of calf thymus D N A  com ­
plexed with A^.A^-dioleoyl spermine, Lipofectin, and Lipofectamine.
phosphate (40) not as charge ratio, it is reported that ever)' third 
atom  of PEI polymer is a protonatable nitrogen (40). bu t one in 
five of the protonatable nitrogens in PE I are pro tonated  at pH  
7 (43). How ever, W agner (11) reported that one of every seven 
nitrogens within PEI polymer is protonated at pH  7. T he 
polycations (PE I 2K and PLL 9.6K) are known for their ability 
to condense D N A  efficiently at a relatively low charge ratio  
compared to  spermine. On the other hand, the results revealed  
that /V4A;9-dioleovl spermine is able to condense D N A  at a 
lower charge ratio than PLL 9.6K and spermine (Fig. 4). and 
produces a 50%  fluorescence decrease at charge ra tio  0.52. 
Also, Fig. 5 shows D N A  condensation ability of /V4JV9-dioleoyl 
spermine in comparison with the commercially available, cationic 
lipid, liposomal formulations Lipofectin and Lipofectamine. All 
three cationic lipid formulations have the ability to  condense 
completely D N A  through the displacement of E thB r leading to 
fluorescence quenching. A t lower charge ratios A^JV ^dioleoyl 
spermine has better ability to suppress the fluorescence than 
Lipofectin and Lipofectamine. On studying the effect of N 4,N 9- 
dioleoyl sperm ine on the type of D N A  (calf thymus D N A , and 
plasmid pE G FP), it was found that there is no significant 
v a r ia tio n  in  the  co n d en sa tio n  ab ility  o f  th e  s tu d ie d  
lipopolyamine on the type of DNA.
Light Scattering  Assay
This experim ent has been carried out to investigate  the 
condensation  of D N A  by polyam ines and the fo rm atio n  of 
particles (44). The apparent U V  absorbance a t 320 nm  
(where th ere  is no D N A  absorbance above 300 nm ) was 
m easured (28,45.46) showing light scattering. T he resu lts 
from  Fig. 6 ind ica ted  the  fo rm ation  of p a rtic le s  up o n  
in teraction  of sperm ine, PLL 9.6K and PEI 2K. In add ition , 
Fig. 7 shows th a t the light scattering due to particle fo rm ation  
increases w ith  the increase in the displaced E th B r  and 
reaches the  m axim um  at approxim ately the sam e charge 
ratio  at which there is a m aximum EthB r d isp lacem ent, 
although the  concentration of D N A  used in light sca tterin g  
experim ents is ten  tim es the concentration used in fluo res­
cence quenching experim ents which is related to  the  lack of 
sensitivity o f light scattering experim ent in com parison  with 
fluorescence assay. Also, from light scattering results , th e re  
is a decrease in the % relative maximal apparent ab so rbance  
(%  rel. m ax. app. abs.) after reaching the m axim um  abso r­








Fig. 6. L ight scattering assay (%  relative maximum apparent 
absorbance at X. = 320 nm) of calf thymus DNA complexed with 
PLL 9.6K, PEI 2K, N 4,A 9-dioleoyl spermine and spermine.
bance. w hich could be a ttrib u ted  to  the form ation  of poly- 
am ine-D N A  aggregates as rep o rted  by Gosule and Schellman
(47).
T ransfection  E xperim ents
T h e  transfection  efficiency of p E G FP  in to  FEK 4 prim ary 
cell line and  the cancer H tT A  cells was studied using N AJV9- 
dioleoyl sperm ine and the  com m ercially available reagents 
(L ipofectin  and L ipofectam ine). T he transfection results of 
p E G F P  in to  FE K 4 indicated  higher transfection ability of 
/V4,/V9-dioleoyl sperm ine (75% ) and L ipofectam ine (66% ) 
fo rm ulations over L ipofectin  (18% ); there is no significant 
difference in the transfection  activity betw een /V4,/V9-dioleoyl 
sperm ine and L ipofectam ine (Fig. 8). On the o ther hand, 
both  N 4,A 9-dioleoyl sperm ine and L ipofectam ine form u­
lations show  a sim ilar transfection  activity in H tT A  cells 
(about 70% ), higher than  L ipofectin  (58% ). A/4,/V9-Dioleoyl 
sperm ine transfects the cells best at charge ra tio  ( + / - )  2.5 
(5.54 pg/m l), L ipofectin at charge ratio  0.6 (5.0 pg/ml), while 
L ipofectam ine transfect bo th  cell lines at charge ra tio  3.7 
(10.0 pg/m l).
E3 N4,N9-Dioleoyl spermine 
■  Lipofectin 
□  Lipofectamine
FEK 4 H tT A
Fig. 8. Lipofection of FEK4 and HtTA cells transfected with pEGFP 
complexed with A 4.A'9-dioleoyl spermine. Lipofectin o r Lipofectamine 
(at their respective N/P ratios for best transfection). The data represent 
3 different experiments (3 replicates each) and the error bars represent 
the standard deviation.
I n  V i t r o  Cytotoxicity
T h e  cytotoxicity o f /V4JV9-dioleoyl sperm ine was studied 
in FE K 4 and H tT A  cells using M i l assay (48) (Fig. 9). The 
IC 50 (the  concentration at which cell grow th is inh ib ited  by 
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Fig. 7. Comparison of E thB r displacement and light scattering assays 
of calf thymus D N A  with /V4./V9-dioleoyl spermine.
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Fig. 9. Viability of HtTA cells (above) and FEK4 prim ary skin cells 
(below) after application of different concentrations of /V4,/Vy- 
dioleoyl spermine either free or complexed with pEG FP.
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Fig. 10. Cytotoxicity effect of pEG FP (2 pg/ml) complexed with 
either Ar4,N g-dioleoyl spermine (5.54 pg/ml), Lipofectin (5 pg/ml) or 
Lipofectam ine (10 pg/ml) in FEK4 and HtTA cells.
cells w ere 20.47 and 6.31 pg/ml respectively, and fo r the  
lipoplex were 19.82 and 8.35 pg/ml respectively. The results 
ind icate  th a t th ere  is no  significant difference in the toxic 
effect (IC 50) of the  free  polycation over the lipoplex in 
the  case o f H tT A  cells and FEK 4 cells fo r the studied li­
popolyam ines. N 4.A,9-D ioleoyl sperm ine show' a significant 
d ifference in the  % viability com paring to  e ither Lipofectin 
and L ipofectam ine in the prim ary skin cell line FEK4, but 
there  is no  difference in the case of the cancer cell line H tT A  
(Fig. 10). T hese results also revealed th a t N 4,7V9-dioleoyl 
sperm ine toxicity is higher (lower concentrations) in the  case 
o f H tT A  cells m ore  than with the prim ary cell line FEK 4 
which could be a ttrib u ted  to  the ease o f transfection of 
im m ortalized  cancer cell lines over prim ary cell lines.
D IS C U SS IO N
N on-viral delivery system s can be defined to  include the  
use o f plasm id D N A  alone (so-called naked  D N A ) (49,50) as 
well as D N A  com plexed to synthetic carriers such as cationic 
lipids (51-54) o r polym ers (55). T he use of an efficient carrier 
for nucleic acid delivery is considered to  be a determ inant 
facto r fo r the  successful application of gene therapy (56). 
This carrie r is responsible for the com plex process of gene 
delivery to  the  nucleus (57).
E th id ium  brom ide (E thB r) (2,7-diamino-10-ethyl-9-phe- 
ny lphenanthrid in ium  brom ide. Fig. 11) is a cationic dye that 
displays a m ark ed  increase in the fluorescence upon binding 
with D N A  and R N A  through the intercalation betw een the 
E th B r phenan thrid in ium -m oiety  and adjacent base-pairs of 
D N A  sequences (36.58). W ithin the p rerequisites for delivery 
of D N A  across in tact cytoplasm ic m em brane are condensa­
tion and m asking the  negative charge o f the  phosphate 
backbone. C ondensation  of D N A  occurs when about 90%  
of the charge on D N A  is neutralized (16,47).
T he ability of the  cationic lipid N’4JV9-dioleoyl sperm ine 
to  com pact D N A  m o re  efficiently than both  sperm ine and 
the pow erful condensing agent PLL a cationic polym er (9), 
(Fig. 4) shows the im portance of the lipid m oiety we have 
b o u n d  to  th e  c a tio n ic  po lyam ine in o rd e r to  ach ieve  
im p rovem en ts in  its ability to  condense D N A , cellu la r 
entry , and low ering th e  toxicity of the polyam ine conjugate 
(11,59,60).
T h e  fo rm a tio n  o f (V4,(V9-d iO leoyl sp e rm in e -D N A  
lipoplex at lower charge ra tio  decreases the  toxicity of 
the D N A  delivering lipopolyam ine. A s the m am m alian 
cell m em brane  is a sem ip e rm eab le  m em b ran e  form ed  
o f  p h o spho lip ids b ila y e r th a t a llow s th e  tran sp o rt of 
m acro m o lecu les  by e n d o cy to sis . n e u tra liz a t io n  of the  
negative charges on the  D N A  by polycations will im prove 
the  delivery of D N A  through the cell m em brane  because of 
the presence of negative charges on b o th  D N A  and cell 
m em brane. Also, the positively charged lipid complex will 
m ediate  transfection by fusion w ith cell m em branes (60.61). 
It was found that bo th  the num ber of positive charges and 
th e ir  d istribution  on  the  surface o f th e  m olecule have 
profound effects on D N A  condensation  (28,62,63).
In addition, in a study on the transfection  activity of 
cholesterol carbam ate cationic lipids (28), B lagbrough and 
co-workers reported  that the carbam ate  w ith a sperm ine 
polyam ine m oiety has the  highest transfec tion  activity with 
its ability to  condense D N A  efficiently. O u r  findings are in 
agreem ent with the  literature, the cationic liposom al form u­
lation Lipofectin, with its cationic m oiety D O T M A  contain­
ing one positively charged quaternary  am m onium  group, has 
low er ability to  displace the E th B r from  D N A  than L ip­
ofectam ine form ulation that contains D O S P A  (Fig. 2) with 
its four positively charged nitrogens (15) an d  N 4.A;9-dioleovl 
sperm ine with its two positively charged  nitrogens. T he 
h igher ability of A?4,N y-dioleoyl sp erm ine  (two positive 
charges) over L ipofectam ine (fo u r positiv e  charges) in 
D N A  condensation, though N 4,A/9-dioleoyl sperm ine has 
a low er n um ber of positive charg es/m o lecu le , m ay be 
a ttribu ted  to  the d istribution of the positive charges on the 
m olecule allowing a h igher affinity o f the  vector for D N A  
and leading to the  efficient displacem ent o f E thB r. A no ther 
variab le  is the liposom al fo rm ula tion  o f L ipofectam ine 
com pared  to the  non-liposom al fo rm u la tio n  of N 4.N 9- 
dioleoyl sperm ine.
The helper lipid D O P E  which is the  second com ponent 
of the cationic liposom es is used to  increase  the transfection 
activity  of the cationic  liposom e th ro u g h  its ability to  
destabilize lipid bilayers leading to  endosom al destabilization 
with subsequent increase in the to tal cellu lar uptake of the 
delivered D N A  (23.64). L iposperm ines (Fig. 2) w ith their 
cationic headgroup som etim es form  m icelles (in the absence 
of D N A ) ra ther than the bilayer p ro duced  by the small 
cationic quaternary am m onium  headgroup  o f  D O T M A  (L ip­
o fec tin  fo rm u la tio n ) (43,65). N 4,7V9-D io leo y l sperm ine  
com bines in its structure the two oleoyl chains that have the 
characteristics of the fusogenic lipid D O P E  and the cationic 
polyam ine sperm ine (Fig. 2). Thus, D N A  is condensed by the
NH.
Fig. 1L Structure of ethidium bromide.
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two prim ary  am ines and coated by the  dioleoyl lipophilic 
m oiety. T he D N A  condensation results of W4JV9-dioleoyl 
sperm ine (Fig. 5) show a higher efficiency than  e ith e r li­
posom al form ulation . T he transfection results reveal higher 
transfection  ability (levels of expression) of /V4,7V9-dioleoyl 
sperm ine com pared  to  Lipofectin (Fig. 8) in FEK 4 and  H tT A  
cells. T h ese  resu lts  indicate  the ro les of bo th  n u m b er 
and d istribution  of positive charges along the polyam ine 
backbone on the  ability of the com pound to  condense D N A . 
O n the  o th er hand, there  is no significant difference in the 
transfection  activity betw een A^.A^-dioleoyl sperm ine and 
L ipofectam ine in bo th  FEK4 and H tT A  cell lines, which 
indicates the  im portance of lipid coating over the  D N A  
m olecule on bo th  the  condensation and cellular delivery of 
D N A  in case of the liposomal and non liposom al fo rm u­
lations (65). 7V4.A 9-Dioleoyl sperm ine achieved high levels 
of transfection  in both  a cancer cell line and a prim ary skin 
cell line (73% ), which indicates the ability of this vector to  
deliver D N A . Cell viability results revealed im proved FE K 4 
viability m ore  than  the cancer cells H tT A  (Fig. 9). A lso, 
yV4,/V9-dioleoyl sperm ine showed a significant im provem ent 
in prim ary  FE K 4 cell viability over the liposom al form u- 
latios (Fig. 10), bu t no significant difference in H tT A  cells. 
P rev io u s  s tu d ie s  on L ip o fectin  and  L ip o fec tam in e  on 
different cell lines showed the cytotoxic effects of these  
lip o so m a l fo rm u la tio n s  (66 -70). In co n c lu sio n , a l ip o ­
polyam ine vector has been developed for D N A  delivery. 
This new non-liposom al form ulation has the ability to  tran s­
fect prim ary  skin cells m ore efficiently than the com m ercially 
available liposom al Lipofectin form ulation.
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Varying the Unsaturation in V 4,A^-Dioctadecanoyl Spermines: Nonviral 
Lipopolyamine Vectors for More Efficient Plasmid DNA Formulation
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Purpose. The aim of the study is to analyze the effect of varying the degree of unsaturation in syn­
thesized jV4,N 9-dioctadecanoyl spermines on DNA condensation and then to  com pare their transfection 
efficiency in cell culture.
M ethods. The A 4JV9-di-C18 lipopolyamines—saturated (stearoyl), C9-cis- (oleoyl), and C9,12-di-m- 
(linoleoyl)— were synthesized from the naturally occurring polyamine spermine. The ability of these 
novel compounds to condense DNA and form nanoparticles was studied using ethidium bromide 
fluorescence quenching and nanoparticle characterization techniques. Transfection efficiency was 
studied in several primary skin cells (FEK4, FCP4, FCP5, FCP7, and FCP8) and in an immortalized 
cancer cell line (H tTA) and was compared with the commercially available nonliposomal transfection 
formulation Transfectam® (dioctadecylamidoglycyl spermine), which also contains two saturated C18 
lipid chains.
Results. N 4,N 9-Dilinoleoyl spermine (C18, di-m-9,12) is efficient at circular plasmid DNA (pEGFP) 
condensation and gives the most effective transfection in a series of primary skin cells and cancer cell 
lines at low charge ratios of 5.5 (± ammonium/phosphate).
Conclusions. The dienoic fatty acyl spermine conjugate N 4,N 9-dilinoleoyI sperm ine efficiently condenses 
D NA and achieves the highest transfection levels among the studied lipopolyamines in cultured cells.
KEY WORDS: FCP; FEK4; gene delivery; HtTA; lipopolyamine; Ar4^V9-dilinoleoyl spermine; 
yV4,N 9-dioleoyl spermine; N 4,N  ^ -distearoyl spermine; primary skin cells; transfection.
IN T R O D U C T IO N
As viral gene therapy continues to  suffer significant 
problem s with m am m alian toxicity (1 -3), the  possibility of 
reaching the goal of in tracellu lar p ro te in  levels at therapeutic  
concentrations m oves even m ore tow ard utilizing nonviral 
gene therapy (NV GT). W ithin this b road  term , we are con­
centrating on lipopolyam ines com posed of a lipophilic steroid 
a ttached either to  a polyam ine chain (4 -8 ) o r to a single or 
double long-carbon chain covalently bound to  a polyam ine, 
e.g., sperm ine (A ^ A ^ -d ia m in o ^ ^ -d ia za d o d e ca n e ) (9-11). 
O ther research groups are investing in a variety o f a lte r­
native approaches classified under the  N V G T  um brella, 
including the  following: naked  D N A  (12), gene gun (bound 
to  gold particles) (13,14), e lectroporation  (15), polycation-
1 Departm ent of Pharmacy and Pharmacology, University of Bath, 
Bath BA2 7AY, UK.
2 To whom correspondence should be addressed, (e-mail: prsisb@ 
bath.ac.uk)
ABBREVIATIONS: D OGS, dioctadecylam idoglycyl sperm ine; 
DOPC, dioleoylphosphatidyl choline; D O PE , dioleoylphosphatidyl 
ethanolamine; EGFP, enhanced green fluorescent protein; EMEM, 
E arle’s Minimal Essential Medium; EthBr, ethidium  bromide; FCS, 
fetal calf serum; HRMS, high-resolution mass spectroscopy; NVGT, 
nonviral gene therapy; PE, phosphatidyl ethanolamine; PLL, poly-L- 
lysine.
m ediated D N A  delivery, and the use of a wide variety of 
cationic lipids (lipoplexes) (16), e.g., bolaamphiphiles (17), 
and cationic polym ers (polyplexes) (18-20) [for reviews, see 
(21-25)]. F o r gene th erap y  to  realize its potential and 
becom e an efficient m edicine for the treatm ent of diseases 
such as cancer, cystic fibrosis, inflam mation, or for vaccina­
tion, key obstacles m ust be overcome. The essential requ ire­
m ents for gene delivery are the  transport of D N A  through 
the cell m em brane and  ultim ately to  the nucleus. The design 
of an efficient fo rm ula  for the delivery of genetic m aterial 
requires a deta iled  understanding of the barriers that hinder 
this process. Thus, efficient form ulations, lipoplexes (16,17), 
and polyplexes (18-20) m ust be able to deliver safely the 
required  D N A  across the various cellular barriers to  the  
nucleus. B arriers to  D N A  delivery also include complex 
form ation betw een the  D N A  and the lipopolyamine leading 
to  D N A  nan o p artic le  fo rm ation  by electrostatic charge 
neutralization (to  about 90% of the total negative charge) 
and overall packing as condensed D N A  nanoparticles (26). 
So, a key first step in  this m ethod of gene form ulation is 
m asking the negative charges of the phosphate backbone. 
This titration  with a lipopolyam ine causes alleviation of 
charge repulsion be tw een  rem ote  phosphates along the  
D N A  helix leading to  collapse into a m ore compact structure 
that facilitates cell entry.
For NV GT, except fo r naked (free, uncomplexed) D N A  
being trapped inside cells by direct association with the
0724-8741/06/0100-0031/0 © 2006 Springer Science + Business Media, Inc.
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chrom atin  during  m itosis, th e  (prodrug) D N A  m ust be 
form ulated . Small m olecule synthetic  cationic lipids are one 
of the m ajo r gene carriers fo r N V G T, often classified as 
liposomal and nonliposom al nonviral delivery vectors. They 
condense D N A  into nanopartic les that are readily endocy- 
tosed by cu ltu red  cells and  facilitate  endosom al escape 
leading to  efficient delivery  to  the nucleus presum ably 
crossing th rough  the nuclear po re  complex. A fter nuclear 
entry, the  payload DNA should ultim ately be able to  give the 
desired p ro te in  through transcrip tion  and translation.
The first cellular barrier for the delivery of the D N A  
nanoparticles is the eukaryotic cell membrane, which is com­
posed mainly of phospholipids (50-90%  of total lipid content; 
most phospholipids are derivatives of diacyl-glycerol-3-phos- 
phate), sterols (5-25% ), and glycol lipids (usually less than 
5%). The diacyl-glycerol chains (C14-C24) are derived from 
linear fatty acids with varying degrees of unsaturation (27). In 
NVGT, cationic lipids, which interact with the D N A payload, 
also m ediate cell-membrane transport, typically through ad­
sorptive endocytosis or m ediated by cations (28-30), both routes 
leading to  internalization of the D N A  complex nanoparticles. 
Such endocytosis is via the clathrin-coated pits (250-300 nm) 
(31), followed by fusion of the early endosome and sorting to 
the late endosom al compartm ent, hence avoiding degradation in 
the lysosome. O ne of the im portant factors improving the 
release of free D N A  or the lipoplex into the cytoplasm is the 
influence of the cationic lipid chain. Xu and Szoka (32) have 
reported that unsaturated hydrocarbon chains increase the 
transfection efficiency of the lipoplex by decreasing the rigidity 
of the bilayer and favoring a higher intermembrane transfer rate 
and lipid mixing, compared with their saturated counterparts. 
However, Roosjen et a l (33) recently reported that, in certain 
cases, sa tu rated  fatty chains afforded better results than 
unsaturated chains. Herein, we investigate the effects on D N A  
formulation of a circular plasmid with variation in the degree of 
unsaturation in the two C18 fatty chains in our lipospermines, the 
saturated V 4,V 9-distearoyl sperm ine, the alkenoic N 4,N 9- 
dioleoyl sperm ine, and the dienoic fatty acyl spermine conjugate 
V 4jV 9-dilinoleoyl spermine. W e report the synthesis and char­
acterization of the nanoparticles, summarize transfection results 
with the synthesized lipospermine formulations in a panel of 
both primary and cancer cell lines, and compare these results 
with those obtained with the commercially available nonlipo­
somal liposperm ine T ransfectam ®  [dioctadecylamidoglycyl 
spermine (D O G S)] formulation (3435).
M A T E R IA L S  A N D  M E T H O D S  
M aterials
Chem icals, including sperm ine, acyl chlorides (linoleoyl, 
oleoyl, an d  stearoyl chlorides), solvents, buffers, and D N A  
were rou tinely  purchased from  Sigma-Aldrich, D orset, U K , 
except w here indicated. Transfectam ®  was from Prom ega 
(Southam pton, UK ), and cell cu lture m aterials were from  
Life Technologies (Paisley, Scotland).
Preparation o f  Plasm id D N A
W e have chosen to  deliver a 4.7-kbp plasmid encoding 
for enhanced  green fluorescent pro tein  (pEG FP), with a
m olecular weight of about 3.1 M D a (given an average of 330 
D a p e r nucleotide, 660 D a per base pair (36), carrying 9400 
negative charges). D N A  plasm id pEG FP, purchased  from  
C lontech (B asingstoke, U K ), was transform ed in to  Escher­
ichia coli JM  109 bacterial strain  (Prom ega) and was purified 
by a Q iagen Maxi kit (Q iagen, Chatsw orth, C A , U SA ). D N A  
yields and purity  were determ ined spectroscopically (O D 26o/ 
O D 280 = 1.80-1.90 O D , optical density) and by agarose gel 
(1% ) analysis.
Synthesis o f  L iposperm ines V 4,A 9-D ilino leoy l S perm ine, 
A'4../V9-D io leo y l Sperm ine, and V 4,V 9-D istearoyl Sperm ine
Sperm ine was used as the starting m aterial for the synthetic 
process, outlined in Fig. 1. The tetra-am ine was p ro tected  on 
both  the prim ary am ino functional groups with ethyl trifluoro- 
acetate (2.2 eq.) in m ethanol, and the reaction m ixture was 
stirred fo r 18 h a t 20°C. The solvent was evaporated to  dryness 
in vacuo to  form V 1r/V12-ditrifluoroacetyl-l,12-diam ino-4,9- 
diazadodecane. Fa tty  acyl chloride (linoleoyl, oleoyl, and 
stearoyl; 2.2 eq) and triethylamine (2.5 eq) were added to  the 
d iprotected  sperm ine solution in C H 2CI2 and m ethanol (1:1). 
The solution was stirred for 72 h a t 20°C and then evaporated  
to  dryness in vacuo. T he residue was dissolved in C H 2C12, and 
the solution was filtered and evaporated to dryness in vacuo to 
form  V 4rV 9-[dilinoleoyl, dioleoyl (37), or distearoylj-TV1 JV12- 
d itrifluoroacety l-l,12 -d iam ino-4 ,9 -d iazadodecane. F o r  the 
rem oval of the ditrifluoroacetyl protecting groups, the  tetra- 
am ide was dissolved in m ethanol, and the pH  of the solution 
was increased by saturating with am m onia gas, then  it was left
F-COCHN' ^ ^ nhcocf3
H
F3COCHN-— N -— N—
III
h2n ^ - n ' ^ - n - ^ n h 2
Fig. L  Synthetic scheme of spermine-based cationic lipids: N 4,N 9- 
distearoyl spermine 1, TV4, A 9-dioleoyl spermine 2, and N 4,N 9- 
dilinoleoyl spermine 3. Reagents: (i) ethyl trifluoroacetate, methanol, 
18 h at 20°C; (ii) fatty acyl chloride, R = (stearoyl 1, oleoyl 2, and 
linoleoyl 3), triethylamine, CH2C12, and methanol (1:1), 72 h a t 20°C; 
(iii) m ethanol saturated with ammonia gas, 18 h at 20°C.
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for 18 h at 20°C and then evaporated to dryness in vacuo to 
give a residue th at was purified over silica gel (C H oG z-M eO H  
5:3, v/v, then C H 2Cl2-M eO H -conc . aq. N H 3 25:10:1, v/v/v) 
to  afford  the th ree  desired lipopolyamine conjugates as their 
free bases. All three  synthesized lipopolyamines were hom oge­
nous on  silica gel thin-layer chromatography (C H 2Cl2-M e O H - 
conc. aq . N H 3 25:10:1, v/v/v) and w ere ch arac te rized  by 
^ - n u c l e a r  m ag n e tic  reso n an ce  (NM R; a t 400 M H z) and  
13C -N M R  spectroscopy (assignments follow from  correlation 
sp ec tro sco p y ) and  by high-resolu tion  m ass spectroscopy 
(H R M S):
/S/4v/V9-distearoyl sperm ine 1, R( = 0.41, N M R  inter 
alia (C 2HC13) S *H 0.91 ppm  (t, 2 x CH 3), 1.25-1.75 ppm  (br 
m , m any  x C H 2), 2.40-2.58 ppm  (br s, 2 x N H 2), and 
3.24-3.48 ppm  (b r m , m any x NCH2), S 13C 173 ppm (2 x 
C O N ), C46H95N40 2 found (m /z  [M + H ]+) 735.7458, requires 
735.7455 (A ppm  -0 .4 ) ,  C4513C H 95N40 2 found 736.7500, 
req u ires  736.7489 (A ppm  —1.5).
/V4,/V9-dioleoyl sperm ine 2, R{ = 0.44, N M R  inter alia 
(C ^H C b) 8  XH  0.91 ppm  (t, 2 x C H 3), 1.24-1.70 ppm  (br m, 
m any x C H 2), 2.03 ppm  (app q, 4 x allylic C H 2), 4.55-5.10 
ppm  (b r s, 2 x N H 2), and 5.32-5.41 ppm  (m, 2 x C H C H ), 
8 13C 130 ppm  (2 x  C H C H ) and 173 ppm  (2 x C O N ), 
C46H91N 40 2 fo und  (m /z [M + H ]+) 731.7115, req u ires  
731.7142 (A ppm  3.7), C4513C H 93N 40 2 fo und  732.7145, 
req u ires  732.7176 (A ppm  4.1).
N 4,N  9-dilinoleoyl sperm ine 3, R( = 0.49, N M R inter 
alia (C ^H C b) 8  XH 0.89 ppm  (t, 2 x CH 3), 1.25-2.00 ppm  (br 
m, m any  x C H 2), 2.05 ppm  (app q, 4 x allylic C H 2), 2.77 ppm  
(app  t, 2 x doubly allylic C H 2), 5.29-5.42 ppm  (m, 4 x 
C H C H ), and 5.85-b.20 ppm  (br s, 2 x  N H 2), <5 13C 128 and 
130 ppm  (4 x C H C H ) and 174 ppm  (2 x C O N ), 
found  (m /z [M + H ]+) 727.6846, requires 727.6829 (A ppm  
- 2 .3 ) ,  C 4513C H 87N 40 2 found  728.6857, req u ire s  728.6863 
(A pp m  0.7).
D N A  C ondensation
D N A  condensation  was m onitored using an ethidium  
b rom ide  (E th B r) fluorescence quenching assay as described 
in deta il earlie r (11). Briefly, D N A  (6 pg) was diluted to  3 ml 
w ith  b u ffe r  [20 m M  N aC l, 2 mM 4-(2 -hydroxyethy l)- 
1-p iperazineethanesulfonic  acid (H EPES), 10 pM ethylene- 
d iam inete traacetic  acid (E D T A ), pH  7.4] in a glass cuvette 
s tirred  w ith a m icroflea. E thB r solution (3 pi, 0.5 mg/ml) was 
added  to  the  stirring  solution and was allowed to  equilibrate 
fo r 10 m in. Separately , lipopolyamine aliquots [5 pi, accord­
ing to  the  am m onium /phosphate (±) charge ra tio  required] 
w ere th en  ad ded  to  the stirring solution, and the  fluorescence 
was m easu red  afte r 1-min equilibration using a Perkin-E lm er 
LS 50B lum inescent spectrom eter (Aexcit = 260 nm and Aemiss = 
600 nm  with slit w idth 5 nm ) while stirring using an electronic 
stirre r (R ank  Bros. L td ., Bottisham , Cam bridge, England). 
T he fluorescence was expressed as the percentage of the 
m axim um  fluorescence when E thB r was bound to the D N A  
in the  absence o f com petition  for binding and was corrected 
for background  fluorescence of free E thB r in solution.
A lso , each  sam ple o f plasm id D N A  (0.5 pg), either free 
or com plexed with the  lipopolyamine, was analyzed by gel 
electrophoresis fo r abou t 60 m in under 75 V/cm, through an
agarose  gel (1% ) con ta in ing  E th B r (1 pg/m l) in T ris -  
ace ta te -E D T A  1 x (40 m M  T ris -ace ta te  an d  1 mM  E D T A ) 
buffer. The (unbound) free D N A  in the agarose gel was 
visualized under U V  using G eneG enius (Syngene, Cam ­
bridge, UK).
L ipoplex  Particle S ize and ^-Potential M easurem ents
T he average particle  size for the  lipoplexes form ed (at 
their optim um  charge ra tio  of transfection), a fte r mixing with 
a vortex mixer, was determ ined  using a M alvern  Z etasizer 
(N ano S, M alvern Instrum ents, M alvern, U K ), and ^-po ten­
tial m easurem ents were determ ined  using a M alvern Z eta ­
sizer (Nano ZS, M alvern Instrum ents). A ll m easurem ents 
w ere carried out on lipoplexes with 5 pg/ml plasm id D N A  in 
H E PE S  buffer a t pH  7.4 and 20°C.
C ell Culture and Transfection  E xperim ents
Six cell lines were used in the transfection  experim ent; 
FE K 4 (38), FCP4, FCP5, FCP7, and FC P8 cells are hum an 
prim ary fibroblasts derived from  new born foreskin explants
(39). H tT A  cells are  a hum an cervical carcinom a, H eLa- 
derived and transform ed cell line. Cells w ere cultured  in 
E arle ’s Minimal E ssential M edium  (E M E M ) supplem ented 
with fetal calf serum  (FCS), 15% in the  case of FEK 4 
and  FC P cells and 10% in the  case o f H tT A  cells, penicillin 
and  streptom ycin (50 IU /m l each), g lu tam ine (2 m M ), and 
sodium  bicarbonate (0.2% ). P rim ary cells were passaged 
once a week and used betw een passages 7 an d  15.
For the transfection (gene delivery) and the  resultant gene 
activity (transfection efficiency), cells were seeded in 6-we 11
plates a t a density of 1 x 105 cells/well (in 4 ml EM EM  with 
FCS) for 24 h to  reach a 50-60%  confluency on the day of 
transfection. The complex was prepared  by mixing pE G F P  
(2 pg/ml/well) with each lipopolyamine in O pti-M EM  (serum- 
free media, Gibco BRL, Berlin, G erm any) according to  the 
charge ratio  at 20°C for 30 min and then incubated with the 
cells for 4 h at 37°C in 5%  C 0 2. Then the  cells were washed 
and cultured for a further 44 h in growth m edium  at 37°C in 
5%  C 0 2.
Levels of E G F P  in the transfected  cells w ere detected  
and  corrected for background fluorescence of the control 
cells using a fluorescence-activated  cell sorting  (FA C S) 
m achine (Becton D ickinson FA CS V antage dual L aser Instru ­
m ent, argon ion laser 488 nm). T he transfection  efficiency 
was calculated based on the percen tag e  o f  th e  cells th at 
expressed E G FP  (positive cells) in  the  to ta l num ber of 
cells.
I n  V i t r o  Cytotoxicity
Briefly, FEK4, FCPs, and H tT A  cells w ere seeded in 96- 
well plates at 8000 cells/well and incubated  fo r 24 h a t 37°C in 
5%  C 0 2. Lipoplexes with p E G FP  were added  at the sam e 
concentra tion  as in the transfection  pro toco l (2 pg/ml). 
Cytotoxicity was evaluated after incubation  for 44 h; sterile- 
filtered  3-(4,5-dim ethylthiazol-2-yl)-2,5-diphenyl tetrazolium  
brom ide (M TT) solution (10 pi, 5 mg/ml; Sigm a-A ldrich, 
U K ) was added to  reach a final M TT concentra tion  o f 0.5 
mg/ml. The color produced was m easu red  using a p late
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reader (V ER SA m ax™ ) at X = 570 nm . The p e rcen t viability 
re la ted  to control wells containing un trea ted  cells (w ithout 
naked D N A  and without lipopolyam ine-D N A  lipoplex) is 
calculated by [O D  (m easured)/O D  (un trea ted  cells)] x 100
(40). The sam e protocol was follow ed for the  com m ercially 
available reagent Transfectam® (34,35).
R E SU L T S
Synthesis o f  L iposperm ines
T he te tra-am ine  sperm ine was used as th e  starting  
m aterial for the synthesis o f the  th ree  desired  lipopoly­
am ines: /V4,N 9-d istea ro y l sp e rm in e  1, /V4,/V9-d io le o y l 
sperm ine 2, and N 4,N 9-dilinoleoyl sperm ine 3 (Fig. 1). The 
te tra -am in e  was p ro tec ted  on b o th  the p rim ary  am ino 
functional groups with ethyl trifluoroacetate  (2.2 eq .) in 
m ethanol. Each corresponding fatty acyl chloride (stearoyl, 
oleoyl, or linoleoyl) was used as the acylating agen t together 
with triethylam ine in CH 2CI2 and m ethanol (1:1). D ep ro ­
tection in m ethanol saturated  with am m onia gas and  flash 
colum n chrom atography  affo rded  the th ree  ta rg e t lipo­
spermines, homogenous on silica gel thin-layer chromatography, 
/VV^-dilinoleoyl spermine Rt = 0.49, N 4, N 9-dioleoyl spermine 
R { = 0.44, and  N 4,/V9-d istea ro y l sp e rm in e  R { = 0.41 
(CH 2C12-M eO H -co n c . aq. N H 3 25:10:1, v/v/v), an d  fully 
characterized by *H-NMR (at 400 M Hz) and  13C -N M R  
spectroscopy and by HRMS.
D N A  C ondensation
In Fig. 2, we show the D N A  condensation ability of the 
synthesized lipopolyamine form ulations in com parison with 
the commercially available Transfectam® in an E th B r fluo­
rescence quenching assay. Three cationic lipid form ulations 
(/V4,N 9-dilinoleoyl spermine, /V4,/V9-dioleoyl sperm ine, and 
Transfectam®) show similar D N A  condensing ability. They are 
able to  condense D N A  completely [defined as m ore th an  90% 
E thB r fluorescence quenching (26,41)] at N /P charge ra tio  2, 
whereas /V4,/V9-distearoyl sperm ine is only able to  displace 
around 80% of E thB r at the sam e charge ratio.
The binding of our th ree  synthetic lipopolyam ines with 
polyanionic D N A  was also s tud ied  by analysis o f the  






Fig. 2. Plot of EthB r displacement assay of calf thymus D N A  com­
plexed with N 4r/V9-dilinoleoyI spermine, N \N 9-dioleoyl spermine, 
/V4,/V9-distearoyl spermine, and Transfectam®.






diam eter (nm) Polydispersity
N4,N9-Distearoyl 15.0 217 (21) 0.46
spermine
N4,N9-Dioleoyl 2.5 366 (73) 0.32
spermine
/V4,/V9-Dilinoleoyl 5.5 71 (2.5) 0.19
spermine
Transfectam® 5.9 62 (3.2) 0.22
Each lipoplex diameter value represents mean ± SD.
an agarose gel (1% ). A ll fou r sperm ine conjugates (including 
Transfectam®) were able to  condense p E G F P  D N A  effi­
ciently (as a result o f the in teractions betw een  the lipopoly­
amine am m onium  ions and the  D N A  phosphate  charges) at 
their optim ized respective charge ratios (N /P) of transfection 
(see T able I). All these conjugates com pletely inhibited the 
e lectrophoretic  m obility o f circular plasm id D N A  from lip­
oplexes a t these optim ized N /P  charge ratios.
L ipoplexes Particle S ize and ^-Potential M easurem ents
The particle size and ^-po ten tia l characterization m eas­
urem ents were carried  ou t on th e  lipoplexes a t their optimum 
N/P charge ra tio  of transfection  (see T able I). Particle size 
characterization by dynam ic light scattering showed that the 
average particle  size o f N 4JV 9-dilinoleoyl sperm ine was 
c o n sid e rab ly  sm a lle r  (71 n m ) th a n  th o se  of N 4,N 9- 
distearoyl sperm ine and /V4,/V9-dioleoyl sperm ine (Table I). 
T h e  s u r fa c e  c h a rg e ,  a s  d e te r m in e d  by  ^ -p o te n tia l  
m easurem ents, was +43 and +32 m V  for /V4,/V9-dilinoleoyl 
sperm ine (a t N /P charge ra tio  of 5.5) and /V4./V9-dioleoyl 
sperm ine (a t N /P charge ra tio  o f 2.5) lipoplexes. respectively 
(Fig. 3). Transfectam ®  lipoplex shows a ^-potential of +20 
mV (at N /P charge ra tio  o f 6) in  phosphate-buffered saline 
solution (R em y and B ehr, personal com m unication).
^-Potential is an im portan t param ete r helping to  predict 
the stability of the fo rm ulation  as well as the ability of the 














Fig. 3. ^-Potential of /V4,/V9-dilinoleoyl spermine and (V4,/V9-dioleoyl 
spermine complexed with plasmid encoding for enhanced green 
fluorescent protein (pEGFP) at different N/P charge ratios.








FEK4 HtTA FCP4 FCP5 FCP7 FCP8
□  N4.NO-Distearoyl spermine B  N4.N9-Dioleovl spermine □  N4.N9-Diltnoleovl spermine
□  Transfcclam B  Naked DNA
Fig. 4. Lipofection of the primary skin cell lines (FEK4, FCP4, FCP5, FCP7, and FCP8) and the 
cancer cell line H tTA  transfected with pEG FP complexed with N 4,/V9-distearoyl spermine, 
N 4,Ar9-dioleoyl spermine, A/4,N 9-dilinoleoyl spermine, and Transfectam® (at their respective 
N/P ratios for best transfection). The data represent three different experiments (three 
replicates each), and the erro r bars represent SD.
(R em y and  B ehr, P e rsonal C o m m u n ica tio n ), (42). £- 
P o ten tia l depends on several factors, including pH , ionic 
charge, ion size, and concentration of ions in solution (43). 
T he form ed nanoparticles are considered to  be stable when 
they have pronounced ^-potential values, e ith e r positive or 
negative, but the tendency to  aggregate is h igher when the f-  
potential is close to  zero. Charge neu tra lity  (£  = 0) occurred 
a t an N/P charge ra tio  of about 2 fo r bo th  lipopolyam ines 
N 4,Ar9-dilinoleoyl sperm ine and A/4,/V9-dioleoyl sperm ine 
(com parable with our E thB r results; Fig. 2). Ciani et al. 
(43) found neutralization N /P charge ra tio s of 6 and 2 with 
intact liposomes. Similarly, also w or-king with liposomes, 
Lobo et al. (44) and W iethoff et al. (45) reported  that 
n e u tr a l iz a t io n  c h a rg e  r a t io s  o f  c a t io n ic  l ip id -D N A  
com plexes occurred at N /P charge ratios o f 3.5, 2.5, and 1.5.
Transfection Experim ents
The transduction of E G F P  into a series o f prim ary skin 
cell lines (FEK4, FCP4, FCP5, FCP7, and FC P8) and a cancer 
cell line (H eLa-derived H tT A ) was investigated. T he opti­
m um  concentrations (and corresponding N /P  charge ratios) 
fo r transfec tion  w ere experim en tally  d e te rm in e d  to  be 
JV4,/V9-distearoyl sperm ine (33.4 pg/ml, N /P  = 15.0), N *,N 9- 
dioleoyl sperm ine (5.5 pg/ml, N/P = 2.5), 7V4,/V9-dilinoleoyl 
sperm ine (12.1 pg/ml, N /P = 5.5), and Transfectam ®  (15.0 
pg/ml, N/P = 5.9). The results indicate the improved transfection 
ability of /V4,/V9-dilinoleoyl spermine, greater than 85% in many 
of the studied primary cell lines (80% for FCP8 cells) and 99% 
in the case of the cancer cell line H tT A  compared to the 
saturated /V4,/V9-distearoyl spermine (18-32% ), the m ono­
unsaturated  /V4,/V9-dioleoyl sperm ine (62-75% ), and the 
commercially available Transfectam® (46-79% ; Fig. 4). As a 
negative control, naked (uncomplexed circular) pE G FP D N A 
typically gave 1-2%  transfection of these cell lines. Also, the 
shift in the E G FP positive cells compared to the untransfected 
cells in FACS analysis (Fig. 5) shows the high efficiency of 
A/4,A/9-dilinoleoyl sperm ine by transfecting  both prim ary 
(e.g., FEK4) and cancer (H tTA ) cell lines.
m^Tn| i i i
102 
FL1-H
Fig. 5. Fluorescence-activated cell sorting analysis of FEK4 (above) 
and H tTA  (below) cells after 48-h transfection of pEGFP complexed 
with /V4,N 9-dilinoleoyl spermine: ■ ,  untransduced cells; □ , E G FP 
positive cells.
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FEK4
□N4.N9-Distcaroyl spermine ■N4,N9-Dioleoyl spermine DN4.N9-Dilinoleoyl spermine DTranslcctam ■  Naked DNA
Fig. 6. Cytotoxicity effect of pEG FP (2 pg/ml) free (naked D N A ) or complexed with Af4,A'9-distearoyl spermine 
(33.4 pg/ml), /V4,/V9-dioleoyl spermine (5.5 pg/ml), /V4,N 9-dilinoleoyl spermine (12.1 pg/ml), and Transfectam® 
(15.0 pg/ml) in the tested  cells.
In V itro  Cytotoxicity
Cell viability [M TT assay (46)] results indicate that there  
is no significant difference in  lipoplex toxicity in the case of 
H tT A  and FC P8 prim ary skin cells for all four studied 
lipopolyam ines (Fig. 6). O nly  small differences were ob ­
served across the  o ther fou r cell lines, often with percentage 
cell v iab ility  ab o u t 80% . /V4,/V9-D ilino leoyl sperm ine  
typically shows 70%  cell viability  in most of the studied cell 
lines, and  such a value has recently  been reported  to  be 
acceptable fo r a safe D N A  delivery  vector (47).
D ISC U SSIO N
In this study, we have investigated  the  change in the 
degree of unsaturation  o f th e  di-C18 fatty chain form ulation 
of liposperm ine on D N A  condensation  and cellular delivery. 
The resu lts  from  p E G F P  condensation , investigated by 
E thB r fluorescence quenching assay, revealed th at two of 
our synthetic  lipopolyam ines and the commercial form ula­
tion Transfectam ®  were able to  condense D N A  to less than 
10% E th B r fluorescence, w here  D N A  is defined as con­
densed (41); however, N 4,N  9-distearoyl sperm ine had not 
reduced (quenched) the  E th B r fluorescence to 10% by N/P 
charge ra tio  3.5 (Fig. 2). P artic le  size of the  final gene for­
m ulation is also an im p o rtan t factor in improving gene 
delivery (48,49). Particle size resu lts (Table I) showed larger 
particles w ith both  A 4,7V9-dioleoyl sperm ine and N 4,N 9- 
distearoyl sperm ine fo rm ulations over those obtained with 
N 4.N  9-dilinoleoyl sperm ine and  Transfectam®. These results 
are in concordance w ith the  im provem ent in transfection 
achieved w ith /V4,7V9-dilinoleoyl sperm ine over our o ther two 
form ulations. O n the o th er hand , although Transfectam® has 
the sm allest particle  size (62 nm ), the  saturation of the di-C18 
fatty chains could possibly con tribu te  to  the lower trans­
fection efficiency of this sperm ine conjugate in com parison to 
our fo rm ulation  results w ith /V4,/V9-dilinoleoyl sperm ine. 
Gao and H uang  (51) re p o rted  th a t the addition of poly-L- 
lysine (PL L ) or p ro tam ine to  D C -C hol liposomes reduces 
the size o f the com plex as well as its heterogeneity in all 
ratios of lipid/D N A  th a t im prove transfection efficiency.
Noguchi et al. (16), also working with protam ine, rep o rted  
th a t sm aller-sized particles transfect cells efficiently. The 
inco rpora tion  of protam ine as a nuclear localization signal to 
liposom es incorporating  a cationic cholesterol derivative 
reduced  th e  size of the form ed particles from  0.4-1.8 pm, 
for the D N A -liposom e complex, to  0.1-0.8 pm , for the 
D N A -p ro tam in e -lip o so m e  com plex. On the  re la tionsh ip  
betw een particle  size and transfection efficiency, th e re  are 
no  defin ite  lim its to  the nanoparticle size that are  su itab le  for 
tran s fec tio n  (51). N an o p artic les  have re la tiv e ly  h igher 
in trace llu la r uptake than m icroparticles (52). A lso , on the 
nanoscale, smaller-size polyplexes are more able to  en ter 
cells and thereby increase the efficiency of transfection  (53). 
S im ila r ly , in  2004, R e jm a n  et al. (54) sh o w ed  w ith  
fluorescently  labeled nanospheres (latex beads) th a t size 
itself can determ ine the pathw ay o f entry. O gris et al. (55) 
rep o rted  larger particles (1000 nm ) exceeding th e  trans­
fection efficiency achieved with sm aller particles (40 nm ) 
u sing  D N A /tra n sfe rr in -p o ly e th y len im in e  c o m p le x es  a t 
physiological salt concen tra tion . W ith a d iffe ren t D N A  
condensation  system, they also reported  th at sm all toro id  
structures of D N A /transferrin -P L L  complexes (80-100 nm ) 
show ed high transfection efficiency as their d iam ete rs are in 
the range of the coated  pits involved in the  endocytosis 
process (56).
W e have previously reported  (5-10) the im p o rtan ce  of 
the  substituen ts in the  lipid m oiety conjugated to  th e  cationic 
polyam ine to  achieve im provem ents in D N A condensation  
efficiency fo r nonliposom al form ulations w here th e  lipid 
m oiety m ust be considered in shape (volume) an d  substituen t 
p a tte rn , as well as the polyam ine m oiety and its p/Ca values. 
T he design and synthesis of novel cationic lipids b ased  on the 
te tra-am ine  sperm ine, as nonliposom al form ulations, w here  
the lipid m oiety is a long carbon chain, were largely insti­
ga ted  by B ehr et al. (34) and Rem y et al. (35) w ith their 
design and  preparation  of the highly efficient lipopolyam ine 
D O G S  (Transfectam®). A  leading nonviral vector following 
from such structure-activity considerations is R P R 120535 (57) 
where th e  di-C18 saturated  alkyl chains are substituents 
pendan t from  a diam ide at one end of the  tetra-am ine 
sperm ine, used as the cationic moiety to take advantage of 
D N A  binding by polyamines (58). Unsaturated chains have
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also b een  incorporated  as the  lipophilic m oiety in lipo­
polyam ine vectors.
W e (11) and others (37) have used two covalently bound 
oleoyl chains in nonliposom al form ulations fo r im proved 
transfection  efficiency by fusion with cellular m em branes. In 
liposom al form ulations, dioleoylphosphatidyl ethanolam ine 
(D O P E ) is often  used as a helper lipid for its fusogenic ability 
as it has the  characteristics of nonbilayer form ing activity
leading to  destabilization of the lipid b ilayer (59). Oleoyl and 
oleyl chains have also been bound as e sters and ethers in 
liposomal form ulations: D O S P E R  [l,3-dioleoyloxy-2-(6-car- 
bo x y sp erm in e)] (60), D O S P A -D O P E  (3:1 w/w, L ip o ­
fectam ine™ ), and D O T M A -D O P E  (1:1 w/w, Lipofectin®) 
(F ig . 7). N o n lip o so m al ca tio n ic -lip id  d e liv e ry  vectors 
com bine both  the characteristics of cation ic  and of helper 
lipids. So a factor th a t is im portan t for b o th  facilitating cell
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Fig. 7. Chemical structures of spermine and spermine conjugates together with D O T M A  (cationic) and neutral helper
lipids and gene delivery formulation excipients.
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Fig. 8. Typical diagram of the change in lipid phase structure from 
the lamellar L a phase to the inverted hexagonal H n phase.
entry and the  efficient intracellu lar release of free D N A  (or 
lipoplexes) in to  the  cytoplasm is the  influence of the  cationic 
lipid chain. T he lipid moiety in our cationic lipids in teracts 
with the  phospholipid bilayer of the cell m em brane  and, 
e ither in crossing the m em brane bilayer o r in helping to 
w eaken the endosom al bilayer, thereby  aids the  escape into 
the  cytosol.
C ationic lipids in aqueous solutions exhibit d ifferent 
polym orphic phases. The two m ost im portan t organizational 
form s are L a  (lam ellar organization with fluid hydrocarbon 
chains) and H n (two-dim ensional hexagonal state; Fig. 8) 
(61). F arhood  et al. (59) have rep o rted  that the  rep lacem ent 
o f D O P E  with a trim ethylated structural analog dioleoyl­
phosphatidyl choline (D O PC ; Fig. 7), in cationic liposom al 
form ulations, abolishes m ost of the  transfection  activity of 
the lipoplex, as D O P E  exhibits a high tendency to  form  the 
inverted hexagonal (H n) phase particularly  a t acidic pH .
Lipids th at are cylindrical in so lu tion  shaps p refer 
bilayer form ations, whereas lipids with large head groups 
and small d iam eter hydrocarbon chains (inverted  cones) 
form m icellar structures (61). L ipids with small head  groups 
and long hydrocarbon chains, e.g., (sa tu rated) phosphatidyl 
ethanolam ine (PE ) and D O P E  (Fig. 7), because o f their 
solution cone shape, favor phase transition  to  an inverted  
hexagonal phase, as a result of steric factors (62). Also, 
increasing the  degree of unsa tu ration  o f the  acyl chain 
(especially in the c«-configuration) favors hexagonal phase 
fo rm atio n  (L a —► Hu phase  tran s itio n ) and  p o te n tia lly  
im proves the  fusogenic characteristics of the  lipid. T h e  actual 
significance of m aximizing such fusogenic characteristics in 
N V G T  rem ains to be proven. G aucheron et al. (63), in  their 
detailed study on fluorinated liposperm ines, specu lated  that 
the im proved transfection with the unsaturated  over the 
sa tu rated  counterparts could be a result of “th e ir g reater 
ability to  p rom ote  m em brane fusion with and destabilization 
of the endosom al m em brane allowing optim al D N A  release 
in the cytosol” and “related to  the  fluidification effect of the 
CC bonds.” Vierling et al. (64) have also rep o rted  that 
unsaturated  fluorinated  lipids show ed lower lam ellar phase 
transition tem pera tu re  than the corresponding fluorinated  
sa turated  lipids. T he fusogenic characteristics o f our synthetic 
nonliposom al lipopolyam ines were taken  u n d er consider­
ation to  account for the observed difference in gene delivery. 
T he two factors head group and chain length are  held 
constant am ong our investigated com pounds. T he degree  of 
unsaturation  of the  C18 fatty  chain may be a key facto r that 
explains the  increase in the  transfection efficiency of the 
lipoplex. T his m ay be a result of the  im proved fusogenic 
characteristics of (V4,/V9-dilinoleoyl sperm ine with its (di-ciy- 
configuration) d ienoic fatty  acyl residue, m ore  th an  the 
m onounsaturated /V4,jV9-dioleoyl sperm ine and the saturated
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7V47V9-distearoyl sperm ine. In conclusion, in this study, we 
have designed and syn thesized  novel gene carriers and 
characterized V 4,V 9-dilinoleoyl sperm ine as a promising 
D N A  delivery fo rm ulation  w ith  its increased degree of 
unsaturation in both of the liposperm ine fatty chains.
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As non-viral DNA-delivery vectors, cationic lipids and polymers have the ability to condense 
DNA into particles. These can be readily endocytosed by tissue-cultured cell lines and ultimately 
delivered to the nucleus. Our aims are the design and formulation of a novel non-viral vector 
capable of efficiently and safely delivering DNA to the nucleus in a variety of cell lines. The 
characteristics of lipospermines as cationic and lipophilic substances render these compounds 
promising carriers for DNA through the formation of lipoplexes (Blagbrough et al 2003). In this 
study, we synthesized and characterized a novel lipospermine in which the tetra-amine spermine 
(the cationic moiety) and dioleoyl chains (the lipophilic moiety) are linked by amide bonds at the 
secondary amino groups of spermine to form previously unreported A2,A3-dioleoyl spermine 
(LipoGen®). As among the prerequisites for delivery of DNA across intact cytoplasmic 
membranes are masking the negative charge of the phosphate backbone leading to DNA 
condensation, we studied the ability of N2, A3-dioleoyl spermine to condense calf thymus DNA 
and plasmid DNA ((3-galactosidase, Promega) using an ethidium bromide (EthBr) (?ieX = 260 nm, 
= 600 nm) fluorescence-quenching assay (Gershon et al 1993, Geall & Blagbrough 2000) in 
comparison with poly-L-lysine (PLL, average molecular weights 9.6 and 27 kDa) and 
polyethylenimine (PEI, average molecular weights 2 and 60 kDa) as model DNA condensing 
agents. To quantify the ability of these polyamines in DNA condensation, the binding constants 
of these polyamines with DNA was calculated. Also, particles of condensed DNA were detected 
using a UV light scattering assay at X = 320 nm. The results indicate the ability of A2, A3- 
dioleoyl spermine to condense DNA by the significant decrease in (intercalated) EthBr 
fluorescence intensity and the increase in apparent absorption in light scattering experiments. The 
transfection results revealed high transfection efficiency in both an immortalized cancer cell line 
(HeLa) and in primary skin cells (FEK4) (in culture) using plasmid DNA encoding for enhanced 
green fluorescent protein (pEGFP) (Clontech) as the reporter macromolecule with its fluorescent 
imidazolidinone moiety analysed by FACS. The transfection efficiency and toxicity of A2, A3- 
dioleoyl spermine were studied in comparison with other commercially available liposomal 
cationic lipids Lipofectin® and Lipofectamine™. The DNA condensation and gene delivery using 
A2, A3-dioleoyl spermine was achieved at a small ammonium/phosphate (N/P) charge ratio (2.5 
+/-) that minimises the toxic effects observed at higher N/P charge ratios. These results obtained 
with novel A2, A3-dioleoyl spermine show it to be efficient in both lipoplex formation and 
lipofection.
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The use of an efficient vector for nucleic acid delivery is one of the determining factors for the 
successful application of gene therapy to difficult-to-treat diseases. Among non-viral delivery 
systems, non-liposomal cationic lipids are promising, non-toxic gene carriers. The synthesis by 
Behr et al (1989) of the lipopolyamine dioctadecylamidoglycylspermine (DOGS, Transfectam), as 
an efficient non-viral transfection agent, encouraged several laboratories to focus on the synthesis of 
novel cationic lipids based on the naturally occurring polyamine spermine. In an effort to improve 
DNA delivery, we investigated novel spermine-based cationic lipid formulations. Following on 
from our promising results obtained with A /^V -^dioleoyl spermine (Ahmed et al 2005), we have 
investigated the effect of the degree of unsaturation in the lipophilic moiety of our novel 
lipopolyamines on the overall transfection efficiency. The synthesis of saturated C l8 
distearoyl spermine), and the doubly-unsaturated C l8 (cis 9, 12) A /^V -^dilinoleoyl spermine 
followed that of the mono-unsaturated Cl 8 (cis 9) N4,Ng-dioleoyl spermine (Ahmed et al 2005).
The binding affinities of these compounds for calf thymus DNA were determined using an ethidium 
bromide (EthBr) fluorescence-quenching assay (XeX = 260 nm, = 600 nm, Geall & Blagbrough 
2000) utilising the ability of EthBr as a cationic dye that displays a marked increase in fluorescence 
on binding with DNA through the intercalation of the EthBr phenanthridinium moiety between 
adjacent base-pairs along DNA sequences. The increase in the apparent absorbance due to light 
scattering as a result of the formation of condensed DNA nanoparticles was also detected at A, =
320 nm. N4,Ng-Dilinoleoyl spermine induced a marked decrease in intercalated EthBr fluorescence 
intensity from 100% (EthBr-DNA complex without cationic lipid) reduced to 10% at an 
ammonium/phosphate (N/P) charge ratio of 1.5 and a maximum (100%) relative apparent 
absorption at this same charge ratio. The transfection efficiencies of the synthesized lipopolyamines 
were studied in primary skin cells (FEK4 and FCP cells) and in an immortalized (HeLa derived 
HtTA) cancer cell line using plasmid DNA encoding for enhanced green fluorescent protein 
(pEGFP, Clontech) as the reporter macromolecule with its fluorescent imidazolidinone moiety 
analysed by Fluorescent Activated Cell Sorter (FACS). The results revealed improved transfection 
with A ,^A -^dilinoleoyl spermine, typically 90% efficiency in primary cell lines, higher values than 
were obtained with the saturated N4, A -^distearoyl spermine, about 25-40% transfection efficiency in 
primary cell lines. The cytotoxicity of these compounds was studied in both primary skin and 
immortalised cancer cell lines using an MTT assay (about 70% viability at N/P 5.5). All these 
studies were compared with commercially available non-liposomal cationic lipid DOGS 
(Transfectam, Promega, typically 75% transfection and 75% cell viability at N/P 7.8). The results 
show that an increase in the number of double bonds in the long Cl 8 fatty chain of the cationic lipid 
improves the ability of the non-viral vector to deliver the DNA payload to the cultured cells.
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The design and formulation of novel non-viral gene transfer (nano) particles have to overcome 
different barriers from the site of administration until they actively transport the DNA payload to the 
nucleus of target cells. Cationic lipids, as a major class of non-viral gene carriers, can be further 
classified as liposomal and non-liposomal non-viral DNA-delivery vectors. Lipopolyamines, 
especially those based upon the tetra-amine spermine, are promising non-viral gene delivery 
vectors, with significantly less toxicity and more controlled production than cationic polymers 
(Blagbrough et al 2003). These polyamine conjugates efficient condense DNA into nano-particles 
for cellular uptake by endocytosis, with ultimate DNA delivery to the nucleus in a variety of cell 
lines. In this study, we synthesized and formulated a novel non-liposomal lipospermine in which 
the tetra-amine spermine (the cationic moiety) and two C14 dimyristoyl fatty acid chains (the 
lipophilic moiety) are linked by amide bonds at the secondary amino groups of spermine to form 
/V^A -^dimyristoyl spermine. These amide linkers have the advantages of being both biodegradable 
and less toxic than the ether bonds in DOTMA (Tranchant et al 2004). Furthermore, the 
characteristics of this specific lipospermine with its cationic headgroup and two saturated long fatty- 
acid derived chains, render this conjugate a promising carrier for DNA-lipoplex formation. The 
binding affinity of this novel non-viral vector for calf thymus DNA (Sigma-Aldrich) was 
determined using an ethidium bromide fluorescence-quenching assay (XeX = 260 nm, Xem = 600 nm, 
Geall & Blagbrough 2000). To quantify the ability of this polyamine conjugate in DNA 
condensation, the binding constant with DNA was calculated. Also, particles of condensed DNA 
were detected using a UV light scattering assay at X = 320 nm. The results indicate the ability of 
/V^A -^dimyristoyl spermine efficiently to condense DNA by the significant decrease in 
(intercalated) EthBr fluorescence intensity and the increase in apparent absorption in light scattering 
experiments. The transfection results revealed high transfection efficiency in both an immortalized 
cancer cell line (HeLa derived HtTA cells) and in primary skin cell-lines (FEK4 and FCP cells in 
culture) using plasmid DNA encoding for enhanced green fluorescent protein (pEGFP) (Clontech) 
as the reporter macromolecule with its fluorescent imidazolidinone moiety analysed by Fluorescent 
Activated Cell Sorter (FACS). The viability of the cells was studied using an MTT assay. All the 
studies were investigated in comparison with the commercially available non-liposomal cationic 
lipid Transfectam (Promega). These results obtained with novel A^A^-dimyristoyl spermine show it 
to be an efficient non-viral gene delivery vector for both lipoplex formation and lipofection.
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The use of an efficient vector for nucleic acid delivery is one of the determining 
factors for the successful application of gene therapy to difficult-to-treat diseases. Among 
non-viral delivery systems, non-liposomal cationic lipids are promising, non-toxic gene 
carriers. The synthesis of the lipopolyamine dioctadecylamidoglycylspermine (DOGS, 
Transfectam) by Behr and co-workers (Behr et al 1989) as an efficient non-viral transfection 
agent, encouraged several laboratories to focus on the synthesis of novel cationic lipids 
based on the naturally occurring polyamine spermine. In an effort to improve DNA 
delivery, we are investigating novel spermine-based cationic lipid formulations. Following 
on from our promising results obtained with TV^ A^ -dioleoyl spermine (Ahmed et al 2005), 
we have investigated the effect of the degree of saturation in the lipophilic moiety of our 
novel lipopolyamines on the overall transfection efficiency. The synthesis of saturated C l8 
(A^A^-distearoyl spermine), and the double-unsaturated C l8 (cis 9, 12) N4,N9-dilinoleoyl 
spermine followed that of the mono-unsaturated C l8 (cis 9) of A^A^-dioleoyl spermine 
(Ahmed et al 2005). The binding affinities of these compounds for calf thymus DNA were 
determined using an ethidium bromide (EthBr) fluorescence-quenching assay (A*x = 260 nm, 
= 600 nm, Geall & Blagbrough 2000) utilising the ability of EthBr as a cationic dye that 
displays a marked increase in fluorescence on binding with DNA through the intercalation 
between the EthBr phenanthridinium-moiety and adjacent base-pairs along DNA sequences. 
The increase in the apparent absorbance due to light scattering as a result of the formation of 
condensed DNA nanoparticles was detected at X = 320 nm. The transfection efficiencies of 
the synthesized lipopolyamines were studied in primary skin cells (FEK4 and FCP cells) and 
in an immortalized cancer cell line (HeLa derived HtTA cells, stably transfected with a 
tetracycline-controlled transactivator) using plasmid DNA encoding for enhanced green 
fluorescent protein (pEGFP) (Clontech) as the reporter macromolecule with its fluorescent 
imidazolidinone moiety analysed by Fluorescent Activated Cell Sorter (FACS). The 
cytotoxicity of these compounds was studied in both primary skin and immortalised cancer 
cell lines using an MTT assay. All the studies were compared with the commercially 
available non-liposomal cationic lipid Transfectam (DOGS, Promega). The results show 
that an increase in the number of double bonds in the long Cl 8 fatty chain of the cationic 
lipid improves the ability of the non-viral vector to deliver the DNA payload to the cultured 
cells.
We acknowledge the financial support of the Egyptian Government (studentship to 
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The design and formulation of novel non-viral gene transfer (nano) particles have to 
overcome different barriers from the site of administration until they actively transport the DNA 
payload to the nucleus of target cells. Cationic lipids, as a major class of non-viral gene carriers, 
can be further classified as liposomal and non-liposomal non-viral DNA-delivery vectors. 
Lipopolyamines, especially those based upon the tetra-amine spermine, are promising non-viral 
gene delivery vectors, with significantly less toxicity and more controlled production than cationic 
polymers (Blagbrough et al 2003). These polyamine conjugates efficient condense DNA into 
nano-particles for cellular uptake by endocytosis, with ultimate DNA delivery to the nucleus in a 
variety of cell lines. In this study, we synthesized and formulated a novel non-liposomal 
lipospermine in which the tetra-amine spermine (the cationic moiety) and two C14 dimyristoyl 
fatty acid chains (the lipophilic moiety) are linked by amide bonds at the secondary amino groups 
of spermine to form A^A^-dimyristoyl spermine. These amide linkers have the advantages of 
being both biodegradable and less toxic than the ether bonds in DOTMA (Tranchant et al 2004). 
Furthermore, the characteristics of this specific lipospermine with its cationic headgroup and two 
saturated long fatty-acid derived chains, render this conjugate a promising carrier for DNA- 
lipoplex formation. The binding affinity of this novel non-viral vector for calf thymus DNA 
(Sigma-Aldrich) was determined using an ethidium bromide fluorescence-quenching assay (A** = 
260 nm, Aem = 600 nm, Geall & Blagbrough 2000). To quantify the ability of this polyamine 
conjugate in DNA condensation, the binding constant with DNA was calculated. Also, particles 
of condensed DNA were detected using a UV light scattering assay at X = 320 nm. The results 
indicate the ability of A^A^-dimyristoyl spermine efficiently to condense DNA by the significant 
decrease in (intercalated) EthBr fluorescence intensity and the increase in apparent absorption in 
light scattering experiments. The transfection results revealed high transfection efficiency in both 
an immortalized cancer cell line (HeLa derived HtTA cells) and in primary skin cell-lines (FEK4 
and FCP cells in culture) using plasmid DNA encoding for enhanced green fluorescent protein 
(pEGFP) (Clontech) as the reporter macromolecule with its fluorescent imidazolidinone moiety 
analysed by Fluorescent Activated Cell Sorter (FACS). The viability of the cells was studied 
using an MTT assay. All the studies were investigated in comparison with the commercially 
available non-liposomal cationic lipid Transfectam (Promega). These results obtained with novel 
A^A^-dimyristoyl spermine show it to be an efficient non-viral gene delivery vector for both 
lipoplex formation and lipofection.
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As viral gene therapy continues to suffer significant mammalian toxicity problems (1,2), the 
possibility of reaching the goal of intracellular protein levels at therapeutic concentrations moves 
even more towards utilising non-viral gene therapy (NVGT). Among non-viral delivery systems, 
non-liposomal cationic lipids are promising, non-toxic gene carriers. We have designed novel 
spermine-based lipopolyamines and studied the effect of the degree of unsaturation in the lipophilic 
moiety on the overall transfection efficiency. The synthesis of saturated C l8 (A^A^-distearoyl 
spermine), doubly-unsaturated C l8 (cis-9, cis-12) A ,^A -^dilinoleoyl spermine (3), and mono­
unsaturated C18 (cis-9) A .^A -^dioleoyl spermine (4) uses A7,/Vy2-ditrifluoroacetyl spermine as a 
practical, selectively protected intermediate, amide synthesis, followed by NH3/MeOH deprotection.
Y ^ n^ nh2




DNA condensation was studied using an ethidium bromide (EthBr) fluorescence-quenching assay 
(A*x = 260 nm, Xem = 600 nm) (5). A^A^-Dilinoleoyl spermine induced a marked decrease in 
intercalated EthBr fluorescence intensity from 100% (EthBr-DNA complex without cationic lipid) 
reduced to 10% at an ammonium/phosphate (N/P) charge ratio of 1.5. Light scattering by 
condensed DNA nanoparticles was detected at X = 320 nm and a maximum (100%) relative 
apparent absorption (UV scattered light) at N/P charge ratio of about 1.5. The transfection 
efficiencies of the synthesized lipopolyamines were studied in primary skin cells (FEK4 and FCP 
cells) and in an immortalized (HeLa derived HtTA) cancer cell line using plasmid DNA encoding 
for enhanced green fluorescent protein (pEGFP) as the reporter macromolecule with its fluorescent 
imidazolidinone moiety analysed by Fluorescent Activated Cell Sorter (FACS). The results 
revealed high transfection with A^ /V9-dilinoleoyl spermine, typically 85-90% efficiency in primary 
cell lines, higher values than were obtained with the saturated N4,A -^distearoyl spermine about 25- 
40%, A^A^-dioleoyl spermine about 60-75% transfection efficiency. The cytotoxicity of these 
compounds was studied in both primary skin and immortalised cancer cell lines using an MTT assay 
(about 70% viability at N/P charge ratio 5.5). These results were compared with non-liposomal 
cationic lipid Transfectam, around 46-79% transfection, in the various cell lines, and 75% cell 
viability at N/P charge ratio 5.9. Naked (uncomplexed circular) pEGFP DNA typically gave 1-2% 
transfection of these cell lines. The results show that an increase in the number of double bonds in 
the long Cl 8 fatty chain of the cationic lipid improves the ability of the non-viral vector to deliver 
the DNA payload to the cultured cells.
We acknowledge the financial support of the Egyptian Government (studentship to O.A.A.A.). We 
are grateful to Prof R. M. Tyrrell (University of Bath) for the FEK4 and HtTA cell lines.
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Introduction
Among non-viral delivery systems, non- 
liposomal cationic lipids are promising, 
non-toxic gene carriers. The synthesis of 
dioctadecylamidoglycylspermine (DOGS, 
Transfectam) by Behr and co-workers [1] 
as an efficient non-viral transfection 
agent, encouraged several laboratories to 
focus on the synthesis of novel cationic 
lipids based on the naturally occurring 
polyamine spermine. The use of an 
efficient vector for nucleic acid delivery 
is one of the determining factors for the 
successful application of gene therapy to 
difficult-to-treat diseases. In an effort to 
improve DNA delivery, we are 
investigating novel spermine-based 
cationic lipid formulations. Following on 
from our promising results obtained with 
A^A^-dioleoyl spermine [2], we have 
investigated the effect of the degree of 
unsaturation in the lipophilic moiety of 
our novel lipopolyamines on the overall 
transfection efficiency, achieved by the 
synthesis of saturated Cl8 (N4,^9- 
distearoyl spermine), doubly-unsaturated 
C l8 (cis-9, 12) A^X-dilinoleoyl 
spermine, and mono-unsaturated Cl8 
(cis-9) A^A^-dioleoyl spermine [2].
Experimental methods
Synthesis of lipospermines
Spermine was used as the starting material for 
the synthetic process. The tetra-amine spermine 
was protected on both the primary amino 
functional groups with ethyl trifluoroacetate. 
Fatty chains were added to the secondary amino 
group using fatty acyl chloride. The tetra-amide 
was dissolved in methanol and the pH of the 
solution was increased by saturating with 
ammonia gas (deprotection of the primary amine 
groups). After silica gel column 
chromatography, all three synthesized
lipopolyamines were homogeneous by thin-layer 
chromatography.
DNA condensation
DNA condensation was monitored using an 
ethidium bromide (EthBr) fluorescence 
quenching assay (A  ^= 260 nm, A^m = 600 nm
[3]) utilising the ability of EthBr as a cationic 
dye that displays a marked increase in 
fluorescence on binding with DNA through the 
intercalation between the EthBr 
phenanthridinium-moiety and adjacent base- 
pairs along DNA sequences. Also, the increase 
in the apparent absorbance due to light scattering 
as a result of the formation of condensed DNA 
nanoparticles was detected at X = 320 nm.
Lipoplex particle size and zeta potential 
measurements
The average particle size and ^-potential 
measurements (at their optimum charge ratio of 
transfection) were determined using a Malvern 
Zetasizer (Nano S or ZS, Malvern Instruments, 
UK). All measurements were carried out on 
lipoplexes with 5 |Hg/ml plasmid DNA in 
HEPES buffer at pH 7.4 and 20 °C.
Transfection experiments
The transfection efficiencies of the synthesized 
lipopolyamines were studied in primary skin 
cells (FEK4 and FCP cells) and in an 
immortalized cancer cell line (HeLa derived 
HtTA cells, stably transfected with a 
tetracycline-controlled transactivator) using 
plasmid DNA encoding for enhanced green 
fluorescent protein (pEGFP) as the reporter 
macromolecule with its fluorescent 
imidazolidinone moiety (and analysis by FACS).
In vitro cytotoxicity
The cytotoxicity of these compounds was 
studied in both primary skin and immortalised 
cancer cell lines using an MTT assay.
Results and Discussion 
DNA condensation
Three cationic lipid formulations (A4,N9- 
dilinoleoyl spermine, A^A^dioleoyl 
spermine, and Transfectam®) show 
similar DNA condensing ability. They 
are able to condense DNA completely 
(defined as more than 90% EthBr 
fluorescence quenching [4] at N/P charge 
ratio 2, while A^A^distearoyl spermine is 
only able to displace around 80% of 
EthBr at the same charge ratio.
100 ■N4,N9-Distearoyl spermine 
■N4,N9-Dioleoyl spermine 
■ N4,N9-Dilinoleoyl spermine 
i Transfectam
charge ra tio
Figure 1. Plot of EthBr displacement 
assay of calf thymus DNA complexed 
with A /^V -^dilinoleoyl spermine, A4,A9- 
dioleoyl spermine, A^A^-distearoyl 
spermine, and Transfectam®.
Lipoplex particle size and zeta 
potential measurements
Particle size characterization showed that 
the average particle size of A^A9- 
dilinoleoyl spermine was considerably 
smaller (71 nm) than that of A^A9- 
distearoyl spermine and A4,A9-dioleoyl 
spermine (366 nm). The surface charge, 
as determined by ^-potential 
measurements, was +43 and +32 mV for 
A4,A9-dilinoleoyl spermine (at N/P charge 
ratio of 5.5) and A4,A9-dioleoyl spermine 
(at N/P charge ratio of 2.5) lipoplexes 
respectively.
Transfection experiments
The results indicate the improved 
transfection ability of A^A^-dilinoleoyl 
spermine, greater than 85% in many of the 
studied primary cell lines (80% for FCP8 
cells) and 99% in the case of HtTA cells 
compared to the saturated A^^-distearoyl 
spermine (18-32%), the mono-unsaturated 
^A^-dioleoyl spermine (62-75%), and 
Transfectam® (46-79%).
FL1
Figure 2. FACS analysis of FEK4 cells 
after 48 h transfection of pEGFP complexed 
with A4,A9-dilinoleoyl spermine: I  
untransduced cells, □  EGFP positive cells.
In vitro cytotoxicity
Cell viability results indicate that there is no 
significant difference in lipoplex toxicity in 
the case of HtTA and FCP8 primary skin 
cells for all four studied lipopolyamines. 
A4,A9-Dilinoleoyl spermine typically shows 
70% cell viability in most of the studied cell 
lines, and such a value has recently been 
reported to be acceptable for a safe DNA 
delivery vector [5].
Conclusion
The results show that an increase in the 
number of double bonds in the long Cl 8 
fatty chain of the cationic lipid improves the 
ability of the non-viral vector to deliver the 
DNA payload to cultured cells.
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Introduction
The formulation of novel non-viral gene 
transfer (nano) particles has to overcome 
different barriers from the site of 
administration until they actively transport 
the DNA payload to the nucleus of target 
cells. Cationic lipids, as a major class of 
non-viral gene carriers, can be further 
classified as liposomal and non-liposomal 
non-viral DNA-delivery vectors. 
Lipopolyamines, especially those based 
upon the tetra-amine spermine, are 
promising non-viral gene delivery vectors, 
with significantly less toxicity and more 
controlled production than cationic 
polymers [1,2]. These polyamine 
conjugates efficient condense DNA into 
nano-particles for cellular uptake by 
endocytosis, with ultimate DNA delivery 
to the nucleus in a variety of cell lines. In 
this study, we synthesized and formulated 
a novel non-liposomal lipospermine in 
which the tetra-amine spermine (the 
cationic moiety) and two C14 dimyristoyl 
fatty acid chains (the lipophilic moiety) 
are linked by amide bonds at the 
secondary amino groups of spermine to 
form A^A^-dimyristoyl spermine. These 
amide linkers have the advantages of 
being both biodegradable and less toxic 
than the ether bonds in DOTMA [3]. 
Furthermore, the molecular characteristics 
of this specific lipospermine with its 
cationic headgroup and two saturated long 
fatty-acid derived chains, render this 




The tetra-amine spermine was protected on both 
the primary amine functional groups using ethyl 
trifluoroacetate. Dimyristoyl chains were added 
to the secondary amine groups using myristoyl
chloride. Then, the tetra-amide was dissolved in 
methanol and the pH of the solution was 
increased by saturating with ammonia gas to 
remove the protecting groups, followed by 
purification to homogeneity using silica gel 
column chromatography.
Ethidium bromide and light scattering 
experiments
The binding affinity of this novel non-viral 
vector for calf thymus DNA (Sigma-Aldrich) 
was determined using an ethidium bromide 
fluorescence-quenching assay (X«x = 260 nm,
= 600 nm [4]. To quantify the ability of this 
polyamine conjugate in DNA condensation, the 
binding constant with DNA was calculated.
Also, particles of condensed DNA were detected 
using a UV light scattering assay at X = 320 nm.
Lipoplex particle size and zeta potential 
measurements
The average particle size and ^-potential
measurements (at their optimum charge ratio of
transfection) were determined using a Malvern
Zetasizer (Nano S or ZS, Malvern Instruments,
UK). All measurements were carried out on
lipoplexes with 5 p.g/ml plasmid DNA in
HEPES buffer at pH 7.4 and 20 °C.
+ 43 mV
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Figure 1. Diagram illustrating the 
particle size and C, potential of the 
nanoparticles formed.
Transfection experiments and 
cytotoxicity
The transfection efficiencies of the 
synthesized lipopolyamines were studied 
in primary skin cells (FEK4 and FCP 
cells) and in an immortalized cancer cell 
line (HeLa derived HtTA cells, stably 
transfected with a tetracycline-controlled 
transactivator) using plasmid DNA 
encoding for enhanced green fluorescent 
protein (pEGFP) as the reporter 
macromolecule with its fluorescent 
imidazolidinone moiety analysed by 
FACS. The cytotoxicity of these 
compounds was studied in both primary 
skin and immortalised cancer cell lines 
using an MTT assay.
Results and Discussion
Ethidium bromide and light scattering 
experiments
The results indicate the ability of A^ /V9- 
dimyristoyl spermine efficiently to 
condense DNA by the significant 
decrease in (intercalated) EthBr 
fluorescence intensity and the increase in 










0.0 1.0 2.0 3.0 4.0 5.0
charge ratio
Figure 2. Comparison of ethidium 
bromide fluorescence quenching assay 
(Kxdt = 260 nm and A^s = 600 nm with 
slit width 5 nm) and light scattering assay 
(% relative maximum apparent 
absorbance at A, = 320 nm) of /V4,N9- 
dimyristoyl spermine complexed with 
pEGFP.
Lipoplex particle size and zeta 
potential measurements
N4,N9-Dimyristoyl spermine-pEGFP 
complex at N/P ratio (+/-) 15, shows an 
average particle size of 62 nm and has a 
^-potential of + 43 mV (at the optimum 
charge ratio of transfection).
Transfection experiments and 
cytotoxicity
The transfection results revealed high 
transfection efficiency in both an 
immortalized cancer cell line (HeLa 
derived HtTA cells) and in primary skin 
cell-lines (FEK4 and FCP cells in culture) 
in comparison with the commercially 
available non-liposomal cationic lipid 
Transfectam (Promega). Cell viabilities 
in the investigated cell lines were around 
50%.
Conclusion
These results obtained with novel /V4,^9- 
dimyristoyl spermine show it to be an 
efficient non-viral gene delivery vector 
for both lipoplex formation and 
lipofection.
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Cationic lipids are non-viral DNA-delivery vectors. These vectors have the ability to condense 
DNA into particles which can be readily endocytosed in tissue-cultured cell lines. Ultimately, the 
DNA pay-load is delivered to the nucleus. The aim of this study is DNA formulation with a 
lipospermine non-viral vector capable of efficiently delivering the desired plasmid to the target 
nuclei in a variety of cell lines e.g. primary skin and cancer cells (Ahmed et al 2005 and 2006).
We have synthesized and characterized a lipopolyamine in which the tetra-amine spermine, the 
cationic moiety, and two oleoyl chains as the lipophilic moiety are linked by amide bonds at the 
secondary amino groups of spermine to form A /^V -^dioleoyl spermine. Among the prerequisites 
for delivery of DNA across intact cytoplasmic membranes are masking the negative charge of the 
phosphate backbone leading to DNA condensation, we have therefore studied the ability of A4,A9- 
dioleoyl spermine to condense linear calf thymus DNA and circular plasmid DNA ((3- 
galactosidase) using an ethidium bromide (EthBr, = 260 nm, = 600 nm) fluorescence- 
quenching assay (Geall & Blagbrough 2000) and compared the results with those obtained using 
poly-L-lysine (PLL, average molecular weights 9.6 and 27 kDa) and polyethylenimine (PEI, 
average molecular weights 2 and 60 kDa) as model DNA condensing agents. Our results show 
that A4,A9-dioleoyl spermine is able to condense DNA with > 90% fluorescence quenching at 
ammonium/phosphate N/P charge ratio 2 more efficiently than PLL9.6 and the commercially 
available formulations Lipofectin® and Lipofectamine™. The DNA binding constants of these 
lipopolyamines were calculated, and particles of condensed DNA were detected using a UV light 
scattering assay at X = 320 nm. A4,A9-Dioleoyl spermine is able to condense DNA, shown by the 
significant decrease in (intercalated) EthBr fluorescence intensity and the related increase in 
apparent absorption in the light scattering experiments. The transfection efficiency and toxicity of 
non-liposomal A4,A9-dioleoyl spermine were also studied in comparison with commercially 
available liposomal cationic lipid formulations Lipofectin® and Lipofectamine™. Transfection was 
performed using plasmid DNA encoding for enhanced green fluorescent protein (pEGFP) as the 
reporter macromolecule, with its fluorescent imidazolidinone moiety analysed by FACS. We 
found higher transfection efficiency in both primary skin cells (FEK4, 75%) and in an 
immortalized cancer cell line in culture (HtTA HeLa, 70%) than Lipofectin® that showed 18% and 
58% transfection efficiency respectively. Our synthetic lipospermine showed comparable results 
with Lipofectamine™ (66% and 70%) in FEK4 and HtTA cells respectively. Using the cationic 
lipid A4,A9-dioleoyl spermine, both DNA condensation and gene delivery were achieved at a small 
N/P charge ratio (2.5 +/-) minimising the toxic effects seen at higher charge ratios (MTT assay). 
From our results, we conclude that A4,A9-dioleoyl spermine is efficient in both lipoplex formation 
and lipofection.
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